



NEWS SUMMARY

GENERAL

Rocket attacks hit Paris

Three terrorists armed with what appeared to be a Soviet-made bazooka fired rockets at Government buildings in central Paris.

An extremist group called Direct Action claimed responsibility for the attacks which damaged Ministry of Transport buildings but injured no one.

The group said attacks would continue until the release of 25 suspected "sympathisers" who have been charged with bombing, attempted murder and subversion. Back and Page 2

Ulster bombs

At least six people were hurt in three Ulster bomb attacks which coincided with the Dublin visit of Northern Ireland Secretary Humphrey Atkins.

£1.5m drugs haul

Customs men and police seized £1.5m of cannabis and made six arrests in an ambush on an Anglesey beach. Twenty other arrests were made in country-wide dawn swoops.

Murder charges

Two Libyan students appeared before Marylebone magistrates charged with murdering Libyan journalist Mohammed Ramaden in London. Ben-Hassan Elmasri and Nagib Gasmi were remanded in custody.

Titles suspended

British United Press became the first big provincial newspaper owner to suspend publication as a result of selective action by members of the National Graphical Association over an earnings claim. Back Page.

Petrol lead move

Shell and BP renewed their Appeal Court attempt to block actions by parents over the alleged harmful and unlawful effect on children of lead in car exhaust fumes.

£2m gems raid

Armed gang escaped with diamonds worth at least £500,000 after a raid on a jewellers in London's Hatton Garden.

Concorde flights

British Airways plans to increase Concorde flights between London, New York and Washington this summer following Braniff airline's decision to drop the aircraft from its Dallas-Fort Worth service. Page 6

Lebanon strike

Lebanon's Shitate Moslems went on strike in protest at the arrest by Iraq of Imam Mohammed al-Bakr Sadr, spiritual head of Iraq's Shi'ite Shias. Page 4

Tito has jaundice

President Tito of Yugoslavia developed jaundice and his weight has dropped to just over six stones.

Liberia order

Liberia's military government ordered all off-duty soldiers back in barracks in an attempt to bring stability to Monrovia after Saturday's coup.

Briefly . . .

Textile worker was charged with the attempted murder of Indian Premier Indira Gandhi. Film Kramer vs Kramer won five Hollywood Oscars.

May will be mainly dry and warm, says the long-range forecast. Back Page

PUBLISHER'S NOTICE

The Financial Times apologises for errors contained in this issue which are due to difficulties in the reading department.

CHIEF PRICE CHANGES YESTERDAY

(Prices in pence unless otherwise indicated)		
RISES		
Eviction, Apr 1980	£70.00	+
Abertaxi Cement	180	+
Automated Security	235	+
Burton	115	+
Crating Warehouses	54	+
Guinness Peat	106	+
Hambro	362	+
Hoga Robinson	112	+
Mk Electric	188	+
Mallinson-Denny	70	+
Meyer (Mont. L.)	110	+
News Int'l	153	+
Niven Engineering	42	+
Stile Shoes	160	+
Tate and Lyle	136	+
Whessle	76	+
Wills Faber	245	+
LASMO	385	+
FALLS	10	+
RITZ	308	+
Rustenburg	208	+
West Driefontein	229	+
Exchen 10pm 1980	£57	-
(Prices in pence unless otherwise indicated)		

BUSINESS

Dollar rallies; gold off \$27

● DOLLAR rallied in late nervous trading to close at DM 1.9650 (DM 1.8725) and SwFr 1.7850 (SwFr 1.7425). Its

An extremist group called Direct Action claimed responsibility for the attacks which damaged Ministry of Transport buildings but injured no one.

The group said attacks would continue until the release of 25 suspected "sympathisers" who have been charged with bombing, attempted murder and subversion. Back and Page 2

Ulster bombs

At least six people were hurt in three Ulster bomb attacks which coincided with the Dublin visit of Northern Ireland Secretary Humphrey Atkins.

£1.5m drugs haul

Customs men and police seized £1.5m of cannabis and made six arrests in an ambush on an Anglesey beach. Twenty other arrests were made in country-wide dawn swoops.

Murder charges

Two Libyan students appeared before Marylebone magistrates charged with murdering Libyan journalist Mohammed Ramaden in London. Ben-Hassan Elmasri and Nagib Gasmi were remanded in custody.

Titles suspended

British United Press became the first big provincial newspaper owner to suspend publication as a result of selective action by members of the National Graphical Association over an earnings claim. Back Page.

Petrol lead move

Shell and BP renewed their Appeal Court attempt to block actions by parents over the alleged harmful and unlawful effect on children of lead in car exhaust fumes.

£2m gems raid

Armed gang escaped with diamonds worth at least £500,000 after a raid on a jewellers in London's Hatton Garden.

Concorde flights

British Airways plans to increase Concorde flights between London, New York and Washington this summer following Braniff airline's decision to drop the aircraft from its Dallas-Fort Worth service. Page 6

Lebanon strike

Lebanon's Shitate Moslems went on strike in protest at the arrest by Iraq of Imam Mohammed al-Bakr Sadr, spiritual head of Iraq's Shi'ite Shias. Page 4

Tito has jaundice

President Tito of Yugoslavia developed jaundice and his weight has dropped to just over six stones.

Liberia order

Liberia's military government ordered all off-duty soldiers back in barracks in an attempt to bring stability to Monrovia after Saturday's coup.

Briefly . . .

Textile worker was charged with the attempted murder of Indian Premier Indira Gandhi. Film Kramer vs Kramer won five Hollywood Oscars.

May will be mainly dry and warm, says the long-range forecast. Back Page

PUBLISHER'S NOTICE

The Financial Times apologises for errors contained in this issue which are due to difficulties in the reading department.

No. 28,144

PUBLISHED IN LONDON AND FRANKFURT

Wednesday April 16 1980

Sir William Barlow quits as chairman of Post Office

BY JOHN ELLIOTT, INDUSTRIAL EDITOR

A shake-up at the top of the Post Office was started yesterday when Sir William Barlow announced his resignation from the chairmanship after a year of growing frustration with the Government's tight cash-limit policies for nationalised industries.

Though he stressed that he had not had a major row with the Government Sir William, who is 55, is giving up the chairmanship after holding the job for only three years.

He has refused to become chairman of British Telecommunications when the Post Office is split into two parts early next year.

The registration was announced "with great regret" yesterday by Sir Keith Joseph, the Industry Secretary.

Sir Keith named the senior Industry Department civil servant who will be chairman of Posts and Giro after next year's formal split. He is Mr. Ron Dearing, 48.

Mr. Dearing started his career as a Civil Service clerk at the age of 16, and is deputy secretary in charge of the Post Office and other nationalised bodies.

He is to join the Post Office next month as deputy chairman, and Chairman-designate of the new organisation, at a salary of £36,000 a year—about £12,000 less than Sir William receives for heading the combined corporation.

Mr. Dearing was selected after a firm of executive search consultants interviewed 25 possible

candidates who said they did not wish to be considered.

The Post Office is to be formally split in two next year after a Bill is introduced to Parliament in the autumn becomes law.

The Bill will reduce some of the Post Office's "monopoly" powers, and it is believed that Sir William considers that Sir Keith wants to do this too quickly in the telecommunications sector.

The present corporation's structure is being changed so that the businesses can be run separately within a few months.

Mr. Dearing, 48, is believed to be the most likely to succeed.

Sir William will continue to work on this reorganisation until the autumn. The Government will then have to find a temporary chairman to head the combined corporation until the legal split takes place.

Sir William might be asked to fill this post on a part-time basis, though he made it clear yesterday that he wished to return immediately to the private sector, which he left in 1971.

"I prefer the cut-and-thrust of competition rather than life in nationalised industries," he

Mr. Dearing, 48, is believed to be the most likely to succeed.

Sir William will continue to work on this reorganisation until the autumn. The Government will then have to find a temporary chairman to head the combined corporation until the legal split takes place.

Sir William might be asked to fill this post on a part-time basis, though he made it clear yesterday that he wished to return immediately to the private sector, which he left in 1971.

"I prefer the cut-and-thrust of competition rather than life in nationalised industries," he

Mr. Dearing, 48, is believed to be the most likely to succeed.

Sir William will continue to work on this reorganisation until the autumn. The Government will then have to find a temporary chairman to head the combined corporation until the legal split takes place.

Sir William might be asked to fill this post on a part-time basis, though he made it clear yesterday that he wished to return immediately to the private sector, which he left in 1971.

"I prefer the cut-and-thrust of competition rather than life in nationalised industries," he

Mr. Dearing, 48, is believed to be the most likely to succeed.

Sir William will continue to work on this reorganisation until the autumn. The Government will then have to find a temporary chairman to head the combined corporation until the legal split takes place.

Sir William might be asked to fill this post on a part-time basis, though he made it clear yesterday that he wished to return immediately to the private sector, which he left in 1971.

"I prefer the cut-and-thrust of competition rather than life in nationalised industries," he

Mr. Dearing, 48, is believed to be the most likely to succeed.

Sir William will continue to work on this reorganisation until the autumn. The Government will then have to find a temporary chairman to head the combined corporation until the legal split takes place.

Sir William might be asked to fill this post on a part-time basis, though he made it clear yesterday that he wished to return immediately to the private sector, which he left in 1971.

"I prefer the cut-and-thrust of competition rather than life in nationalised industries," he

Mr. Dearing, 48, is believed to be the most likely to succeed.

Sir William will continue to work on this reorganisation until the autumn. The Government will then have to find a temporary chairman to head the combined corporation until the legal split takes place.

Sir William might be asked to fill this post on a part-time basis, though he made it clear yesterday that he wished to return immediately to the private sector, which he left in 1971.

"I prefer the cut-and-thrust of competition rather than life in nationalised industries," he

Mr. Dearing, 48, is believed to be the most likely to succeed.

Sir William will continue to work on this reorganisation until the autumn. The Government will then have to find a temporary chairman to head the combined corporation until the legal split takes place.

Sir William might be asked to fill this post on a part-time basis, though he made it clear yesterday that he wished to return immediately to the private sector, which he left in 1971.

"I prefer the cut-and-thrust of competition rather than life in nationalised industries," he

Mr. Dearing, 48, is believed to be the most likely to succeed.

Sir William will continue to work on this reorganisation until the autumn. The Government will then have to find a temporary chairman to head the combined corporation until the legal split takes place.

Sir William might be asked to fill this post on a part-time basis, though he made it clear yesterday that he wished to return immediately to the private sector, which he left in 1971.

"I prefer the cut-and-thrust of competition rather than life in nationalised industries," he

Mr. Dearing, 48, is believed to be the most likely to succeed.

Sir William will continue to work on this reorganisation until the autumn. The Government will then have to find a temporary chairman to head the combined corporation until the legal split takes place.

Sir William might be asked to fill this post on a part-time basis, though

EUROPEAN NEWS

EEC's regional fund under attack by MEPs

BY WALTER ELLIS IN STRASBOURG

THE LIMITED scope of the EEC regional development fund came under severe attack yesterday in the European Parliament. Members felt that the fund—worth \$165m in 1978—was much too small to begin to help redress the Community's regional imbalances and was both mismanaged and subject to abuse.

The MEPs were debating a report on the fund's operation produced by the Parliament's regional affairs committee and particularly critical of one member state—known to be France—for impeding the work of Community officials seeking to verify that aid was being allocated in the agreed manner. It called on the European Commission to consider suspending assistance from the fund to those areas where auditing could not take place.

Mr. David Harris, a British Conservative, called the position in France a scandal and demanded an inquiry so that the Commission could discover how regional fund money was being spent in the French industrial sector.

The report observes, as its predecessors have done for some years, that the effectiveness of the funds available depends on the willingness of

Cossiga in UK next week

BY JOHN WYLES IN BRUSSELS

THE ITALIAN Prime Minister, is expected to visit London, Paris and Bonn next week to make his long-awaited personal bid to find a settlement of the row over Britain's contributions to the EEC budget. The collapse of his Government three weeks ago, allied to the then bleak prospects for an agreement, prompted Sig. Cossiga to postpone the EEC-summit which was scheduled in Brussels at the end of last month.

But following his formation of a new centre-left government, the European Council will now be held in Luxembourg on April 27-28. In the meantime, Sig. Cossiga, as president of the Council, will seek to close the gap between the UK and her EEC partners.

During the past two weeks, there has been a palpable increase in optimism within the Community that an agreement can be reached at the next summit.

Virtually everything depends on how much more the other EEC states will pay so that the UK can transfer much less than the £1.1bn which will otherwise go into the Brussels budget this year.

Turkish bank chief may be replaced

BY METIN MUNIR IN ANKARA

THE TURKISH Government is expected to replace Mr. Ismail Hakkı Aydinoglu as governor of the Central Bank after the bank's annual general assembly meeting on April 30, senior officials said yesterday.

Accordingly it repeats a call it made last year for the Commission to pay money directly to the public or private investor instead of through national governments.

Another target for criticism is the operation of the national quota system under which each member state is granted a proportion of the total aid available with little regard being paid to the particular needs of deprived regions.

The Parliament supports the Commission view that the priority areas for aid should be Northern Ireland, Ireland, the Italian Mezzogiorno, Greenland and the French overseas departments.

As the row over the size of Britain's contribution to the EEC budget has grown, officials have begun to look more closely at the regional fund as one possible means of injecting more Community cash into the British economy.

If increased aid to the UK is to become a reality, however, the fund would have to be considerably enlarged.

Regret in London

BY DAVID TONGE IN LONDON

David Tonge adds: Bankers

in London reacted with dis-appointment to reports that Mr. Aydinoglu might be re-placed. "A lot depends on

what would take over, but it

is not a shame to see him go," one

banker commented.

Another said that, when

Turkey was talking of re-

ducing further debts, it

would be a "most unfortunate time" to bring in a new man.

The banks generally be-

lieved that Mr. Aydinoglu had

developed a clear understand-

ing of the problems of Turkey

and the realities of the international financial system.

They also argued that, un-

like a few of his predecessors,

he had at times made a point

of standing up to the Govern-

ment which appointed him,

when he believed that it was

going off course.

27-28 In the meantime, Sig.

Cossiga, as president of the

Council, will seek to close the

gap between the UK and her

EEC partners.

The banks generally be-

lieved that Mr. Aydinoglu had

developed a clear understand-

ing of the problems of Turkey

and the realities of the international financial system.

They also argued that, un-

like a few of his predecessors,

he had at times made a point

of standing up to the Govern-

ment which appointed him,

when he believed that it was

going off course.

27-28 In the meantime, Sig.

Cossiga, as president of the

Council, will seek to close the

gap between the UK and her

EEC partners.

The banks generally be-

lieved that Mr. Aydinoglu had

developed a clear understand-

ing of the problems of Turkey

and the realities of the international financial system.

They also argued that, un-

like a few of his predecessors,

he had at times made a point

of standing up to the Govern-

ment which appointed him,

when he believed that it was

going off course.

27-28 In the meantime, Sig.

Cossiga, as president of the

Council, will seek to close the

gap between the UK and her

EEC partners.

The banks generally be-

lieved that Mr. Aydinoglu had

developed a clear understand-

ing of the problems of Turkey

and the realities of the international financial system.

They also argued that, un-

like a few of his predecessors,

he had at times made a point

of standing up to the Govern-

ment which appointed him,

when he believed that it was

going off course.

27-28 In the meantime, Sig.

Cossiga, as president of the

Council, will seek to close the

gap between the UK and her

EEC partners.

The banks generally be-

lieved that Mr. Aydinoglu had

developed a clear understand-

ing of the problems of Turkey

and the realities of the international financial system.

They also argued that, un-

like a few of his predecessors,

he had at times made a point

of standing up to the Govern-

ment which appointed him,

when he believed that it was

going off course.

27-28 In the meantime, Sig.

Cossiga, as president of the

Council, will seek to close the

gap between the UK and her

EEC partners.

The banks generally be-

lieved that Mr. Aydinoglu had

developed a clear understand-

ing of the problems of Turkey

and the realities of the international financial system.

They also argued that, un-

like a few of his predecessors,

he had at times made a point

of standing up to the Govern-

ment which appointed him,

when he believed that it was

going off course.

27-28 In the meantime, Sig.

Cossiga, as president of the

Council, will seek to close the

gap between the UK and her

EEC partners.

The banks generally be-

lieved that Mr. Aydinoglu had

developed a clear understand-

ing of the problems of Turkey

and the realities of the international financial system.

They also argued that, un-

like a few of his predecessors,

he had at times made a point

of standing up to the Govern-

ment which appointed him,

when he believed that it was

going off course.

27-28 In the meantime, Sig.

Cossiga, as president of the

Council, will seek to close the

gap between the UK and her

EEC partners.

The banks generally be-

lieved that Mr. Aydinoglu had

developed a clear understand-

ing of the problems of Turkey

and the realities of the international financial system.

They also argued that, un-

like a few of his predecessors,

he had at times made a point

of standing up to the Govern-

ment which appointed him,

when he believed that it was

going off course.

27-28 In the meantime, Sig.

Cossiga, as president of the

Council, will seek to close the

gap between the UK and her

EEC partners.

The banks generally be-

lieved that Mr. Aydinoglu had

developed a clear understand-

ing of the problems of Turkey

and the realities of the international financial system.

They also argued that, un-

like a few of his predecessors,

he had at times made a point

Financial Times Wednesday April 16 1980

3

Group

Big rise in Italian trade deficit

By Paul Betts in Rome

THE DRAMATIC worsening in Italy's trade balance was confirmed yesterday by official figures showing a £2,300m (£1,225m) trade deficit during the first two months of this year, more than half 1979's overall trade deficit of £1,725m (£1,235m) of 1979.

According to provisional figures from ISTAT, the national statistical bureau, Italy had a trade deficit of £1,580m in February compared to a surplus of £344.5m during the same month the previous year. In January, the trade deficit totalled £1,124m compared to a deficit of £326.5m in January 1979.

The sharp deterioration in the trade balance is largely due to the substantial rise in the cost of raw material imports, particularly oil, which cost Italy £2,028m during the first two months of this year.

At this stage, Italy's annual oil bill is expected to increase to about £14,000m this year compared to about £8,000m last year. The increase in the oil bill is due, not only to higher OPEC prices but also to the recent strengthening of the U.S. dollar against the lira.

The latest trade figures are further evidence of the growing difficulties facing the Italian economy, as well as an indication of declining Italian export competitiveness.

The largest surplus was recorded by the textile and clothing industry with a surplus of £1,289.5m during the first two months of this year, followed by engineering products with a surplus of £593.5m.

China's newly-appointed Communist party secretary-general, Hu Yaobang, attacked the Soviet Communist party yesterday at the start of talks with the visiting Italian Communist leader, Sig. Enrico Berlinguer. He told reporters that the Chinese party resolutely opposed "that party which under the banner of Communism interferes in the internal affairs of other countries."

He was appointed secretary-general only six weeks ago, praised Sig. Berlinguer as "an outstanding fighter of the international Communist movement."

WEST GERMANY seems at first sight to have changed its alliance role on the Afghanistan and Iran crises from that of cautious counsellor to European activist on behalf of United States policy.

The Bonn Government is not only actively preparing to implement sanctions against Iran as the U.S. desires. It is taking the lead in urging its European Community partners to do likewise, preferably through a decision by the Foreign Ministers of the nine member states early next week. Simultaneously, the Government has made clear that it will shortly recommend to its national Olympic committee that West German athletes should not take part in the Moscow Games, because of the continued Soviet occupation of Afghanistan.

What is responsible for this apparent change in Bonn's position? It is clear that the

course now being followed is full of risks for West German policy in West and East. On both the sanctions and Olympic boycott issues the West Germans are moving beyond the known position of France, close co-operation with whom has long been an axiom of Bonn's foreign policy.

Curiously, the West Germans feel that on sanctions they may also prove to be out of step with Britain, which has constantly expressed support for President Jimmy Carter, but has not sold what practical steps it plans.

At the Chequers meeting late last month between Chancellor Helmut Schmidt and Mrs. Margaret Thatcher, the UK Prime Minister, the West Germans sensed a cooling in British enthusiasm for the way the U.S. Administration was handling the double crisis in the Middle East. They now wonder how far Britain may participate in trade and other

economic measures against Iran.

As for relations with the East, Mr. Vladimir Semyonov, the Soviet ambassador to Bonn, has noted cautiously that a West German Olympic boycott would stick in the minds of the Soviet people and that this would "play a role in politics." The Bonn political opposition has promptly condemned the comment as interference in West German internal affairs.

For the ruling Social Democrat (SPD) and Free Democrat (FDP) parties, it raises the spectre of worsening relations not only with Moscow, but with the rest of Eastern Europe and East Germany above all. It is a bitter pill indeed for those who have struggled for more than a decade of office to improve ties with the East under the banner of Ostpolitik.

Efforts continue to cement those ties, as East-West German talks at the Hanover industrial fair this week bear witness. But both sides know that improving

bilateral relations cannot survive if the superpower relationship deteriorates, as it is now rapidly doing.

The truth is that Bonn has not switched its position suddenly from lack of support for the U.S. to one of uncritical solidarity, but that the options for a diplomatic solution to both the hostages and Afghanistan issues have been gradually removed.

The alliance with Washington was itself never in question because both Chancellor Helmut Schmidt and Herr Hans-Dietrich Genscher, the Foreign Minister, know that, without it, there can be no security for West Germany and West Berlin, and hence no basis for an alternative policy.

This has not always been appreciated fully by everyone in Herr Schmidt's own SPD, and the Government has often been highly critical of U.S. foreign policy strategy (or lack of it). But of all the European allies, West Germany probably has the most highly developed sense of vulnerability and the greatest reliance on the U.S. connection.

Bonn had greatly hoped that diplomacy could find an answer to both the Iranian and Afghanistan crises. It has grave doubts whether economic sanctions and an Olympic boycott will bring the desired results. But it understands why the U.S. feels it must act as it has done, and sees grave dangers for Europe in failing to support Washington's call.

Quite apart from the wider question of mutual solidarity, it is expected that if Iran's main trading partners do not agree to sanctions, the U.S. will quickly impose a naval blockade. This would have a similar economic impact but increase the dangers of wider conflict in the area. Hence Bonn's desire for quick support for sanctions in the EEC and beyond.

It would be hard to over-

estimate the disappointment in Bonn over the course of Soviet policy in the past few months. Not only does the Chancellor's office see no sign that the Soviet Union wants a face-saving device to enable it to withdraw from Afghanistan. It is felt that Moscow is preserving its options for a military intervention across the border into Iran.

Herr Schmidt's recent letter to Mr. Leonid Brezhnev, the Soviet President, on responsibility for world peace received an answer which one aide described as a piece of propaganda which the Chancellor can find any day of the week in Pravda. No clear explanation for this is seen, unless it be that the Soviet military is exerting ever greater pressure in Moscow. The upshot is to cause the West Germans to stress their membership of the Atlantic alliance, whatever other consequences this may entail.

Herr Schmidt: alliance never in question

Karamanlis expected to make a bid for Greek presidency

By N. J. MICHAELSON in ATHENS

POLITICAL FEVER is gaining momentum in Greece as the date for presidential elections draws closer.

Prime Minister Constantine Karamanlis has still not declared officially whether he wants to step up to the presidency, which becomes vacant when the five-year term of President Constantine Tsatsos ends on June 20. But it is commonly accepted that, at 73, he is unlikely to pass up the opportunity. He is expected to announce his decision at a Cabinet meeting on Friday.

After restoring and consolidating democracy in Greece after the seven years of military dictatorship, and leading the country to the threshold of the European Community, Mr. Karamanlis appears to be losing touch with the volatile Greeks. They are disgruntled with many of his policies.

Should he decide to announce his candidacy, he will be relinquishing the premiership without having solved the country's external problems—the disputes with Turkey over Cyprus and the Aegean, and the interrelated problem of Greece's bid to return to NATO's military structure.

Mr. Karamanlis, indeed, could have problems getting elected to

the presidency. The New Democracy commands 174 of the 300 seats in Parliament, 26 votes short of the 200 required for election on the first or second ballot.

Mr. Andreas Papandreou, leader of the Panhellenic Socialist Movement, which has 93 seats, claims the present Parliament no longer represents the composition of the country's political forces and has said his party will boycott the presidential elections.

The Moscow-orientated Greek Communist party, with 11 seats, will not vote for Mr. Karamanlis. But it is generally agreed that he could easily obtain the 180 votes required in a third ballot, with help from independents and members of the five smaller parties. These latter would not stand to gain by precipitating an early general election, which would follow the failure to elect a President on the third ballot.

The departure of Mr. Karamanlis from the premiership is not expected to affect foreign policy because the New Democracy party remains in power until November 1981.

Whoever takes the helm of the ruling New Democracy party will have to tackle these complex and sensitive issues and also domestic economic difficulties, not least that of inflation which this year is again expected to exceed 20 per cent (it reached 24.5 per cent in 1979) and a dangerously widening balance of payments deficit. He will also have to hold together a party, which like most Greek parties, depends on its founder.

Mr. Karamanlis, indeed, could have problems getting elected to

the presidency. The New Democracy commands 174 of the 300 seats in Parliament, 26 votes short of the 200 required for election on the first or second ballot.

Mr. Andreas Papandreou, leader of the Panhellenic Socialist Movement, which has 93 seats, claims the present Parliament no longer represents the composition of the country's political forces and has said his party will boycott the presidential elections.

The Moscow-orientated Greek Communist party, with 11 seats, will not vote for Mr. Karamanlis. But it is generally agreed that he could easily obtain the 180 votes required in a third ballot, with help from independents and members of the five smaller parties. These latter would not stand to gain by precipitating an early general election, which would follow the failure to elect a President on the third ballot.

The departure of Mr. Karamanlis from the premiership is not expected to affect foreign policy because the New Democracy party remains in power until November 1981.

Whoever takes the helm of the ruling New Democracy party will have to tackle these complex and sensitive issues and also domestic economic difficulties, not least that of inflation which this year is again expected to exceed 20 per cent (it reached 24.5 per cent in 1979) and a dangerously widening balance of payments deficit. He will also have to hold together a party, which like most Greek parties, depends on its founder.

Mr. Karamanlis, indeed, could have problems getting elected to

East bloc seeks talks on energy

By Brigitte Khindaria in Geneva

THE SOVIET UNION and its allies are putting increasing pressure on western nations to call a conference of ministers to discuss the growing energy problems of Europe and North America.

The 34-country United Nations Economic Commission for Europe (ECE) opened its two-week annual session here yesterday against a background of intense bargaining over an East bloc demand that co-operation on energy must be made a pillar of economic détente.

The demand, first made four years ago, is being resisted by Western governments, which do not want to be involved in any energy-sharing or similar schemes with the Soviet Union.

A recent ECE report says the Soviet Union has wasted so many resources, including energy, through mismanagement and outdated production methods, that Eastern bloc nations may face economic crises in coming years.

Another major issue at the session will be preparations for the conference in Madrid next November.

A BINDING international treaty to cover mining of the seabed and to set out the rights of all countries to the sea and its resources could be agreed by the end of August.

That is the view of the U.S. delegates to the Law of the Sea Conference. But other countries preparing for what is intended to be the final negotiating session in Geneva from July 28 to August 29 warn that so early a successful outcome is still only an outside possibility.

However, considerable progress was achieved at the latest session of what has become the latest session of what has become the world's largest diplomatic marathon. The four-week session which ended in New York 10 days ago not only narrowed down the number of unresolved issues but also agreed on a second revision of a negotiating text of a sea treaty.

Mr. Elliott Richardson, chief U.S. representative, says that after six years "it is now distinctly possible" that the work will be completed at the Geneva meeting. However, Mr. Shirley Amersinghe, president of the conference, fears that many countries appear to be waiting until the last moment so as to extort final contentious issues.

The most contentious issue is still how many votes will be necessary to block decisions by the proposed council which will run the International Seabed Authority to oversee the exploitation of the mineral resources on the seabed on behalf of mankind as a whole.

This issue was scarcely addressed in New York, but Mr. Amersinghe warns that if no agreement can be reached on this "then the whole thing collapses like a house of cards."

The developing countries insisted that discussion of voting procedures should be held over until agreement had been reached on other mining issues, such as the financing and taxation of seabed mining and the supranational enterprise which will be in charge of this. These issues are crucial, with developed countries such as the U.S. resisting attempts by the developing world to put them under severe obligations on matters such as the transfer of the technology necessary to exploit the seabed.

At the latest session negotiations dragged on causing even those accustomed to the arcane

ways of the UN to near the end of their tether. But sufficient progress was reached on a range of problems—including mining, marine scientific research and the definition of ocean ridges and the outer limits of continental margins—for it to be agreed that new legal formulae on these should be incorporated into the existing negotiating text.

This is to be done before the Geneva meeting. There, the revised negotiating text must be upgraded into a draft convention. In turn, this must then be adopted, preferably by consensus rather than by voting.

The conference has already agreed on the rules to govern navigation of the world's shipping; on rules over pollution; on the exclusive economic zones of up to 200 miles from the coastline; on the fishing concessions to be given to coastal states; on the non-coastal states.

It is also proposed that states with wide continental shelves should share with others a proportion of revenues from oil and other resources found between 200 and 350 miles from the coast. After 350 miles states have no rights.

Agreement in sight on sea treaty but contentious issues remain

By DAVID TONGE

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.

After constant use, it really proved to be economic and reliable, so we bought a second Nashua copier.

Now Barclays own over a hundred.

“During the year, salesmen from probably every copier company in the country telephoned me for an appointment. I saw them all.”

“I chose Nashua.”

John Stock, Barclays Bank

“Before Barclays buy any office equipment, we make a very careful, in-depth evaluation.

As a result of this evaluation, we decided to buy a single Nashua copier.</

OVERSEAS NEWS

Japanese exports of steel to Tehran to wind down

BY CHARLES SMITH, FAR EAST EDITOR, IN TOKYO

JAPAN'S steel industry, while not contracted to ship 650,000 tons to Iran during the first six months of this year, does not expect to negotiate any further export contracts "for the time being."

Nippon Steel, the industry's largest company, said that talks on exports might be restarted in September. This, however, would leave a gap in the shipment schedule from the middle of the year onwards.

Steel companies deny receiving instructions from the

Japanese Government to suspend exports to Iran. Despite this, the industry's decision not to hold further talks on exports must be seen in the context of the Iran-U.S. crisis: Japan is a major exporter of steel to Iran in normal times.

Exports exceeded 3m tons a year in the last few years before the Iranian revolution, although in the first half of 1979 when the revolution was at its height only 150,000 tons were shipped.

Steel companies deny receiving instructions from the



Zia to meet Gandhi at Zimbabwe celebrations

By David Housego

PRESIDENT ZIA-UL-HAQ of Pakistan and Mrs. Gandhi, the Indian Prime Minister, are expected to have talks on the future of Afghanistan during the celebrations in Salisbury later this week on the independence of Zimbabwe.

It will be the first direct contact between the two leaders and follows a flurry of diplomatic activity in the region to find some way of defusing the crisis in the aftermath of the Russian invasion.

No formal meeting has been arranged but it is being

reached that President Zia had his first discussions with the former Indian Premier, Mr. Morarji Desai, during similar circumstances on the occasion of the funeral in Nairobi, President Kenyatta of Kenya.

It will also be the first occasion that President Zia has left Pakistan since recent rumours of an attempt coup against him. Effectively in charge during his absence will be General Mohammed Iqbal Khan who has just been appointed Chairman of the Joint Chiefs of Staff.

His appointment to this post is seen as a sign of General Zia's continuing strength in the armed forces.

Of the senior commanders, General Iqbal was one of the most critical of the execution of Mr. Bhutto and of the post-

poning of elections. His name was also linked with the recent coup rumours.

Recent diplomatic activity in the region has included a visit to Pakistan by the foreign Indian Foreign Minister Mr. Swaran Singh.

He is said to have pleased the Pakistani regime by assuring it that India wanted to continue diplomatic exchanges in the interests of the working people," Mr. Bhavari writes. In Soviet and East European usage, this means rule by the Communist party.

He notes that this will only be possible after the "final result of the struggles between the opposing class forces" and that the central question of the revolution—who defeats whom?—must be decided in favour of the people.

strong links with the Soviet Union.

The third stage of the revolution will consist of the "transformation of social conditions in the interests of the working people," Mr. Bhavari writes. In Soviet and East European usage,

this means rule by the Communist party.

He notes that this will only be possible after the "final result of the struggles between the opposing class forces" and that the central question of the revolution—who defeats whom?—must be decided in favour of the people.

Anti-Iraq strikes in Lebanon

BY IHSAN MIJAZI IN BEIRUT

LEBANON'S Shi'ite community went on strike yesterday to protest the arrest in Iraq of Imam Mohammed al Bakr al Sadr, the spiritual head of over 6m Iraqi Shi'ites.

Shi'ite militiamen dressed in combat fatigues and carrying Soviet-made AK-47 automatic weapons forced shops in Beirut to close and blocked streets with burning tyres.

A demonstration led by Shi'ite clergymen marched in the predominantly Shi'ite southern suburbs of the Lebanese capital. Demonstrators, including women chanted slogans condemning the Iraqi regime of President Saddam Hussein and bailing Iranian religious leader Ayatollah Ruhollah Khomeini.

The demonstrations came as the tension between Iraq and Iran reached a peak. Shi'ites throughout the Arab world have rallied to the support of Tehran against Baghdad giving the conflict a sectarian tinge.

Imam al Bakr al Sadr was reportedly arrested along with several members of his family by the Iraqi authorities in Baghdad about two weeks ago.

He was implicated in the reported discovery of a secret organisation allegedly linked to Ayatollah Khomeini.

Press speculation here that he has already been executed could not be confirmed. The report emanated from a decision taken by Iraq's revolutionary council imposing the

death sentence on all members of the secret organisation, the self-styled "al-Dawa," or the call.

The state-controlled Press in Baghdad on Monday carried a decree issued by President Hussein absolving runaway members of the group from the death penalty if they give themselves up within two weeks and provide the authorities with information about other members and the organisations activity.

Iraqi newspapers said the group was out to overthrow the Iraqi regime by force. The fact that it is being handled by the ruling Revolutionary Council itself demonstrates the gravity with which the Iraqi authorities view the situation.

Communist sees new uprising

BY LESLIE COLITT IN BERLIN

A PROMINENT Iranian Communist says Iran is now in the second stage of its revolution and will enter the third and final stage after a further struggle has taken place and has been decided "in favour of the people."

Mr Ali Asvari, a member of the Politburo of the Iranian People's (Tudeh) Party, has outlined the goals of the Iranian Communists in a leading Communist periodical published in Czechoslovakia.

Until now, the small Tudeh Party has been reluctant to reveal its aims because of its

strong links with the Soviet Union.

The third stage of the revolution will consist of the "transformation of social conditions in the interests of the working people," Mr. Asvari writes. In Soviet and East European usage,

this means rule by the Communist party.

He notes that this will only be possible after the "final result of the struggles between the opposing class forces" and that the central question of the revolution—who defeats whom?—must be decided in favour of the people.

Malaysia law to curb unions

BY WONG SULONG IN KUALA LUMPUR

THE MALAYSIAN Government and unions are set for confrontation following Parliament's approval, after seven hours of debate, of a sweeping law that will drastically curb the unions' powers.

The first test of strength will be on April 21 when the Malaysian Trade Unions Congress which has 126 affiliates with over 500,000 members, holds a nation-wide picket to protest against the law despite Government warnings that the picket is illegal.

The congress said the new law is "anti-Labour, very harsh and very repressive." Along with opposition parties, it accused the Government of selling out the interests of Malaysian workers to foreign investors.

Under the new law, the authorities can suspend any

union for six months on security grounds, ban union funds from being used for political activities, arrest union members for violating any labour laws, and prohibit unions from challenging Government decisions in court, unless on a point of law.

Rules governing strikes are tightening, only workers directly involved in a dispute involving employees of the Malaysian Airline System (MAS).

Transport workers in Australia refused to service MAS aircraft after the Government arrested more than 20 members of the airline employees' association which had ordered a go-slow in pursuit of a pay claim.

The boycott resulted in an MAS aircraft being grounded for over a month in Sydney.

The Malaysian Government, which through its two-thirds majority in Parliament and its Internal Security Act has virtually unlimited powers at home, felt itself vulnerable to pressure from abroad. The Act is aimed at preventing a repetition of

last year at what it considered interference by foreign unions in a dispute involving employees of the Malaysian Airline System (MAS).

Pakistan's diplomatic priority is for the withdrawal of Russian troops from Afghanistan. In line with the decisions of the conference of Islamic foreign ministers in January, it has severed formal contacts with the Kabul regime, though not broken off diplomatic relations.

Afghanistan was also expelled from the Islamic conference. India is seeing both the withdrawal of Russian troops and an end to foreign interference in Afghanistan's affairs. Of continuing concern to Mrs. Gandhi is to prevent the rearmament of Pakistan under what India regards as an unstable military regime.

To date, Sr. Perez has been found responsible in approving the purchase of 'Sierra Nevada for \$5m more than its real price. Government investigators and Congress, however,

have dodged the prickly issue of prosecuting the ex-President.

Early in March, some seven months after the controversy arose, when Judge Hector

Marcano Battistini decided to

AMERICAN NEWS

U.S. steelworkers vote on pay deal

BY IAN HARGREAVES IN NEW YORK

DISTRICT representatives of around 300,000 steelworkers were yesterday voting on a three-year pay contract, the terms of which appear to be year, 20 cents in the second and 15 cents in the final year. It was not possible to judge the value of the offer in percentage terms or to relate it to the maximum three-year increase of 31.3 per cent permitted under the Government's voluntary wage guidelines.

Mr. Joseph Odorich, vice-president of the United Steelworkers Union, who has been leading the talks for the union side because of the illness of Mr. Lloyd McBride, the union president, told regional officials that the proposed contract was the best in the union's history.

Few details were immediately available, but the contract apparently calls for hourly increases of 25 cents in the first

year, 20 cents in the second and 15 cents in the final year. It was not possible to judge the value of the offer in percentage terms or to relate it to the maximum three-year increase of 31.3 per cent permitted under the Government's voluntary wage guidelines.

It did appear, however, that the union had honoured its pledge to avoid stepping up cost pressures on a struggling industry by not insisting upon any improvement in the cost of living formula.

The United Automobile Workers Union won such an improvement last summer and it had been expected that the steelworkers, traditional rivals with the car workers as the country's best paid industrial workers, would seek a similar deal.

The problems of the steel industry were underlined yesterday when the American Iron and Steel Institute reported that employment in the industry in January sank to just over 431,000—its lowest level since late 1973.

The steel union has, however, won at least a substantial part of its claim for improvements in its members' retirement pay, probably as a trade-off over cost of living increases.

Another important point still unresolved is whether the industry's radical six-year-old experimental negotiating agreement, which guarantees there will be no national strike over pay contract bargaining in return for the cost of living component of the contract, will continue.

Campaigning Manley 'fired on'

BY CANUTE JAMES IN KINGSTON

MR. MICHAEL MANLEY, the Jamaican Prime Minister, said yesterday that gunmen had fired shots at him while he and a 500-strong delegation from his People's National Party strolled through the streets.

His charge came as public opinion polls showed that the Opposition Jamaican Labour Party (JLP) is leading the PNP by about 10 per cent in popular support. No date has yet been set for a general election but

Mr. Manley said two months ago that elections could be held by October, by which time he had expected that a bipartisan electoral reform committee would have completed its work on controlling fraudulent voting.

The committee said, however,

that it could not complete its

programme before December, implying the elections could not be held until next year. Following suggestions by the JLP leader, Mr. Edward Seaga, to the reform process, the Prime Minister has asked the committee to make efforts for an early vote and it appears that the elections will be possible during the summer.

The 10 per cent advantage in popular support which the polls show for the JLP indicates that the Opposition party has been dramatically increasing its lead.

The PNP's platform has seen increased agricultural production, increased exports and further austerity such as a reduction by about 20 per cent in the island's food imports.

Part of this economic strategy has been the attempt to

reschedule as much as possible the payments on the island's \$1.5bn of foreign debt. In this way, the PNP, says, the island can be free of the conditions which the IMF sets when it grants its loans.

the lower house. The elections were announced by Mr. Manley so that the people would decide on what economic strategy the Government should follow and whether the International Monetary Fund should have a role in the island's economic life.

The ruling party, in keeping with its recent decision to terminate all negotiations with the IMF for foreign exchange support, has been advocating an economic policy based on alternative sources of funding.

The PNP's platform has seen increased agricultural production, increased exports and further austerity such as a reduction by about 20 per cent in the island's food imports.

It is suggested that together they could take a stake of about 30 per cent in a new

undertaking as well as providing the 90 per cent State guarantee for the Norwegian partners' investment.

This guarantee against possible losses as a result of political upheavals is granted to approved investment in developing countries. Since current allocations for this purpose are almost exhausted, a final decision to go ahead with the Jamaican project would probably have to be submitted to the Norwegian Storting ("parliament").

Because of Jamaica's difficulties in raising foreign finance, it is suggested that together with the IMF, Norway would probably have to help finance Jamaica Bauxite's stake in

per cent Norwegian State guarantee—by three Norwegian aluminium-producing concerns which could become important customers for the oxide, the raw material for aluminium production. The three concerns who were represented on the delegation are Ardal og Lunnad Verk (100 per cent State owned), Norsk Hydro (52 per cent State owned) and Elkem-Spigerverket.

An official Norwegian delegation which has studied the scheme, has recommended participation—under a 90

per cent per year oxide plant, to be created by doubling capacity at an existing facility. Jamaica Bauxite Mining—a Jamaican State-owned company—would have a stake of just under 20 per cent while Alcoa, which owns 94 per cent of the existing plant, would hold 51 per cent of the new one.

Because of Jamaica's difficulties in raising foreign finance, it is suggested that together with the IMF, Norway would probably have to help finance Jamaica Bauxite's stake in

Norway may finance bauxite project

BY PAY GJESTER IN OSLO

NORWAY MAY help finance a \$300m Jamaican Government plan to expand output of aluminium oxide, made by processing bauxite from the island's own mines.

The Norwegian Government announced this week that it would shortly begin negotiations about the project with the Jamaican authorities.

Recent diplomatic activity in the region has included a visit to Pakistan by the foreign Indian Foreign Minister Mr. Swaran Singh.

He is said to have pleased the Pakistani regime by assuring it that India wanted to continue diplomatic exchanges in the interests of the working people.

Recent efforts by the Cuban Foreign Minister, Mr. Indro Malmierca, to mediate between Afghanistan and Pakistan met with no success.

Though little of substance is likely to follow from talks between President Zia and Mrs. Gandhi, Pakistan is leaning closer to the Indian view that the states of the region must consult to prevent the conflict spreading.

Pakistan's diplomatic priority is for the withdrawal of Russian troops from Afghanistan. In line with the decisions of the conference of Islamic foreign ministers in January, it has severed formal contacts with the Kabul regime, though not broken off diplomatic relations.

Afghanistan was also expelled from the Islamic conference. India is seeing both the withdrawal of Russian troops and an end to foreign interference in Afghanistan's affairs.

Of continuing concern to Mrs. Gandhi is to prevent the rearmament of Pakistan under what India regards as an unstable military regime.

To date, Sr. Perez has been found responsible in approving the purchase of 'Sierra Nevada for \$5m more than its real price. Government investigators and Congress, however,

have dodged the prickly issue of prosecuting the ex-President.

Early in March, some seven months after the controversy arose, when Judge Hector

Marcano Battistini decided to

have dodged the prickly issue of prosecuting the ex-President.

Early in March, some seven months after the controversy arose, when Judge Hector

Marcano Battistini decided to

have dodged the prickly issue of prosecuting the ex-President.

Early in March, some seven months after the controversy arose, when Judge Hector

Marcano Battistini decided to

have dodged the prickly issue of prosecuting the ex-President.

Early in March, some seven months after the controversy arose, when Judge Hector

Marcano Battistini decided to

have dodged the prickly issue of prosecuting the ex-President.

Early in March, some seven months after the controversy arose, when Judge Hector

Marcano Battistini

W. Germany and China sign raw materials pact

BY ROGER BOYES IN BONN

WEST GERMANY and China are intensifying their joint efforts to explore, develop and eventually exploit important Chinese mineral reserves and offshore oil deposits.

The two countries yesterday signed an agreement which provides for the financing of teams of German and Chinese geological experts to investigate the raw material potential in China.

The co-operation is seen to be of great long-term significance by the West Germans, principally because it would lessen Bonn's dependence on raw material deliveries from such politically vulnerable areas as southern Africa. At the same time, it is clear that German companies would stand strong chances of winning contracts for the exploitation and marketing of raw materials should preliminary exploration prove successful.

The German geological effort is continued by the Federal Office for Geosciences and raw materials, which is concerned with two principal projects. These are the exploration of the metallic minerals of cobalt and tantalum deposits in the province of Hunan and of offshore oil deposits in the East China Sea. China appears to have shown unusually high-level interest in the co-operation, although it is still at an early stage. The original framework agreement was signed last year by Mr. Fang Yi, Chinese Deputy Premier, and provides for German know-how in exchange for the eventual delivery of some of the minerals involved.

China's interest in exploiting offshore oil reserves has already resulted indirectly in business for W. Germany. Mannesmann Demag, for example, has won a DM 440m contract for the supply and construction of a continuous steel rolling mill.

Some W. German companies — are already supplying China with hydraulic shovels but the main focus so far has been on coal mining. China produces over 600m tonnes of coal a year.

The Chinese have also recently made clear that they would welcome increased credit-financed trade or joint ventures with W. Germany in the near future.

Reuter adds from Peking: A U.S. delegation has arrived here for an initial round of formal negotiations to establish a civil aviation agreement with China.

Mr. B. Boyce Hight, U.S. Deputy Assistant Secretary of State for Transport and Communications, said it was hoped the two sides would at least exchange drafts of agreement.

• A mission of British consultants accompanied by the Duke of Gloucester is to visit China from April 21 to 30 at the invitation of the Chinese State Capital Construction Commission (SCCC).

U.S. judge dismisses TV dumping charges

BY STEWART FLEMING IN NEW YORK

A FEDERAL judge in Philadelphia has dismissed most dumping charges which U.S. electrical goods manufacturers Zenith Radio and National Union Electric (a subsidiary of Electrolux) have brought against Japanese manufacturers.

The decision is a setback for the U.S. producers who have alleged that seven Japanese electronics concerns have conspired to put U.S. electronics companies out of business.

The U.S. television industry has been complaining for several years that the surge in Japanese penetration of the U.S. market has been accompanied by dumping of Japanese manufactured sets. Dumping involves exporting to a foreign market and selling at less than "fair value," that is, below production costs or the prices at

Ford import licences suspended by Spain

By Our Madrid Correspondent

THE SPANISH Trade Ministry has decided to temporarily suspend import licences for two types of Ford saloon car — the Granada and Taurus models — following allegations that Ford is selling the cars in Spain at well below market prices.

The Ministry reached its decision over the weekend after a joint protest by local car manufacturers. They fear the Government's earlier decision to allow Ford to import 15,000 units of the Taurus model this year and to sell them in Spain at extremely low prices, will have a direct negative impact on the sales of locally produced saloon cars.

However, in January, when the Government agreed to allow Ford to import 4,000 cars of the Granada model, which were also to be sold at below market prices, local manufacturers were slow to react. The small number of cars involved and the fact that the Granada only really competed with other imported cars apparently made the local industry feel that a formal protest ... was ... not ... then necessary.

Underpinning the controversy is a series of complicated decisions made by the Administration. Ford originally requested to import the two models late last year, to take advantage of liberalisation measures now being introduced in the car industry with a view to Spain's future membership of the EEC. However, as these measures were not then in force, the Trade Ministry stipulated that both the Granada and the Taurus cars would have to be sold in Spain at prices that were 2.3 times more than their original cif prices in West Germany, where the two cars are produced.

In the case of the Granada, whose market price in West Germany is about Pesetas 900,000 (£5,275), this stipulation suggested that the cost of the car is actually selling for Pesetas 1,080m (£6,870). Similarly the selling price of the Taurus model agreed to in Spain is almost identical to the West German market price.

The reason for the low figures is that, in both cases, Ford declared that the cif prices paid in West Germany were about half the market prices.

However, a question mark that remains in the minds of local manufacturers is why the Spanish Ministry of Trade accepted the low figures when the market prices of the cars in West Germany were available to officials.

which the same product is sold in the producers' domestic market.

U.S. manufacturers have failed, however, to successfully enlist the support of the U.S. Government, and indeed have complained bitterly about the reluctance of the authorities to pursue anti-dumping charges against Japanese producers of TV sets.

The reason for the low figures is that, in both cases, Ford declared that the cif prices paid in West Germany were about half the market prices.

However, a question mark that remains in the minds of local manufacturers is why the Spanish Ministry of Trade accepted the low figures when the market prices of the cars in West Germany were available to officials.

SUCCESS REPORT ON MULTI-OWNERSHIP THE HOLIDAY/INVESTMENT TRIUMPH OF THE 20th CENTURY

FIRST AND FOREMOST —

Multi-Ownership & Hotels Ltd. were the innovators in the UK of this new concept of Property investment, combined with inflation-proof holidays for ever. Investment at prices that most people could afford.

SCOTLAND Loch Rannoch Estate


Our Multi-million pound development situated in the heart of the Scottish Highlands in the 250 acre grounds of our Egon Ronay & Ashley Courtney recommended Hotel, is now very well established. 45 Lodges are built and 16 under construction all with private balconies overlooking beautiful Loch Rannoch. Sleeping 2-8, our larger lodges cost us £90,000 to build and furnish to the ultimate in luxury. Individual saunas, £7,000 fitted kitchens, electric curtains, dishwashers, ceramic hobs, Nu-Tone food centres, to name a few luxuries.

Hunting, fishing, yachting, boating, horse riding, pony trekking, are just a few of nature's natural pastimes that you can enjoy. Use the excellent hotel facilities — restaurant, cocktail & public bars, launderette etc. A luxury indoor pool is planned for Summer 1980.

WALES Plas Talgarth Estate

21 luxuriously fitted Villas and Bungalows set in 46 acres of superb Welsh countryside in the Snowdonia National Park, only 5 miles from the popular yachting resort of Aberdovey. Existing facilities include: Exquisite Georgian Mansion with first class restaurant, cocktail bar etc., luxurious indoor pool featuring underwater music, solarium, gymnasium, clubhouse and bar, all weather floodlit tennis courts, laundry etc. Many other facilities planned.

9 good reasons why you should find out more about the holiday/investment of your lifetime!



1. You actually own a week or weeks in a luxurious property in two of the finest locations in Great Britain.
2. Every Year — for ever more. NOTE: Over 2,000 weeks sold to 1,200 satisfied customers!
3. You buy at a once only, inflation-proof purchase price.
4. You can use, sell or bequeath, as in any other property.
5. Easy purchase terms can be arranged — 20% deposit, balance over 7 years.
6. Major clearing banks appointed as trustees.
7. Interval International exchange accommodation system provides the possibility to exchange your weeks with 147 opportunities all over the world from USA to Italy, Spain, Israel, etc.
8. Company Advantages — Multi-Ownership provides many advantages for companies, partnerships and organisations.
9. Prices range from only £1,000 to £5,600 per week, depending on type of unit and time of year.

Why not have a holiday in beautiful Loch Rannoch this year, by renting a lodge?

You can sample our wonderful Highland Lodges at first hand. This is possible as several of our owners have instructed us to let their week or weeks for them.

SPECIAL LIMITED OFFERS See for yourself

SCOTLAND — Stay in a luxury hotel suite at Loch Rannoch for only £7.50 per person a night, including breakfast and VAT (2 for the price of one.)

WALES — Stay in a splendid Villa at Plas Talgarth, sleeping up to 6 people, for just £1,000 inc. VAT.

Fill in this coupon, call in to see us, write or telephone — for full information, colour brochures and details of our "See for yourself" special offers.

Please tick as required

Loch Rannoch Plas Talgarth

Please send me your list of weeks and types of lodges available for rental in 1980 together with tariffs.

MULTI-OWNERSHIP & HOTELS LTD.
6 Half Moon St. London W1Y 7RA.
Telephone: 01-629 2731 (24 Hour Service)

NAME _____

ADDRESS _____

Tel. No. _____ FT/3

Rhys David examines a special report on the European textiles industry prepared for the EEC

Automation is key to healthy clothes trade

EUROPE'S clothing industry can survive and compete much more effectively against low cost imports if it is given the necessary support to develop the capital-intensive labour-saving technologies.

This is the conclusion of a special report commissioned by the EEC from Kurt Salmon Associates, management consultants specialising in the textile, clothing and retailing industries.

The report which is an attempt by the EEC to find a second string to its textile policy other than protectionism warns, however, that time is not on Europe's side if it wishes to preserve its apparel industry.

The key problem for the industry in developed countries is the labour intensive nature of garment-making operations, most of which still depend on traditional manufacturing methods also available to developing country producers with much lower wage costs.

The area where technology is needed to make a significant breakthrough is in reducing the amount of non-productive time in apparel manufacturing. Making clothing is largely an assembly operation and the parts do not lend easily to other than human manipulation.

Thus, although the sewing process has benefited from constant technical advance, 80 per cent of the workforce in clothing, according to the report, still spends 90 per cent of its time picking up, positioning, manipulating and removing one or more pieces of fabric around a stitch-making device.

The high cost of developing the radical new approaches likely to be needed is such as to make it unlikely that any apparel or machinery manufacturer will be willing to take the risk.

There are several important reasons, the study suggests, why the developed countries will want to stay in clothing and need to find ways of doing so.

These include the strategic need to be able to clothe the population in the event of war, the threat to jobs in upstream sectors such as textiles, the impact of total import dependence on the balance of payments, and the importance of clothing plays as an employer of women.

Industrialised countries cannot hope to overcome the whole of this cost advantage but, with the use of improved technology, some of the advantage can be eliminated. This, together with other assets which the industry in developed countries has — such as its ability to offer better service, marketing support, and more efficient distribution — can, the study claims, bring Western manufacturers back into competition with Third World suppliers. It warns, however, that technology in itself is not a panacea. The industry in developed countries must also make sure it is competitive in other areas such as fashion, styling and delivery.

The KSA study, organised from the firm's UK offices by two of its British-based consultants, Mr. Stephen Webb and Mr. Stuart Hollander, claims that the weighted annual average cost of each of the 2.7m people

employed in clothing in high wage countries is \$12,000 (£5,500) compared with \$2,000 in developing countries.

Industrialised countries are not to overcome the whole of this cost advantage but, with the use of improved technology, some of the advantage can be eliminated. This, together with other assets which the industry in developed countries has — such as its ability to offer better service, marketing support, and more efficient distribution — can, the study claims, bring Western manufacturers back into competition with Third World suppliers. It warns, however, that technology in itself is not a panacea. The industry in developed countries must also make sure it is competitive in other areas such as fashion, styling and delivery.

The area where technology is needed to make a significant breakthrough is in reducing the amount of non-productive time in apparel manufacturing. Making clothing is largely an assembly operation and the parts do not lend easily to other than human manipulation.

Thus, although the sewing process has benefited from constant technical advance, 80 per cent of the workforce in clothing, according to the report, still spends 90 per cent of its time picking up, positioning, manipulating and removing one or more pieces of fabric around a stitch-making device.

The high cost of developing the radical new approaches likely to be needed is such as to make it unlikely that any apparel or machinery manufacturer will be willing to take the risk.

There are several important reasons, the study suggests, why the developed countries will want to stay in clothing and need to find ways of doing so.

These include the strategic need to be able to clothe the population in the event of war, the threat to jobs in upstream sectors such as textiles, the impact of total import dependence on the balance of payments, and the importance of clothing plays as an employer of women.

European association of garment producers is an examination of ways in which clothing manufacture could move forward technically, based on studies by manufacturers and research institutes in the UK, the U.S., Japan, West Germany, Italy, Sweden and France.

The report points out, however, that lack of confidence is a significant factor in discouraging investment within the industry and partly for this reason it urges the EEC to offer a firm lead in implementation of the recommendations. The EEC is urged to publish the study in full, to appoint a steering group and working party to organise symposia, and to determine a budget for assisting the development of apparel manufacturing technology. With action along the lines suggested new technology could within 10 years begin to reverse the decline of the industry.

The overall conclusion drawn by the authors is that technology in existence or at various stages of development can improve the corporate performance of companies in the cloth-

ing industry and enable products to be manufactured at more competitive prices. The scale of investment required — much of it likely to depend on State funds — will tend to the creation of much bigger, more capital intensive clothing enterprises.

The report points out, however, that lack of confidence is a significant factor in discouraging investment within the industry and partly for this reason it urges the EEC to offer a firm lead in implementation of the recommendations. The EEC is urged to publish the study in full, to appoint a steering group and working party to organise symposia, and to determine a budget for assisting the development of apparel manufacturing technology. With action along the lines suggested new technology could within 10 years begin to reverse the decline of the industry.

The 1980s: The Decade for Technology? A study of the state of the art of Assembly of Apparel Products prepared for the EEC Commission. Kurt Salmon Associates, 119 High Street, Eton, Windsor, Berks. SL4 5AN.

4.83bn in 1978, while Bulgaria's Soviet trade increased 8 per cent to Roubles 4.25bn, a 2 per cent increase over the 1978 total of Roubles 4.1bn.

Soviet trade with Rumania, which is less developed than trade with any of the other East European trading partners, totalled Roubles 6.49bn in 1979, an 8 per cent increase over the 1978 total of Roubles 6.14bn while Poland's trade with the Soviet Union increased 7 per cent to Roubles 8.13bn, a 6 per cent increase over the 1978 value of trade in 1978, which was Roubles 7.56bn in 1978.

Cuba's trade with the Soviet Union, which is supported by the Soviets for Cuban sugar and a protected rate for Soviet oil, amounted to Roubles 4.25bn, a 2 per cent increase over the 1978 total of Roubles 4.1bn.

East Germany remained the Soviet Union's largest trading partner in Comecon and its biggest trading partner overall, with two-way trade totalling Roubles 8.13bn, a 6 per cent increase over the 1978 value of trade in 1978, which was Roubles 7.69bn.

Hungary's trade with the Soviet Union increased by almost 7 per cent in 1979 to Roubles 5.15bn from Roubles

7.72m from Roubles 7.43m.

Decline in Comecon partners' share of Soviet trade

BY DAVID SATTER IN MOSCOW

THE SOVIET UNION's trade with its Comecon partners increased by 6.5 per cent in last year but Comecon's share of Soviet foreign trade declined as trade with the West rose on the strength of higher prices for Soviet gas and oil.

The Soviet Union's trade with Comecon totalled Roubles 41.7bn (£28.8bn) in 1979 against Roubles 39.1bn in 1978. Czechoslovakia and Poland showed the biggest increases in trade and Cuba the smallest.

Czechoslovakia's share of total Comecon trade amounted to Roubles 1.76bn last year. Trade with individual Comecon partners was generally fairly well balanced with the exception of Mongolia and Vietnam both of which ran deficits with the Soviet Union.

Czechoslovakia's trade with the Soviet Union's largest trading partner in Comecon and its biggest trading partner overall, with two-way trade totalling Roubles 8.13bn while Poland's trade with the Soviet Union increased 7 per cent to Roubles 8.13bn in 1978, which was Roubles 7.69bn in 1978.

Cuba's trade with the Soviet Union, which is supported by the Soviets for Cuban sugar and a protected rate for Soviet oil, amounted to Roubles 4.25bn, a 2 per cent increase over the 1978 total of Roubles 4.1bn.

East Germany remained the Soviet Union's largest trading partner in Comecon and its biggest trading partner overall, with two-way trade totalling Roubles 8.13bn, a 6 per cent increase over the 1978 value of trade in 1978, which was Roubles 7.69bn.

Hungary's trade with the Soviet Union increased by almost 7 per cent in 1979 to Roubles 5.15bn from Roubles

7.72m from Roubles 7.43m.

Houston, Las Vegas, Los Angeles, San Antonio, Mexico City...

We're fast, we're daily. We're Braniff.

At Braniff, one of the things we're doing to be your airline is making many places in America easier to get to from Europe.

UK NEWS

Powerful sweetener sought from microbe

By David Fishlock, Science Editor

TATE AND LYLE scientists and Kent University genetic engineers are attempting to induce a microbe to create a powerful natural sweetener.

The sweetener, Talin, is a protein harvested from berries growing wild in rain forests of West African countries, including Ghana and Liberia.

The berries are being processed by scientists, in a pilot plant at Reading, to extract a white crystalline powder 3,000 times sweeter than sugar.

Talin, a natural product, has been approved for sale in Japan. It may be approved by the British Government "within the next two years," Tate and Lyle said.

But the company has been unsuccessful in cultivating the fruit—about the size of a tomato and bright red when ripe—in West Africa and elsewhere.

Its venture with Kent University, backed by a £90,000 Wolfson Foundation grant, is an attempt to bring the process into the factory through biotechnology.

The idea is to transfer the ability to make thaumatin, the sweet protein extracted from the berry, to a micro-organism such as yeast by genetic engineering, said Dr. Renton Righelato, group research director. The microbe would then be cultivated in a fermenter.

Another route would be to transfer the ability to synthesize thaumatin to a more readily cultivated plant. Dr. Righelato believes this will prove more difficult.

His collaborator in attempts to modify a microbe as manufacturing agent is Prof. Ken Stacey, director of the Biological Laboratory, Kent University.

ABBEY NATIONAL 1979

More U.S. Concorde flights planned

By MICHAEL DONNE, AEROSPACE CORRESPONDENT

BRITISH AIRWAYS plans to increase the number of Concorde flights between London (Heathrow), New York and Washington this summer.

This follows the decision by Braniff International, Texas-based airline, to end its Concorde agreement with British Airways and Air France from June 1.

Under that agreement Braniff took over BA and Air France Concorde six times a week at Washington, and flew them subsonically to Dallas/Fort Worth and back.

Braniff has dropped the agreement because of soaring fuel costs—124 per cent since the arrangement started in January last year.

Braniff did not share in the transatlantic operation of Concorde, and gained the benefit of only those passengers wanting to start or end their journeys in Texas.

Its load factors—the percentage of seats occupied—were low as a result while British Airways and Air France enjoyed load factors of about 60 per cent out of Washington. Even at those levels the Washington traffic has not been enough to make profits.

British Airways says that on the London-New York route the aircraft is making profits, with 12 flights each way every week at load factors of over 55 per cent.

With the additional Concorde flying time available as a result of the ending of the Braniff agreement, British Airways intends to raise the number of New York flights two each way daily on a date to be fixed.

At the same time, it is studying the possibility of raising the Washington flights from three to four a week each way. Air France is understood to be considering a similar improve-

ment to its Paris-New York and Washington Concorde operations.

Overall, in the 1979-80 financial year which ended on March 31, British Airways is believed to have incurred a loss of about £2m on its total Concorde operations, including the services to Bahrain and Singapore.

The airline has five Concorde, with a sixth due to be handed over this summer. A seventh aircraft is available at British Aerospace's Filton, Bristol, airfield, but it has not yet been decided whether this will also go to BA.

Since Concorde began operations with British Airways in January 1976, it has carried over 275,000 passengers.

Laker seeks routes to Detroit and Baltimore

BY OUR AEROSPACE CORRESPONDENT

LAKER AIRWAYS, which flies the successful Skytrain low fare services to New York and Los Angeles, is seeking two more U.S. destinations, Detroit and Baltimore.

This is in addition to an application for rights to fly to Miami from Gatwick, which is to be considered by the Civil Aviation Authority at a public hearing in London next Wednesday.

Air Europe, another UK independent airline, has also asked for the Gatwick-Miami route.

Laker Airways believes that, with the growing interest being shown by U.S. airlines in flights to the UK, there is an opportunity for more UK operations to the U.S.

It wants its existing licence from Gatwick to New York and Los Angeles to be amended as soon as possible to include Detroit and Baltimore, with rights to fly to those points up to 1990s.

• The Independent Air UK has applied to the CAA for rights to fly between Stansted Airport, Essex, and Paris. The airline was recently denied rights for a limited additional route network from Gatwick to Continental destinations, but believes opportunities exist for scheduled flights from Stansted.

That airports scheduled to expand with the Government's long term policy envisaging its development initially to about 15m passengers a year, and further to 25m or more by the 1990s.

This expansion is still subject to a public planning inquiry, expected to start in autumn, but Air UK believes that there is enough traffic already available to make a service to Paris worthwhile from 1991, next year, using turbo-prop aircraft such as twin-engined Embraer Bandeirantes, or jets such as BA One-Elevens.

Shipyard orders in 1979 show recovery

By WILLIAM HALL, SHIPPING CORRESPONDENT

THE WORLD shipbuilding industry won more new orders in 1979 than at any time since 1974, and there are signs that the worst of the shipbuilding crisis is over.

In its annual report for 1979, Lloyd's Register of Shipping reports that shipowners placed an "unexpected but welcome" 17m gross tons of new orders. This was double the previous year's level of orders.

There was a marked resurgence of ordering by Far Eastern owners.

Lloyd's Register says shipowners ordered batches of ships, a phenomenon not seen for three or four years.

Mr. R. A. Hudspeth, chairman of Lloyd's Register, says in his annual report that "while things are not as critical as they were, the state of the shipbuilding industry remains extremely fragile."

Although the overall capacity of the industry has been reduced, world shipbuilding capacity is still over 30m gross registered tons annually. To help cushion the effects of the recession, the world ship order-book appears to have been "elongated" according to Lloyd's Register.

Under normal circumstances the present order book of 28m gross tons would provide the world's shipyards with work for between a year and 15 months, but it is currently providing work for two years.

Japan won 49.6 per cent of new ship orders last year and increased its market share. Lloyd's Register, however, says that the country which made the biggest impression was South Korea.

Lloyd's Register of Shipping is based in London and is the oldest and biggest ship classification society in the world. It employs about 3,600, of which half are surveyors and technical staff. Last year it contributed £25m to the country's invisible earnings.

BL's Metro project will boost output at Longbridge plant

BY KENNETH GOODING, MOTOR INDUSTRY CORRESPONDENT

BL CARS' expansion plans for the launch of the Mini Metro in October this year should substantially boost efficiency at the Longbridge, Birmingham, plant.

Giving details of the £285m project, the company said yesterday that the introduction of new highly automated production systems at Longbridge, where the Metro will be assembled, should improve output from the current 16 to 17 cars a year per man employed to 20 this year and to 30 by the end of next year.

For example, the parts of the plant which will produce unpainted body shells will employ 400 a shift, whereas a conventional system would have required three times that number and have been totally uneconomic.

By the second quarter of 1981, output of the Metro should reach the planned capacity of 6,500 a week after its Continental European launch.

But Mr. Ray Horrocks, managing director of BL Cars, said the Metro's future was necessarily bound up with the full implementation of the wages and conditions package which is the subject of the current dispute.

"Unless there is a rapid return to work BL Cars will have to think carefully about the future." This did not mean the Metro project would be

Research director to retire early

By Ray Pernam, Scottish Correspondent

THE DIRECTOR of the National Engineering Laboratory at East Kilbride, Lanarkshire, which carries out research and development for the public and private sectors, is to be retired early and his post downgraded as part of Government expenditure cuts.

Mr. Dennis Mallinson, 58, who has been head of the laboratory for six years and was previously director general of the armaments department of the Ministry of Defence, told staff in a circular that he had been under pressure to retire in June rather than in August next year.

His early retirement will enable the Department of Industry, which runs the laboratory, to appoint a new director at the grade and salary of under-secretary, rather than at the present level which is half a grade higher.

The laboratory, which is involved in the structural testing of large welded joints, such as those used in oil platforms and the provision of advice, design, and data services to companies on problems of heat transfer, fluid flow, computer aids to manufacturing, metrology and hydraulic systems, is highly regarded.

In the last 15 years it has changed from being principally an academic research organisation to being more commercially oriented.

A quarter of its running costs are recovered from private contracts, and its work for Government departments is vetted by committees of industrialists to ensure its relevance.

Mr. Mallinson said yesterday that the increase in the laboratory's earnings from industry demonstrated its usefulness to the economy.

Yet the laboratory was being run down as part of spending cuts by the last and the present governments. Staffing had fallen from 960 three years ago to 800 now and was expected to be reduced further to 720 by 1982.

"Inevitably the downgrading of the director's post has been regarded by the staff as a downgrading of the importance of the laboratory in the eyes of the Department of Industry," Mr. Mallinson said.

Disputes insurance plan 'may mean more strikes'

BY DAVID MARSH

THE PROPOSED insurance scheme to cover employers' strikes could lead to more frequent and longer disputes, say two economists writing in Lloyds Bank Review.

But Mr. Brian Chiplin of Nottingham University, and Mr. Neil Doherty of the University of Alberta, Canada, say the scheme outlined by the Confederation of British Industry could reduce the cost of strikes to employers, and might also lead to lower wage settlements.

Such a fund would improve the bargaining stand of employers in negotiations, and against the cost of strikes could lead to lower wage settlements, on the assumption that no strikes took place.

But the fund is likely to increase uncertainty of both parties' bargaining, increasing chances of unfulfilled expectations, which could well mean more and longer strikes.

The authors say union members may have greater expectations than their negotiators, who would be aware of the implications of the employers' anti-strike fund.

These are the reasons why Volvo trucks are more economical.

More than anything the proof of Volvo economy is summed up in independent road tests.

... knocks all economy records into a cocked hat... "Commercial Motor

... surpassed all previous fuel economy figures..." Motor Transport

... excelled on fuel economy, treating the stuff like nasty medicine and swallowing the bare minimum..." Truck Magazine

Let's be honest, there's nothing mysterious about getting good operating economy.

The real answers, like the problems, still lie in the basics: the truck, the driver and the back-up services.

The truck

A truck with a mismatched driveline for instance, can mean a 25% increase in fuel consumption.

That's why we design and manufacture

all major components for our heavy trucks ourselves.

And, because turbocharging reduces fuel consumption by as much as 10%, we introduced it to Volvo engines 25 years ago.

So when you choose Volvo, you'll know you're specifying the right truck.

The driver

Amazingly, incorrect driving techniques can increase fuel consumption by 50%!

Which is why Volvo's rev counters have markings which show the best range for the most thrifty performance.

Just one indication of our total commitment to driver safety, comfort and clear, easy-to-use instrumentation.

The back-up

Back-up is one of the most vital factors influencing operating economy.

41 Volvo truck centres nationwide offer: First class service and maintenance facilities.


Excellent parts availability

Action Volvo 24 hour rescue service. And the Volvo Service Exchange System which not only saves on workshop time and parts stocking but can also mean a 50% saving on the parts themselves.

These are just some of the reasons for Volvo economy. Add them together, then include a Volvo truck's exceptional re-sale value and the total saving is very significant.

VOLVO

The truck other trucks are measured against.



ABBEY NATIONAL

FULL COPIES OF THIS SPEECH, THE ACCOUNTS AND DETAILS OF OUR VARIOUS INVESTMENT SCHEMES CAN BE OBTAINED ON REQUEST FROM THE SECRETARY, ABBEY NATIONAL BUILDING SOCIETY, ABBEY HOUSE, BAKER STREET, LONDON NW1 6XL.

جامعة الملك عبد الله

If you want to get detailed information about a Volvo, ring: ABERDEEN: 0224 622000; BIRMINGHAM: 021 529 0000; CARDIFF: 0222 622000; COVENTRY: 0203 222000; DUBLIN: 01 676 1000; EDINBURGH: 031 555 2222; GLASGOW: 041 881 5551; LIVERPOOL: 051 222 2222; MANCHESTER: 061 222 2222; NEWCASTLE: 091 222 2222; NOTTINGHAM: 0602 222 2222; SHEFFIELD: 0114 222 2222; SOUTHAMPTON: 081 222 2222; WORCESTER: 0527 222 2222; YORK: 0904 222 2222. For further information, contact the Sales Department, ABBEY NATIONAL BUILDING SOCIETY, 100 BAKER STREET, LONDON NW1 6XL. VOLVO TRUCKS (GREAT BRITAIN) LIMITED, IRVINE, SCOTLAND.

Research
lirector
o retire
early

Ray Perman, Scottish
respondent

DIRECTOR of the Re-
sponsibility, Engineering, and
Technology, and Research
and Development, is to be
retired in the next few
months, and his post down-
graded to a director of Government
departments.

Dennis Mallinson, who
was head of the department
for 10 years and was pro-
fessor of Defense, is re-
sponsible for the post. He
is currently the only member of the
Government to be a member of the
House of Commons.

Listening, per head per
week to Radio One rose 6 per
cent in the first quarter of
1979, compared with 1978.

There was a similar rise for
Radio Two and a 5 per cent
increase for Radio Four.

Meanwhile Listening to ILR
was down by 3 per cent, said
the BBC.

Lock suspected
in air-crash

A FAULTY lock in the flight
control system may have caused
last year's fatal air crash in
Shetland. Seventeen people
were killed when a Dan-Air
Hawker Siddeley 748 crashed on
take-off from Sumburgh.

A Department of Trade
investigator told an inquiry in
Aberdeen that the "gusto" part
of the system, which is responsible
for the aircraft's nose downwards,
had jammed, forcing the
aircraft's nose downwards.

Toy jobs to go

EIGHTY WORKERS are to be
made redundant at the Lesney
toy factory in Peterborough,
because of a sharp drop in
profits in the past six months.

Tidal barrier

A TIDAL surge barrier costing
£3.9m, built to protect the
centre of Hull from flooding,
was inaugurated by Mr. Dennis
Matthews, chairman of the
Yorkshire Water Authority.

Transport studies

ROLLS-ROYCE MOTORS and
five other transport companies
have joined with Commercial
Motor Journal to sponsor a
series of awards for transport
studies, which will be worth
£6,000 a year to the winners.

Belvoir inquiry

FORECASTS OF coal demand
had been exaggerated, the
Council for the Protection of
Rural England told the Vale of
Belvoir Inquiry. Any mining in
the area should be on a reduced
scale, it said.

£1.5m Welsh aid

AID for Welsh language education
is to be increased to £1.5m in
1981-82. Mr. Nicholas
Edwards, Secretary of State for
Wales, announced in Caernarfon.

Chain cuts prices

DEBENHAMS is cutting prices
on a wide range of goods at its
79 UK stores, in a campaign to
increase sales.

Flights return

AN OVERTIME ban by 2,500
British Airways ramp workers
and baggage loaders ended at
midnight last night and the airline's
flights were expected to be
normal today. The workers' two-week
dispute, which caused
cancellations to at least 12
European flights a day, was
over-productivity.

BBC has increased radio audience'

Sue Cameron looks at a U.S. chemicals incursion

Big UK companies oppose Dow ethylene plant move

LARGE CHEMICAL companies, including BP Chemicals, Shell Chemical UK and Imperial Chemical Industries, are putting pressure on the Government to stop the U.S. Dow Chemical building a world-scale ethylene plant at Cromarty, north Scotland.

One company says that the Dow plan to build an ethylene plant using ethane gas from the North Sea as a raw material could ruin the British petrochemical industry.

It is believed to have told the Energy Department that other big chemical plants would have to be shut if the Dow project was allowed to go forward.

It is understood that representations are being made to the Department of Industry.

At least one company has told the Government that the Dow plan would effectively enable a U.S. group to use North Sea gas to damage UK companies.

The groups say that the Cromarty plant would enable Dow to sell ethylene, the so-called building block of the chemical industry used to make plastics, solvents and many other products, more cheaply than its British competitors.

There is already sufficient ethylene production capacity in the UK, so that Dow would take away other companies' markets.

The Cromarty plan is dependent on British Gas Corporation and Mobil going ahead with proposals for a new North Sea gas gathering system.

In February Dow applied for permission to build a £150m gas separation plant, underground storage tanks and a terminal at Nigg on Cromarty Firth.

A petrochemical complex, including the ethylene plant, would go up later there.

The Highland Regional Council has put off considering Dow's planning application until June.

UK chemical majors believe the project, including the ethylene plant, is being given a warm welcome by Government departments, and that the project is given strong backing by

Mr. Hamish Gray, MP for Ross and Cromarty and Minister of State at the Energy Department.

One British chemical company admitted yesterday that Dow had "up-staged" its UK counterparts in that they had been forced on the defensive.

It said that the Dow ethylene plant would probably use \$300,000-800,000 tonnes of ethane a year, meaning "no ethane for any other UK chemical plants unless another North Sea pipeline were built as well as the proposed British Gas-Mobil line."

Ethane was a more economic raw material for producing ethylene than naphtha, which is made from oil.

Existing UK plants, as they stand, could probably use

250,000 tonnes a year of ethane. Modified, they could use "significantly more."

The joint BP Chemical and ICI ethylene plant at Wilton, in the North-East, which has just come on stream, could use between 80,000 and 90,000 tonnes of ethane a year.

Dr. Rah Telfer, chairman of ICI petrochemicals division, said yesterday that this plant could use naphtha, propane, butane, and ethane as raw materials. Savings by this flexibility gave ICI and BP Chemicals "strength to withstand threats from U.S. competition."

Dr. Telfer said that though Teesside had the capacity to process over 1m tonnes of liquid petroleum gases a year this amount was not yet available.

Imports of electronic goods rise

BY ELAINE WILLIAMS

IMPORTS of consumer electronic products increased by 5 per cent last year, according to figures published yesterday by the British Radio Equipment Manufacturers' Association.

In spite of higher UK deliveries in the final quarter, British manufacturers' share of total deliveries fell from 41 to 36 per cent.

Colour television deliveries

were 1.9m last year, compared with 1.8m in 1978. Imports increased their share from 19 to 25 per cent. But much of the increase came from smaller television sets, which showed the largest growth.

Small screen sizes represented about 61 per cent of colour television imported deliveries and the small screen market more than doubled—from 175,000 to 360,000 last year.

BREMA says there were indications that not all imports reached the trade last year, so increasing stock levels, while overall consumer sales were lower than in 1978.

Videotape recorders, of which there are no UK makers, continue to show a dramatic increase. Last year's deliveries were 155,000 compared with the previous year's total of 80,000.

BREMA said much of the growth was due to a larger distribution network for this relatively new product. It noted that strong seasonal sales accounted for a larger proportion of the year's sales than is the case with other video products.

increased by more than 13 per cent last year to 800,000 units compared with UK manufactured goods totalling 335,000, which fell from last year's figure of 420,000.

It is thought that Mr. Atkins outlined his plans for restoring local political powers to Northern Ireland. These plans, it is widely assumed, include a blueprint for some kind of assembly which would fall short of Unionist demands for a fully devolved assembly, but which would also not give the Catholic minority a share in power.

The first meeting between Mr. Haughey and Mrs. Thatcher will be at the EEC summit in a couple of weeks. However, it is not expected that there will be time for discussion of Northern Ireland then.

Mr. Haughey will want to see Mrs. Thatcher some time after the summit. A bland statement was issued yesterday after the meeting with Mr. Atkins. It said that in the context of the regular contacts between the two governments the ministers discussed a full range of topics of mutual interest.

Atkins and Haughey hold first meeting

BY JOHN GRIFFITHS

DEMAND FOR commercial vehicles in the UK continued at a high level in March. Sales were 5.09 per cent higher than in March last year, according to the Society of Motor Manufacturers and Traders statistics published yesterday.

New registrations in the first quarter of this year numbered 17,906, 9.02 per cent higher than in the same period of 1979.

Imported vehicles continued to gain ground, although slowly. They accounted for 24.06 per cent of the market in March, compared with 21.20 per cent in March, 1979.

For the first quarter they accounted for 23.81 per cent, compared with 20.57 per cent in the 1979 first quarter.

As with the new car market, there are few signs of the widely-predicted 10 per cent downturn in the UK market this year.

Light car-derived vans fell 8.52 per cent to 23,155 in the quarter. Vans weighing up to 3t tons continued to climb, by 23.63 per cent to 33,131.

Commercial vehicles still in demand

BY JOHN GRIFFITHS

The biggest gain in volume was achieved by Ford, with 13,539 registrations for the quarter compared with 8,437 a year earlier. Japanese imports and Volkswagen also gained ground.

Heavy trucks, weighing more than 3.5 tons, and artics showed slower growth—by 3.2 per cent in the 1979 first quarter—and numbered 13,684.

Ford showed the biggest increase, with registrations increased from 2,726 to 4,271. However, last year's figures reflected the effects of the prolonged strike in the autumn of 1978.

Leyland vehicles' registrations were down from 3,380 to 3,091—1,060 in March compared with 236 in March 1979—but the company has yet to feel the impact of last month's launch of its T45 truck range.

Of the imports, Volvo's registrations increased by 23 per cent during the quarter, numbering 1,001; Mercedes-Benz imports increased by 24.8 per cent, numbering 971.

Agreement near on takeover of Marathon

BY RAY PERMAN, SCOTTISH CORRESPONDENT

OBSTACLES TO the French takeover of the Marathon oil drilling rig construction yard at Clydebank could be cleared by the end of the month.

M. Louis Garrigue, London representative of Union Industrielle et d'Entreprise, said yesterday lawyers were again ready to discuss outstanding issues after a break in talks for consultation.


"We cannot commit ourselves to a date to take over the yard, but we definitely hope to reach agreement within a fortnight," he said.

All of these bonds having been placed, this announcement appears for purposes of record only.

INTERNATIONAL BANK FOR RECONSTRUCTION AND DEVELOPMENT Washington, D.C.

DM 150,000,000
10% Deutsche Mark Bonds of 1980, due 1986

DM 200,000,000
10% Deutsche Mark Bonds of 1980, due 1990



Deutsche Bank
Aktiengesellschaft
also for
Deutsche Bank Berlin
Aktiengesellschaft

Dresdner Bank
Aktiengesellschaft
also for
Bank für Handel und Industrie
Aktiengesellschaft

Commerzbank
Aktiengesellschaft
also for
Berliner Commerzbank
Aktiengesellschaft

Westdeutsche Landesbank
Girozentrale

Baden-Württembergische Bank
Aktiengesellschaft

Benkens Trust GmbH

Bayerische Vereinsbank

Berliner Handels- und Frankfurter Bank

Richard Daus & Co. Bankiers
vormals Hans W. Petersen

Deutsche Girozentrale
— Deutsche Kommunalbank —

Conrad Hinrich Donner

Hamburgische Landesbank
— Girozentrale —

Georg Hauck & Sohn

Bankhaus Hermann Lampe
Kommanditgesellschaft

Landesbank Schleswig-Holstein
Girozentrale

National-Bank
Aktiengesellschaft

Sal. Oppenheim jr. & Cie.

Karl Schmidt Bankgeschäft

Simonbank
Aktiengesellschaft

Vereins- und Westbank
Aktiengesellschaft

Württembergische Kommunale Landesbank
Girozentrale

Allgemeine Deutsche Credit-Anstalt
Badische Kommunale Landesbank
— Girozentrale —
Bayerische Hypotheken- und Wechsel-Bank
Aktiengesellschaft
Joh. Berenberg, Gossler & Co.
Bankhaus Gebrüder Bethmann
Deutsche Bank
Bank für Gemeinwirtschaft
Aktiengesellschaft
Bayerische Landesbank
Girozentrale
Berliner Bank
Aktiengesellschaft
Bremer Landesbank
Deutsche Bank Saer
Aktiengesellschaft
Deutsche Länderbank
Aktiengesellschaft
Hallbaum, Maier & Co. AG
— Landkreditbank —
Hardy & Co. GmbH
von der Heydt-Kersten & Söhne
Landesbank Saar Girozentrale
Merck, Finck & Co.
Norddeutsche Landesbank
Girozentrale
Reuschel & Co.
Schröder, Münchmeyer, Hengst & Co.
J.H. Stein
M.M. Warburg-Brinckmann, Wirtz & Co.

Bankhaus H. Aufhäuser
Bank für Gemeinwirtschaft
Aktiengesellschaft
Bayerische Landesbank
Girozentrale
Berliner Bank
Aktiengesellschaft
Bremer Landesbank
Deutsche Bank Saer
Aktiengesellschaft
Deutsche Länderbank
Aktiengesellschaft
Hallbaum, Maier & Co. AG
— Landkreditbank —
Hardy & Co. GmbH
von der Heydt-Kersten & Söhne
Landesbank Saar Girozentrale
Merck, Finck & Co.
Norddeutsche Landesbank
Girozentrale
Reuschel & Co.
Schröder, Münchmeyer, Hengst & Co.
J.H. Stein
M.M. Warburg-Brinckmann, Wirtz & Co.

We'll answer for your business success

A phone left unanswered could mean a lost opportunity to a professional man.

The Agovox C380 will help you succeed.

RING

01-778 7255

— or send the coupon anytime

Agovox

answering

Agovox Answering 4 Sydenham Road, London SE26 5QY

Please send Agovox literature and phone
number of your local representative.
Name _____
Company (if applicable) _____
Address _____
Phone No. _____

UK NEWS

Bukta drops replica Olympia kits

Financial Times Reporter

SPORTSWEAR manufacturer Bukta, of Stockport, Cheshire, which is producing the official strip for Britain's Olympic competitors, has abandoned plans to sell replica garments to the public because of the controversy surrounding the Moscow Games.

Mr. Christopher Buck, Bukta's sales director, said because of public feeling about the Games the company had written off potential sales worth £200,000.

"We didn't want to be left as piggies-in-the-middle, with retailers complaining either that they couldn't sell the garments on the one hand, or that we hadn't manufactured enough," he said.

Bukta won the order to produce the shorts, vests and track suits for the 370 British competitors and officials last June. The company also bought a licence to use the official Olympic motif on a range of replica garments.

"Our decision not to use the motif simply means that we won't be paying royalties," said Mr. Buck.

"We had been aiming for a turnover of £200,000, but we will be able to make it up elsewhere. We have a super order book at the moment, in complete contrast to the rest of the textile trade."

Tidal barrier

A £3.9m TIDAL surge barrier on the River Hull was officially opened yesterday by Mr. Dennis Matthews, chairman of Yorkshire Water Authority. It will be operated when abnormal tides are forecast, to prevent flood damage in Hull.

Stockholders come out on top

THE CONSTRUCTION and engineering industries face difficulties in obtaining some types of heavy steel after the three-month national strike.

The steel market is confused now, the stoppage has ended. Steel traders and industrial users are reluctant to build up new stocks as the British Steel Corporation fights an uphill battle to win back business.

Mr. Christopher Buck, Bukta's sales director, said because of public feeling about the Games the company had written off potential sales worth £200,000.

"We didn't want to be left as piggies-in-the-middle, with retailers complaining either that they couldn't sell the garments on the one hand, or that we hadn't manufactured enough," he said.

Bukta won the order to produce the shorts, vests and track suits for the 370 British competitors and officials last June. The company also bought a licence to use the official Olympic motif on a range of replica garments.

"Our decision not to use the motif simply means that we won't be paying royalties," said Mr. Buck.

"We had been aiming for a turnover of £200,000, but we will be able to make it up elsewhere. We have a super order book at the moment, in complete contrast to the rest of the textile trade."

likely to abandon those foreign lines until BSC proves that its prices and deliveries can at least match the best service obtainable from foreign companies.

Mr. Cliff Keesler, director of British Steel Service Centres, the stockholding section of BSC, said it was too early to assess the effect of the strike on stockholders, because BSC production since it ended had been interrupted by the Easter holiday, and many BSC customers had closed for that period.

Mr. Ernest Barrett, of Barrett and Sons, Bradford, was confident that stockholders would retain custom gained during the strike, although sales were still too early to pinpoint gains.

Roy Hodson and David Holmes examine the confusion in the steel market after the 13-week national strike

from increased trade during the strike, as BSC had effectively been back at work for only a week.

He expected the stockholding trade to keep its increased market share, however. He felt consumers had benefited from the strike by learning to live with lower stocks.

With high rates of interest and the high cost of keeping large stocks on site, he thought consumers would in future rely more heavily on stockholders.

To hedge against the possibility of further industrial action at BSC, consumers might start to spread their purchases more widely across the market — either between BSC and foreign producers, or between BSC and stockholders, he said.

Mr. Richards believed that once stocks had been replenished, stockholders would be depressed at the moment because steel was in such short supply that it was impossible to build up stocks.

He thought there was a general view among consumers that BSC could no longer be relied upon to maintain stocks. Although the steel strike had been the first for 50 years, he thought steel union militancy could spell further industrial trouble for BSC.

Although his company had always bought only British steel in the past — from both the public and private sectors — he now intended to import some steel, to ensure continuity of supply. "We will no longer be putting all our eggs in one basket."

Stocks were now being sold as soon as they reached the yard, and the company was having particular difficulty

maintain sales at their increased level: "I have always believed that if industry was using the stockholding service properly, it would go beyond 50 per cent of the market."

Stockholders, he thought, should emphasise their value to steel purchasers, particularly by drawing attention to the disparity between the invoice price of steel and the true cost of maintaining large stocks bought direct from the producer.

Mr. Ernest Barrett, of Barrett and Sons, Bradford, was confident that stockholders would retain custom gained during the strike, although sales were still too early to pinpoint gains.

obtaining heavy steel sections and hollow steel.

Once stocks were replenished, however, stockholders would keep the increased market share gained during the strike, and he agreed that 45 per cent of the market was not an unrealistic target for stockholders in general.

Collieries linked by conveyor

NORTH STAFFORDSHIRE'S two largest collieries, Hem Heath and Florence, merged in a £30m project capable of producing more than 2m tonnes of coal a year, were linked in an underground ceremony yesterday by Mrs. Mary Stringer, Lord Mayor of Stoke-on-Trent.

She started Britain's largest cable-belt conveyor, officially opening the Trentham Drift, a two-mile seam-to-surface shaft to raise both collieries' coal. The conveyor is suspended from twin cables, each six miles long.

Design award for Plessey

THE GROUNDSAT military communications equipment made by Plessey Avionics at Ilford, Essex, has won a Design Council award in the engineering products category.

The portable Groundsat can be used in the field to transmit and receive simultaneously on the same radio channel, previously considered impossible because of interference problems.

Budget measures deepen gloom

By David Churchill, Consumer Affairs Correspondent

FOUR OUT of every 10 consumers thought last month's Budget would be bad for the country, according to the latest Financial Times survey of consumer confidence.


But 36 per cent of the 1,000 consumers surveyed were in favour of the Budget measures helping the economy. The remaining 24 per cent thought the Budget's effect would be neutral.

Published today, the survey of consumer response to the Budget shows that men in social groups A, B and C1 (professional and executive workers) viewed the Budget most favourably while C2, D and E (social groups (manual workers) were generally against the Budget measures.

There were also striking regional differences in Budget reaction, with consumers in the South in favour of, and those in Scotland and the North East opposed to the measures.

Pessimism about the Budget led the index of future confidence to fall sharply this month after its recovery in March.

The survey found only 13 per cent of consumers expected conditions to get better, while 50 per cent expected them to get worse. This gave an index of minus 37 per cent, compared with



minus 32 per cent last month.

The six-month index, which reflects consumer confidence in the past half year, remained at minus 38 per cent, its lowest level in the survey's 10-year history.

The main reason for pessimism — cited by 39 per cent of consumers surveyed — was the impact of rising prices. Some 28 per cent gave their belief that the Government was pursuing the wrong policies, as the reason for pessimism.

There was a fall in numbers taking strike action as a reason for pessimism, but more than a fifth of pessimistic consumers felt the trend would get worse.

Of the small number of optimists in the survey, 52 per cent could only give the reason that "things must improve" as the main factor behind their optimism. Just over a third also believed that the Government was pursuing the right policies.

Analysis of the survey shows that the confidence of A, B and C1 women fell sharply by 14 points, but they remain the least pessimistic in spite of concern about the

future, the survey showed a rise in consumers' feeling about their past prosperity. Some 27 per cent of the survey considered themselves better off than a year ago, while 41 per cent considered themselves worse off.

This gave an index of minus 14 per cent, compared with minus 19 per cent in March.

But the decline in future confidence affected the index showing consumer readiness to buy, but large consumer durables, while 36 per cent thought it was a bad time. This gave an index of plus 1 per cent, compared to plus 7 per cent last month and plus 13 per cent in January.

The highest drop among the sub-groups was recorded by A and C1, whose index for buying durables dropped 17 points to plus 13 per cent.

The survey also showed a sharp increase in those consumers expecting unemployment to increase.

The Financial Times survey was carried out between March 27 and April 2 by the British Research Bureau. A sample of 1,047 adults was interviewed.

ANGLOVAAL GROUP

Mining Companies' reports — Quarter ended 31 March 1980

Prieska Copper Mines (Proprietary) Limited

Issued capital 54 000 000 shares of 50 cents each

	Quarter ended 31 March 1980	Quarter ended 31 Dec. 1979	6 months ended 31 March 1980
Operating results			
Orn milled	709 000	781 000	2 216 000
Concentrates produced	25 469	27 832	76 643
Copper	25 627	30 030	76 556
Zinc			
Concentrates despatched	30 450	20 265	76 363
Copper	27 021	29 668	80 273
Zinc			
Financial results	R000	R000	R000
Operating profit	6 128	3 259	15 671
Non-mining income	170	259	705
	6 296	3 518	16 376
Interest paid	250	311	907
	6 046	3 207	15 469
Less: Prior year adjustment	—	—	1 538
Net profit	8 046	3 207	13 931
Loan repayments	47	4 028	4 120
Capital expenditure	1 941	2 048	6 097
	1 968	6 076	10 217
Development	Advanced	8 101	6 636
			19 337
Financial results			
Despatches, which vary from quarter to quarter, are brought to account at their estimated receivable value. Operating profit takes into account adjustments following final price determinations on despatches made during previous quarters.			
Taxation			
No taxation was payable as the Company has an associated loss.			
Capital expenditure			
Outstanding commitments at 31 March 1980 are estimated at R2 042 000 (31 December 1979: R1 874 000).			
General			
Tonnage milled during the quarter was adversely affected by the failure of a rod mill motor. A claim is being lodged with the Company's insurers.			

Hartebeestfontein Gold Mining Co. Ltd.

Issued capital 11 200 000 shares of R1 each

	Quarter ended 31 March 1980	Quarter ended 31 Dec. 1979	6 months ended 31 March 1980
Operating results			
Gold			
Orn milled	717 000	716 000	2 136 000
Gold recovered	6 030 40	6 041 46	24 182 50
Yield	kg/g/t	kg/g/t	kg/g/t
Recovery	11.2	11.2	11.3
Costs	R/milled	R/milled	R/milled
Profit	44.73	42.59	42.59
R/milled	149.48	84.00	87.06
Revenue	R000	R000	R000
Costs	R000	R000	R000
Profit	R000	R000	R000
	107 181	60 310	207 331
Financial results			
Uranium oxide			
Pulp treated	kg	kg	kg
Gold produced	kg	kg	kg
Yield	kg/g/t	kg/g/t	kg/g/t
Recovery	0.14	0.14	0.14
Financial results	R000	R000	R000
Working profit — gold mining	107 181	60 310	207 331
Profit from sales of uranium oxide, pyrite and sulphuric acid	3 389	10 138	23 916
Non-mining income	5 426	3 154	11 257
	115 986	73 802	242 804
Interest paid	244	200	487
	45 840	30 749	88 772
Profit before taxation and State's share of profit			
Taxation and State's share of profit	63 611	42 653	143 246
Profit after taxation and State's share of profit	45 840	30 749	88 772
Dividend			
Interim dividend No. 48 of 300 cents per share, declared in December 1979, was paid in February 1980.			
Capital expenditure			
Outstanding commitments at 31 March 1980 are estimated at R6 315 000 (31 December 1979: R6 670 000).			
State loan levy			
In accordance with the 1980/1 budget proposal, no loan levy will be payable for the current financial year.			

Consolidated Murchison Ltd.

Electricians denounce TUC day of action

BY PAULINE CLARK, LABOUR STAFF

THE ELECTRICIANS' union (EEETPU) yesterday became the first major industrial trade union to advise its members not to take part in the TUC's May 14 "day of protest" against Government economic policies.

Leaders of the union decided at an executive meeting publicly to denounce the planned "Day of Action" as "unwise and untimely".

Although the union has left the ultimate decision on participation to individual members, it issued a strongly worded warning that there was a "serious danger that such action will push us closer to a general strike".

The statement by the 420,000-strong union followed a decision by the Amalgamated Union of Engineering Workers, Britain's

second largest union, to close its offices throughout the country, including its London headquarters, on the "Day of Action". It has already asked its 1,230,000 members to support the TUC call.

The TUC said yesterday it had received a variety of responses from unions to its call for maximum support on May 14. There would be many local events and nine rallies had been organised in London alone.

"There is very widespread support and not much doubt about that."

The EEETPU executive, however, challenged the TUC's whole approach to opposition in Government policy.

Its statement said: "We ask whether this is the appropriate way to conduct ourselves in a

democracy, particularly since in May the voters will have an opportunity in recording their views through the ballot box in the local government elections.

It said: "A resounding defeat for the Tories there would be a far more effective way of showing the feelings of the British people than a day of action."

And the executive asked that if as a result of the Day of Action the Government did not change its course "Will we have more 'Days of Action' until they do?"

It said the action would "further weaken support for the trade unions, not only among the electorate but even among union members as well."

And would not affect the direction of Government policy.

Prior union law pledge

BY OUR LABOUR STAFF

THE GOVERNMENT would take every precaution to keep trade unionists from being jailed for refusing to comply with the provisions of the Employment Bill when it became law, Mr James Prior, Employment Secretary, said yesterday. But he said: "I do not think we should go so far as to write into the legislation an undertaking that no-one will go to prison, because there will be a few people doing their damnest to go to prison."

Speaking at the annual conference in London of the National Federation of Profes-

sional Workers, Mr Prior said the Government would make it as hard for such people to go to jail as it possibly could. There was no need for anyone to be imprisoned if trade unionists sought to obey the law.

He said he feared for the future of parliamentary democracy if an elected government could not fulfil the legislation it passed through Parliament or was fearful of putting it through because it might be abused.

The issue went beyond industrial relations, to the "heart

and root of Parliamentary democracy."

He rejected suggestions from the floor that the removal of the immunities from civil action now enjoyed by trade unionists would expose workers to judge-made law.

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at Hogg Robinson Group

because of the "limitations on co-operation" imposed by the company.

Yesterday, ACAS said that in the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

Steel 'blacking' talks

BY ROBIN REEVES, WELSH CORRESPONDENT

THE BLACKING of lorries which crossed picket lines during the national steel strike and the British Steel Corporation's radical retrenchment plans will be high on the agenda of a national executive meeting of the main steel union, the ISTC, in London today.

Disputes over the loading of lorries which ignored the three-month strike led to fighting at walkouts at Port Talbot and in South Yorkshire just before Easter—only 24 hours after the industry had returned to work.

There remains a strong feeling among many steelworkers that the worst offenders should never be allowed into BSC plants again, and the executive is expected to draw up a national "blacklist".

On BSC's retrenchment, the union will discuss the revised timetable for implementing a further 13,000 redundancies at Welsh steel plants not 30,000 as reported yesterday due to a transmission error, the closure of Consett steelworks in County Durham, and other major demanding proposals.

COMPUTEL AND THE 2900

Computel are one of the leading Telecommunications based Computer Service Bureaux in Europe and second to none in ICL based operations. Our unrivalled expertise and experience in offering a complete range of ICL DME and VME/B based bureau services makes us the natural choice whatever your application.

With five large 2900 series computers housed in our Computer Centre in Berkshire, Computel can offer a comprehensive range of facilities - from highly specialised project and financial planning services, to providing a complete alternative solution to operating an 'in-house' computer.

- Program Development facilities for DME & VME/B
- Financial & Network planning
- Running custom built systems in DME or VME
- Machine Standby & Capacity Overflow
- Facilities Management & Machine Replacement
- Transaction Processing Systems
- Database Management Systems
- Business Systems packages
- Direct Data Entry
- Consultancy
- Training

computel

Computel Limited, Eastern Road, Bracknell, Berkshire, RG12 2UP
Tel: Bracknell (0344) 26767

Engineering workers to seek 60% rise

BY OUR LABOUR STAFF

CALLS FOR PAY rise of more than 60 per cent will dominate the pay and conditions demands to be put before the policy-making national committee of the Amalgamated Union of Engineering Workers when it meets in Blackpool next week.

Resolutions from the divisions of Britain's second largest union also emphasise mounting pressure for reinstatement of the 35-hour week as a target to be achieved as soon as possible.

This follows the dropping of the demand in what at least one division calls a "division" of the national claim during last year's prolonged dispute over pay and conditions in the engineering industry. Negotiations

settled then on a one hour cut in the working week from November 1981.

The committee of the union's engineering section, representing more than 1,230,000 workers in the industry will discuss numerous resolutions asking for a £120 a week basic wage against the present £73 a week.

Demands in some cases go as high as £140 a week and several motions for the committee include threats of industrial action.

It is expected, however, that union leaders will seek a managed deal to work on the basis of a "substantial increase" pay target.

ACAS inquiry dropped

BY OUR LABOUR STAFF

THE Advisory Conciliation and Arbitration Service has dropped its inquiry into union recognition at the DP Hotel (Scarborough) in the second case of limited co-operation on the part of employers reported by the service in just over two weeks.

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer."

ACAS said at the beginning of this month that it had ended work on a union recognition

claim at the Scarborough case, a survey of opinion of staff at the hotel received a very much lower response "than we would normally have expected to obtain from a survey carried out by our usual methods with the full co-operation of the employer

UK NEWS - PARLIAMENT and POLITICS

Olympics chief attacked by PM

Thatcher rejects criticism of economic policies

BY PHILIP RAWSTORNE

THE PRIME MINISTER attacked British Olympics chief Sir Denis Follows in the Commons yesterday for his determination to send a British team to the Moscow Olympics.

Mrs. Thatcher said she "fully understood and agreed" with Mr. Cranley Onslow (C. Woking) who urged her to "get it into the thick skull of Sir Denis Follows that there is a war going on in Afghanistan."

It would be a "matter of national disgrace" for British athletes to go to Moscow, Mrs. Onslow said.

Mrs. Thatcher told him: "I understand Sir Denis said only a war would change the decision of the British Olympic committee to go to Moscow. There is just such a war going on in Afghanistan."

"Russia is using troops to hold down a people, and in those circumstances it would be quite wrong for British athletes to go to Moscow if they value their freedom as much as we do," she said.

Housing grant scheme

By Andrew Taylor

LOCAL AUTHORITIES improving homes for sale will be able to apply for a Government grant under a new scheme announced by Mr. John Stanley, Housing Minister, yesterday.

Grants, up to £3,250 a dwelling, will be available for projects where the cost of acquisition and improvement is higher than the sale price.

The Environment Department estimate that around 200,000 dwellings would be eligible for grants at an annual cost to the Exchequer of around £6m.

Mr. Stanley, announcing the scheme during the committee stage of the Housing Bill, said: "I see improvement for sale as an important new area of activity by local housing authorities."

"It provides a means of simultaneously improving the older stock, bringing empty dwellings back into use and helping first time buyers by providing a new source of what will be relatively low cost homes."

MRS. MARGARET THATCHER yesterday curiously rejected Labour charges that the Government's economic policies were crippling British industry.

"Absolutely ridiculous," she declared dismissively.

But throughout question time, the Prime Minister faced a persistent Labour attack on the issue.

Mr. Barrie Sheerman (Lab., Huddersfield E) called on her to reverse policies that would turn the country into a "banana republic."

Strategy

Britain's industrial base was being destroyed by a Government strategy that was also creating 20 per cent inflation, rising unemployment and crippling interest rates, he said.

Industry was not being destroyed. Mrs. Thatcher retorted. "Large areas are flourishing... our export performance, apart from cars, is holding up extremely well, which is a very good compliment to many industries."

"Textiles?" a Labour MP queried. "Even that industry was enjoying quite a number of export successes," Mrs. Thatcher added.

Unemployment was high, she agreed, and unfortunately would get higher. "But if we go on printing money we should have not only higher inflation but also even higher unemployment."

If the Government's policy was working, why was it anticipating four years of decline in manufacturing output? Mr. James Callaghan demanded.

"Doesn't that show very clearly that the Government's whole economic policy is based on a gigantic fallacy?" he asked.

"Of course it doesn't," Mrs. Thatcher said. There was a time lag between changes in the money supply and the rate of inflation.

"It only stands to common sense that if you print more money than is backed by goods and services it will find its way through into increased prices in time."

Mr. Robin Cook (Lab., Edinburgh Central) suggested that if the Government's forecast of a 6 per cent fall in industrial production were realised, output would reach a lower level than it had in the three days week in 1974.

How could that encourage investment and expansion or help unemployment?

The Government had deliberately been "very cautious indeed" about the future, Mrs. Thatcher said.

Mr. Callaghan's own extremely optimistic assessments of output, in which he had based his public spending forecasts, had not come about and he had to avert for the IMF.

Mr. Callaghan snapped that the present Government's cuts in public spending were not only socially unjust but economically crippling.

The only alternative, Mrs. Thatcher retorted, were very much higher taxation or printing more money. "I reject those solutions."

Mr. Michael Meacher (Lab., Oldham W.) pointed out that Switzerland, Germany and Belgium had achieved lower inflation rates with much the same level of money supply as Britain.

A SURPRISE Government announcement removing the threat of prosecution from British companies

contravened sanctions by trading with Rhodesia after the illegal declaration of independence in 1965 was bitterly attacked by Opposition leaders in the Commons last night.

There were shouts of "double standards" from the Labour benches when the Cabinet's decision to authorise a blanket amnesty was revealed by Sir Ian Gilmour, the Lord Privy Seal and Deputy Foreign Secretary.

He made the announcement at the tail end of a statement promising aid totalling £75m over the next three years for the new state of Zimbabwe, which Rhodesia will become with legitimate independence on Friday.

Mr. Peter Shore, Labour's shadow Foreign Secretary, described the decision to give an amnesty to British companies who had broken British sanctions as "a mistake and a serious mistake."

He argued that such a decision was not justified by the earlier and necessary political amnesty covering all offences committed inside Rhodesia itself during the years of illegal independence.

With Labour backbenchers cheering approval, Mr. Shore declared: "We have a duty to uphold our own laws and it is necessary for us to do so if we are to get respect for law in Britain in the future and if we are to carry the right impact in countries abroad as well."

Sir Ian accused Mr. Shore of exaggerating the effect of the amnesty, particularly as no prosecutions were pending.

This brought further protests

from Labour MPs who made it clear that the lack of prosecutions was the main burden of their complaint.

Sir Ian insisted that it would be quite wrong now to bring prosecutions "for offences that are no longer offences."

He recalled that the Zimbabwe Act 1979 granted an amnesty in UK law for political offences connected with UDL.

A similar amnesty was granted in Rhodesian law, and had subsequently been extended by the Governor in a general pardon covering all political offences up to the elections.

"Now that full amnesty has been granted to all those responsible for the situation which led to the imposition of sanctions, the Government feel that it would no longer be appropriate for any further prosecutions to be initiated for sanctions offences."

Sir Ian, who stressed that the measures applying sanctions in UK law had already been revoked, said he had been informed by the Attorney General that only one case, an appeal, was at present before the courts.

The amnesty would not re-open past judgments. Effect would be given to the amnesty by an Order in Council which would have to be approved by the Queen.

Supporting the amnesty for British companies, Mr. Percy Crieve, (C. Solihull) maintained that a policy of magnanimity abroad and vindictiveness at home would be the wholly wrong way to set Zimbabwe on its new course.

The only way to get a good start, he said, was to wipe the slate clean of past offences.

Mr. Charles Fletcher-Cooke (C. Darwen) asked if the



SHORE: "Decision a serious mistake."

Sir Ian told MPs that because of the marked extent to which the general aid programme was already committed over the next two years, and in order to minimise the impact of "this very substantial pledge" to Zimbabwe on the level of UK assistance to other countries, the Chancellor of the Exchequer had authorised a special arrangement to be made.

He had agreed, exceptionally, that a sum of £3m should be made available from the public expenditure contingency reserve in 1980-81 (with consequent adjustment of the cash limit) and of £7m in 1981-82.

Sir Ian was also critical of the way in which the Government had determined the amount of aid to be provided for Zimbabwe over the next three years.

He contended that it was absurd to decide how much money should be allocated to Zimbabwe before the ODA mission had been able to examine the extent of the balance of payments problem facing Zimbabwe and the costs likely to be incurred through resettlement and making provision for refugees.

Sir Ian argued that Britain had been right to take the lead in announcing the provision of aid for Zimbabwe. The Government believed that many other countries would also wish to offer aid to Zimbabwe and he was confident that the total would amount to a substantial sum.

He indicated that an early announcement will be made naming the British high commissioner who will take up residence in Salisbury when Zimbabwe becomes the 43rd member of the Commonwealth.

Euro MPs' plea for cash aid

EURO-MP yesterday put in a special plea for more EEC cash to help Scotland and Northern Ireland.

Ulster and the Scottish Highlands and Islands deserved special consideration, the European Parliament in Strasbourg, and Britain in tackling Northern Ireland's serious economic problems.

Official Unionist member Mr. John Taylor said when the EEC decided to give certain projects funds, the British Government deducted the same amount about the resources devoted to agriculture but then blocked moves to increase spending on the regional fund.

The criterion for allocation of funds should be restricted to need alone, he said. He insisted that Community money should be spent on transport projects, especially an Ulster rail system and a tunnel linking Northern Ireland to Scotland.

SDLP leader Mr. John Hume condemned the "scandalous" disparity between the rich and poor nations of the EEC. He denounced the hypocrisy of Governments which complained about the resources devoted to agriculture but then blocked moves to increase spending on the regional fund.

Voters will be urged to ensure a strong SNP presence on Scotland's district councils to show the Government Scotland cannot be ignored, said Mrs. Helen Davidson, local government spokesman.

She was speaking at a press conference in Glasgow to launch the party's campaign.

The Nationalists currently either hold or control five of Scotland's 53 district councils, and are the biggest single party in a further three.

They will field 416 candidates, and for the first time will be mounting a big push in Dundee, where 17 SNP members will stand for the 44-seat council.

In Kyle and Carrick they hope controversial plans for test drilling to assess possible dumping of nuclear waste will fuel nationalist sentiment.

Some observers predict Labour as the biggest vote-catcher in Scotland in view of that party's local success in last year's general election.

But the SNP claims Scotland's 44 Labour MPs have failed to win concessions from Westminster.

"They have been powerless in the face of savage Tory cuts from a Government 80 per cent of Scots did not even vote for," said Mrs. Davidson.

She said the Nationalists were offering the "common sense" local government approach of spending money wisely without either Labour "extravagance" or Tory "peppering."

The party claims healthy cashflow returns and an increase in its 70,000-strong membership.

SNP votes campaign will centre on cuts

THE Scottish National Party will make the Government's "totally unnecessary" spending cuts a major plank in its campaign for the May 1 local elections, party leaders said yesterday.

The controversial proposal on strikers' benefits is contained in the Social Security (Number Two) Bill, which was having its second reading yesterday.

During the debate, it was apparent that there were misgivings amongst some Tory MPs about the effect which the provision would have on workers who were forced out on strike against their will.

The Nationalists currently either hold or control five of Scotland's 53 district councils, and are the biggest single party in a further three.

They will field 416 candidates, and for the first time will be mounting a big push in Dundee, where 17 SNP members will stand for the 44-seat council.

In Kyle and Carrick they hope controversial plans for test drilling to assess possible dumping of nuclear waste will fuel nationalist sentiment.

Some observers predict Labour as the biggest vote-catcher in Scotland in view of that party's local success in last year's general election.

But the SNP claims Scotland's 44 Labour MPs have failed to win concessions from Westminster.

"They have been powerless in the face of savage Tory cuts from a Government 80 per cent of Scots did not even vote for," said Mrs. Davidson.

She said the Nationalists were offering the "common sense" local government approach of spending money wisely without either Labour "extravagance" or Tory "peppering."

The party claims healthy cashflow returns and an increase in its 70,000-strong membership.

THE GOVERNMENT'S proposal to reduce supplementary benefit to strikers' families by £12 a week will apply equally to non-trade unionists and to those affected by a lockout. Mr. Patrick Jenkin, Social Services Secretary, made clear in the Commons yesterday.

The controversial proposal on strikers' benefits is contained in the Social Security (Number Two) Bill, which was having its second reading yesterday.

During the debate, it was apparent that there were misgivings amongst some Tory MPs about the effect which the provision would have on workers who were forced out on strike against their will.

The Nationalists currently either hold or control five of Scotland's 53 district councils, and are the biggest single party in a further three.

They will field 416 candidates, and for the first time will be mounting a big push in Dundee, where 17 SNP members will stand for the 44-seat council.

In Kyle and Carrick they hope controversial plans for test drilling to assess possible dumping of nuclear waste will fuel nationalist sentiment.

Some observers predict Labour as the biggest vote-catcher in Scotland in view of that party's local success in last year's general election.

But the SNP claims Scotland's 44 Labour MPs have failed to win concessions from Westminster.

"They have been powerless in the face of savage Tory cuts from a Government 80 per cent of Scots did not even vote for," said Mrs. Davidson.

She said the Nationalists were offering the "common sense" local government approach of spending money wisely without either Labour "extravagance" or Tory "peppering."

The party claims healthy cashflow returns and an increase in its 70,000-strong membership.

He came under renewed pressure from his own backbenchers to give a firm assurance that the family of a non-trade unionist who was forced out on strike would not suffer hardship as a result of the Bill.

He said that the final supplementary benefit bill for the steel strike totalled £9m. But that sum would have been

halved had the provisions in the present Bill been in force at the time.

Mr. Jenkin listed many of the sums which had been paid in social security to strikers in recent years. In most cases the unions had paid nothing out of their substantial funds to support the families of their members.

"There has been a rising tide of criticism of successive Governments for allowing this state of affairs to continue," he said.

"Many of these strikes have been directed at the public itself. In these circumstances it really is unacceptable that the public should have to find substantial sums to finance a strike. The time has come to put this right."

"Nowhere in the world does a striker's family qualify for social assistance more readily than here," said Mr. Jenkin.

Mr. Stan Orme, Labour Social Security spokesman, said there were strong rumours that the regulators powers in the Bill were to be used by the Government to protect non-trade unionists from the effect of the supplementary benefit provisions.

"This is an extraordinary Bill," he protested. "In recent times no Government has introduced a Bill coming anywhere near to the diabolical proposals contained in it."

NOTICE OF REDEMPTION

Monsanto International N.V.

8% Guaranteed Sinking Fund Debentures Due May 15, 1980

NOTICE IS HEREBY GIVEN that, pursuant to the provisions of the Indenture dated as of May 1, 1970 under which the above described Debentures were issued, Citibank N.A. (formerly First National City Bank), as Trustee, has drawn for redemption on May 15, 1980 through the operation of the Sinking Fund provided for in the said Indenture, \$501,000 principal amount of Debentures of the said issue.

The Debentures drawn for redemption, each in bearer form with coupons attached, and each of \$1,000 principal amount and bearing the prefix letter M, are:

All Debentures bearing numbers ending in the digit 6, which lie in the range 00016 through 19376, inclusive.

All Debentures bearing numbers ending in the digit 4, which lie in the range 00004 through 11434, inclusive.

The Debentures specified above are to be redeemed for the said Sinking Fund at the Capital Markets Division - Multinational Securities Department of the Trustee, 111 Wall Street - 5th Floor, New York, New York 10045, and the main offices of Citibank N.A. in Amsterdam, Frankfurt/Main, London, Milan, Paris, Rome, or Citibank (Belgium) S.A., Brussels, or Citibank (Luxembourg) S.A., Luxembourg, being the Company's paying agents, and will become due and payable on May 15, 1980 at the redemption price of 100% of the principal amount thereof plus accrued interest on said principal amount to such date. On and after such date, the Debentures will cease to accrue interest.

The said Debentures should be presented and surrendered at the offices set forth in the preceding paragraph on the said date with all interest coupons maturing subsequent to the redemption date. Coupons due May 15, 1980 should be detached and presented for payment in the usual manner.

For MONSANTO INTERNATIONAL N.V.

Technical Page

EDITED BY ARTHUR BENNETT AND TED SCHREETERS

• COMMUNICATIONS

New developments in optical fibre links

TWO MAJOR companies, Corning in the U.S. and BICC in the UK, have made significant announcements in the optical fibre communications field.

Corning is the name of the BICC development which consists of an optical fibre embedded in the centre of an overhead power conductor, thus providing a telecommunications link while preserving the electrical and mechanical integrity of the conductor.

In theory this development means that the overhead grid system of any country could be used for the transmission not only of the electricity authority's internal traffic but also for communications purposes in general.

In most countries, including the UK, such use would require a change in the monopoly position held by the PTT for line transmission. The potential, however, is clear enough. A

large number of ready-made routes would become available with no additional way-leve problems. Furthermore, with optical fibre the capacity could be almost limitless.

For some time, electricity authorities have sent signals down power lines using the existing copper, but the problems of carrying both high currents at 11 kV say, with low level information carrying signals are severe; but by including a fibre in the power cable they are immediately overcome, since the fibre is separate from and has nothing in common with the cable.

Fibre has been designed to withstand the rigours of overhead line construction and working including vibration, thermal changes, ice and wind loading and creep. It can be used either as a shield wire or a phase conductor at the line design phase or can be substituted into existing lines.

GEOFFREY CHARLISH

• MATERIALS

Will make building slabs

TRIALS OF a plant for making multi-purpose building material for installation in Malawi later this year have nearly been completed by technologists at the Tropical Products Institute, a scientific unit of the Overseas Development Administration.

The plant is a small scale unit for producing wood-wool cement slabs, a composite material which it is hoped will replace certain building materials imported into Malawi.

On arrival in Malawi it will go into production for the Forest Industries Division of the Government of Malawi's Department of Forestry as part of the British aid programme. It will produce two thicknesses of board, one of 4 inch for use as a roof lining or ceiling and a further one of 2 inches for use as a cladding material. Initially, these materials will be used largely by the Department of Forestry and by the Ministry of Works and Supplies in their own building programmes.

• HEATING

Portable gas-fired heaters

SPECIALLY FOR operation on propane or butane gas is a range of infrared industrial heaters called the Miniray Series from Schunk, 11a St. George's Road, London SW19.

Outputs range from 6,250 to 25,000 BTUs an hour and each self-contained heater offers three options in use—upright on the floor, or hung from a wall (with the angle of the heater adjusted as required in either case), or horizontally (on its back) for boiling a kettle.

These portable models can be used in small offices, site huts, outdoor working (even camping sites) and be wheeled to any location together with their gas bottles.

• MAINTENANCE

Makes access much easier

WHETHER IT is being used by the do-it-yourself enthusiast, or in professional or commercial applications, a work tower is not only easy to erect but promises a safe platform (4 ft 4 in square). Apart from offering security to the operator it also allows plenty of room for tools, paint, pots, or even the ubiquitous cup of tea.

Instead of having to move a ladder to extend an operator's reach, the tower allows him to cover an area of about eight

by seven feet at any given time.

Inside the home, the unit can be used as a decorator's platform, stair-well unit, or even as a workbench.

Available from Easy-Rect Products, Shenstone Trading Estate, Bromsgrove Road, Halesowen, West Midlands (021 550 7426).

DESIGN AWARD FOR NEW LEADER IN CONTAINER-HANDLING.

Lansing's new 25TR Ro-Ro container-handler has won a Design Council Award—professional recognition of this relatively small lift truck's remarkable ability in the severely restricted between-decks space of container ships, to load and unload huge containers with exceptional speed and efficiency.


Design Council Awards are not lightly given. They mean that the Design Council Judges, who include some of Britain's most experienced engineering minds, have really put this Lansing truck through the hoops. Every aspect of the 25TR's design—mechanical efficiency, accessibility, controls, fuel economy, safety factors, driver comfort—is minutely examined. And operators and drivers are impartially questioned on its record in actual service.

So a Design Council Award for a lift truck says the very things about that truck that you,

the customer, are really looking for.

And the fact that this is Lansing's second Design Council Award says a great deal about Lansing's ability to design trucks of unparalleled excellence. That first Award was for a truck that could hardly have been more different—the unique Lansing Narrow Aisle Turret Truck with its remarkable 12 metre lift mast, now in highly productive use all over the world.

For full details of our award-winning 25TR, or of any other Lansing truck, engine-powered or electric, look now in your Yellow Pages for your local Lansing sales, parts and service depot. And get Britain's most cost-effective lift trucks working for your company.



LANSING
BAGNALL HENLEY

We do more for you

General Enquiries:
Basingstoke (0256) 3131.



• MACHINE TOOLS

Cuts tube at high speed

LATEST parting-off lathe for tubing up to 60 mm diameter put on the market by TI Brookes is capable of rates up to 2,600 pieces per hour and has a cutting programme controlled by microprocessor.

High speed action is produced principally by applying a cutting tool in an over-centre position, allowing deeper cutting into the metal with each rotation and reducing the parting time typically by 50 per cent. The cut is also cleaner, causing minimum burr inside and outside the tube and in addition the tool post is easily accessible, a tool change taking no more than 30 seconds. Operation is pneumatic via standard metric cylinders, with electrical limit switches.

Among the options available are an automatic magazine feeder unit, a second tool post for simultaneous operations and a swarf and small component separator.

The microprocessor allows considerable flexibility. For example, if the operator wants to dispense with the trim cut on a new length, he just dials in a code and adjusts the value of the trim cut to zero using increment/decrement buttons.

More from Braden Road, Oldbury, Warley, West Midlands B69 2DL (021 552 5311).

GENERATORS

UP TO 500 kVA

WATER PUMPS

UP TO 8 INCHES

MANUFACTURED BY

ATALANTA Engineering Ltd., Hanworth Trading Estate, Hanworth Lane, Chertsey, Surrey KT16 5JX, England. Tel: Chertsey 62655. Telex: 857250. ATALANTA Chertsey SURVEY.

• LIGHTING

Emergency lamp

INTENDED FOR use in banks, shopping centres, small offices and hotels is emergency lighting equipment in the form of a self-contained hot cathode fluorescent lamp from Carters, Sycamore Avenue, Burnley, Lancs (0282 27911).

Should the mains fail, a light output of 140 lumens is provided for up to three hours by sealed nickel cadmium batteries matched to a constant current type charger.

This provides a normal operational life of at least four years, says the company, even at a constant ambient temperature of 30 degrees C, and eliminates the possibility of cell damage in the event of prolonged discharge.

IN BRIEF

• Model 308 data analyser can be used for the state and timing analysis of serial digital data and for signature analysis. It has a reference memory which enables two separate sets of data to be compared and a display memory which allows 252 bits to be displayed. Tektronix, PO Box 69, Harpenden, Herts (Harpenden 63141).

• Burndeut Electronics, St. Fidelis Road, Erith, Kent (03224 39121) has a remote controller for radiotelephone systems that allows the base station operator to use a remote transmitter and serial system over Post Office telephone lines.

• Supercorder, from Russet Instruments is a multi-channel galvanometer recorder which uses up to eight high power feedback units to drive heated point stylus. "Unparalleled" linearity, bandwidth and accuracy are claimed. RRL House, Sheen Park, Richmond, Surrey, TW9 1UN (01 940 9981).

Sometimes even kings had to rely on the resourcefulness of merchant bankers to mobilize funds.



Without the ingenuity of merchant bankers many a coronation might not have taken place.

Emerging industries and governments also relied on these financial craftsmen to achieve their goals.

BHF-BANK traces its history to the mid-nineteenth century when its founders were among the most influential merchant bankers of their time. From the outset, they specialized in assessing new projects, helping to create new industries and tapping available sources for the necessary funds.

Traditional merchant banking expertise is the cornerstone of BHF-BANK's strong position in international underwriting today. The top managers of DM issues and regularly acts as co-manager of dollar issues.

BHF-BANK continues to concentrate on what it has always done best: acting as advisor to corporations, governments and public entities on the most suitable means of financing, selecting the appropriate instruments, putting together a syndicate, or arranging for private placements. The Bank is also well placed to initiate stock exchange listings in Germany.

For the unrivalled financial expertise of a management with personal liability, rely on a merchant banker BHF-BANK. A Member of the Inter-Alpha Group of Banks.

BHF-BANK

BERLINER HANDELS- UND FRANKFURTER BANK

Merchant Bankers by Tradition.
Resourceful by Reputation.

Head Office: Bockenheimer Landstr. 10, D-6000 Frankfurt 1, Tel: (0611) 7181. New York Branch: 450 Park Avenue, New York, N.Y. 10022, Tel: (212) 758 3800. London Representative Office: 25, Brixton Lane, London EC3, Tel: 6239715. BHF-BANK International, 88 Grand-Rue, Luxembourg—BHF-FINANZAG, Mythenquai 28, Zurich. Offices: Bogota—Hong Kong—Johannesburg—London—Los Angeles—Madrid—New York—Rio de Janeiro—Singapore—Teheran—Tokyo.

Protecting the bottom line by helping the inner city

Jason Crisp on what the Americans have been teaching British companies about community involvement

OVER the last 20 years leading American companies have been forced radically to rethink their relationship with local communities and society in general.

Many corporations were caught up with the problems of the urban crisis of the late 1950s and 1960s as inner city areas became less and less habitable. Added to that has been the growth of powerful environmental consumer and minority lobbies.

As the cities deteriorated, such companies began to find themselves increasingly isolated in depressed areas as smaller, more mobile, businesses and the middle classes fled to the suburbs. One giant corporation found

that its head office had become surrounded by a red light district—making it very difficult to find secretaries, who were repeatedly accosted on their way to and from work.

The companies were left with the option of either moving, at considerable cost, or becoming involved in improving the local area.

Twenty years later a number of British companies are beginning to face up to similar issues. Rising unemployment, deteriorating inner city areas, racial tension and a growing hostility to business has led to a realisation by some companies—that though not very many so far—that they can

not close their eyes to the society around them.

Last week a small group of leading American and British companies—including General Motors, Shell, BP, Marks and Spencer and Ford—met at a seminar in England ostensibly to exchange information on their experiences with community involvement and other forms of what has become known as "corporate responsibility." But for the most part it was the Americans who were giving the British the benefit of their much greater experience.

The conference, held at the Civil Service College in Sunningdale, was jointly sponsored by the U.S.

Embassy in London and the Department of the Environment.

Although the American companies were preaching to the converted, it came over very strongly that they regarded involvement in community affairs as a necessary part of safeguarding "the bottom line." Although the UK companies would relate corporate responsibility activities to long-term profitability in a fairly loose way, they did not perceive it as clearly or determinedly as did the Americans.

A major difference between UK and U.S. experience has been in the degree of co-operation between business and local authorities. In

America the dividing line between the two was very much less rigid, the conference confirmed.

Many of the U.S. projects had involved considerable co-operation between companies and City bodies which looked unachievable in Britain at present. One of the reasons for this, it was suggested, was that the broad similarity in attitudes to business on the part of the American political parties made it much easier for companies to become involved in City affairs.

Corporate headquarters in the U.S. are also much more widespread throughout the country than in the UK, where most are in London;

in City affairs.

This is a further incentive for the Board to become interested in local affairs. The considerable involvement of Pilkington—Britain's largest glassmaker—in St. Helens, Lancashire, would not have developed, suggested one delegate, had it not kept its head office there.

Tom King, Britain's Minister for Local Government and Environmental Services, reflected after the conference that it had demonstrated just how wide the gap between business and local government was in the UK.

"There is clear need for more co-operation," he said.

There was also a difference in the type of problems in which companies were

involved. The Americans were paying particular attention to capital projects in inner cities (the example of Detroit is described below) and to helping alienated youth, particularly from ethnic minorities. One of the problems in America was that not only did companies have to be persuaded to employ minorities, but frequently those from minority groups needed pre-employment training before they were suitable for appointments.

The British attitude and practices in community involvement and corporate responsibility were much more governed by the state of the economy. First it was widely felt that there was less money available to be spent on such activities and second that many of the problems resulted anyway from the country's poor economic performance.

A number of large British companies have recently become involved in schemes to help small businesses, either through individual efforts such as those of Shell, ICI and Pilkington, or through organisations like the London Enterprise Agency.

The agency—which has now been imitated in several other English cities such as Birmingham—was set up in April 1978, by a group of major London based companies to help small business. It is staffed by a group of managers seconded from the sponsoring companies.

At such an early stage it is

impossible to judge what will come of the conference. It would seem that the enthusiastic and hard-nosed approach of the Americans encouraged the British to be more determined and to appreciate the need to stimulate other companies. As one delegate put it: "It is no good just saying these problems don't exist, or it's not my responsibility, and then putting your head back in the sand."

The Americans may be ahead, but they share a common problem with the British in that only a relatively few companies in both countries can see any need for business to respond to social problems and social change.

Spotty

As James Langton, Bank of America's senior vice-president for social policy told the conference: "What has been businesses' performance in the socio-political mainstream of the past 20 years? In a few companies it has been good, in others it has been spotty, but on the whole it has been miserable. If corporate response to changing performances in the marketplace for products and services were as tortuous as the response to social change, there would be a killing number of bankruptcies in the American business system. Yet, in the long run, failure to adapt to societal change may prove as lethal as failure to adapt to market change."

The phoenix rising from Motown's ashes

THE RECENT riot in the St. Paul's area of Bristol may have alarmed much of the British public, but compared with the incidents which occurred in Detroit 18 years ago it was, thankfully, a pretty tame affair.

At a time when many large American cities were witnessing scenes of growing urban violence, Detroit stood out as having some of the worst problems of all. Marauding discontented blacks burned and looted this already hideously ugly town which had grown up around the heart of the U.S. car industry—sometimes known as Motor City or Motown.

Inevitably, the city's fortunes have always been closely tied to those of the motor industry, which directly employs one in five of Detroit's labour force, and indirectly a good many more.

Over 60 per cent of the city's population of 1.2m is black and total unemployment has recently risen to around 13 per cent. Employment prospects are not seen to be good either—not least because the rust by car manufacturers into small cars is likely to mean less jobs rather than more.

The present recession, the fall in sales of large cars and the ailing state of Chrysler—the largest single employer in the city—might make it look as though the return of civil disruption is imminent.

But the future of Detroit, troubled as it is, is not quite as bleak as it might have been. The major corporations have not moved their headquarters away and they remain committed to the future of the city.


A recognition of the changes in the last ten years will be the holding of the Republican National Convention there in July. Detroit itself is mainly Democratic.

There have been a number of changes since the upheavals of the 1960s. In 1974 Detroit elected its first black mayor, Coleman A. Young, who, according to a number of accounts has been a powerful and unifying force within the city. He has, with notable political skill, attracted considerable federal financial assistance to help alleviate its problems, and to rebuild and revitalise the city.

Although much of the funds for this work have come from Government coffers, local industry too has been investing large sums in the city. In the short term, at least, not all the investments have been as commercially profitable as they would have been had they been made in a less run down area.

The most visible effort is the "Renaissance Center" which dominates the "down-town" area of Detroit. It is a gigantic complex of offices, shops, cinema and a hotel, set by the edge of the river which divides the city. At the centre of its five soaring towers is one 75 storeys high, containing a 1,400-room hotel. The surrounding four towers house 2m sq ft of office space.

Apart from its size the remarkable thing about the centre is that this \$350m investment was begun in the early Seventies in a disused and decaying part of the city at a time when business and the middle classes were getting



The Renaissance Center in Detroit as it will look when the two towers in the foreground—which have been superimposed on the picture—have been built

without public sector support. If the city is putting money in we are going to keep its commitment."

One of the first priorities of Detroit Renaissance was to invest in bricks and mortar as a way of demonstrating "business commitment" to the city. "It was in a very hostile climate and at a time when there was absolutely no investment in downtown Detroit other than by banks and the utilities

who were tied to the city. Traditional enterprise was not willing to take the risk—it was easier to build in the suburbs," says McCabe, who was in London last week for the Anglo-American conference on community involvement.

"We wanted to demonstrate with a large scale, multi-purpose project that it was a place worth investing in and that it would be a catalyst for further development."

The site on which the centre was built consisted of old car parks, a disused warehouse, grain elevators and old railway sidings where there were no families or businesses to rehouse. With the mayor on the board of Detroit Renaissance, as an ex-officio member, the City went out of its way to expedite planning permission and to close where," says McCabe.

Henry Ford II managed to persuade the unions to agree to a no-strike clause on the construction work, and also got a total of 51 Detroit companies to invest \$38m in equity for the building. Loan finance was obtained from five local banks and insurance companies.

"This was to be a profit-making venture although it was very clear from the start that we would not get as high a return as we would elsewhere," says McCabe.

The site was assembled and the development plan produced in five months. A year later work began and in 1976 the first offices were occupied.

A further two towers are being built now—the steel structure is just going up—this time as a joint venture by the Ford Motor Land Development and the Rockefeller Centre. The latter is seen as particularly important by McCabe, as it is a strictly commercial investment which has come from outside Detroit.

McCabe boasts that the office centre has created a ripple effect through the rest of the community: a firm of outside management consultants claimed to have identified a \$1bn stimulus to the Detroit economy.

Although there is a 95 per cent occupancy of the office space there has been less success with the 340,000 square feet of shopping and commercial area, where occupancy is only 65 per cent. According to Fortune magazine some of the shops have been doing badly and the hotel has long stretches of low occupancy.

Detroit Renaissance's second major scheme is to try and revitalise the "retail core" of the downtown area, which has been losing market share to the suburbs for a long time. A \$250m project, supported by urban development grants is being started to build a giant new shopping mall in the centre of the town.

A third and key part of Detroit Renaissance's programme is the encouragement of private housing in the downtown area. Over 7,000 units are to be built or converted at three

MAKE IT IN LIVINGSTON


the welcome's warm, the grants are great.

We'll make it easy for you in our New Town. As a professional team we've already helped over 140 companies...

And Government Grants, loans and allowances are at the highest level because Livingston is a Special Development Area.

Write to James Pollock, A.R.I.C.S., Industrial Development and Estates Manager, Livingston Development Corporation, LIVINGSTON, Scotland. Telephone Livingston (0589) 31177. Telex 727178. London 01-9302631.

Business Equipment



For the desk bound. Or the outward bound.

No longer do you have to choose between a portable dictating machine and a desk top model.

Because the remarkable new Philips 320 does both jobs superbly.

So, it'll help you make the best use of your own time and your staff's.

For example, it's the first portable to offer the Philips Visual Mark & Find system.

This unique visual and acoustic cueing device allows you to pinpoint where letters begin and end, even to record special instructions.

Additionally, a quick glance at the Mini Cassette 2 tells you how much has been

Simply years ahead.



Please send me more information about the Philips 320 Portable Dictating Machine and the Philips range of dictation equipment.

NAME _____

COMPANY _____

POSITION _____

ADDRESS _____

TELE. _____

To: Philips Business Equipment, Arundel Great Court, 8 Arundel Street, London WC2R 4DT

WFT 28

You'll never feel like this at Ramada Hotels.

That's why our guests come back again and again. Next time, stay with Ramada and enjoy the personal touch. For reservations, telephone 01/235 5264 or your travel agent.

Brussels, Frankfurt, Geneva, Paris, Liege, Düsseldorf, Wetzlar, Gothenburg, Jönköping, Jerusalem, Tel Aviv, Gulf States, Abu Dhabi, Bahrain, Dhahran, Jeddah, Doha, Sana'a. Worldwide over 650 Ramada Hotels.

RAMADA
HOTELS INTERNATIONAL



Ramada Hotels welcome American Express Cards.

3rd WARNING

BEFORE YOU BUY A HIGH PERFORMANCE CAR ASSUME YOU WILL HAVE A HIGH-SPEED BLOW-OUT.

The thought of a front tyre blowing out on the motorway is almost too horrific to contemplate, particularly if you were to have the family on board. Yet it is a possibility that every responsible person considering a high performance car, or for that matter any other car, should think long and seriously about.

For a high-speed blow-out is liable to leave even the most accomplished drivers helplessly out of control, as the car goes slewling off the road or smashing into the oncoming traffic.

Yet, if you were driving the fuel-injected Citroën CX GTi, with hydropneumatic suspension, this potentially very terrifying event would be a non-event.

This is because Citroën's hydropneumatic suspension would enable you to go on driving, even steering the car round corners, until it was safe to stop.

The inconsequential chore of changing the wheel would become something of a joy as you reflected on what could have happened. Especially as you can jack up the car most of the way from the driver's seat.


A further contribution to safety, as well as performance, is the advanced aerodynamics, which extend even to the underside of the car, so that it is literally sucked down on to the road.

While VariPower steering, which becomes firmer as you increase speed and prevents the wheels from being deflected by stones or irregularities in the road, enhances still further your feeling of absolute security.

Front-wheel drive and self-levelling hydropneumatic suspension which irons out all the bumps in the road surface complete a road-holding capability that has to be experienced to be believed. Indeed the Citroën CX GTi has many more advanced features than any other high-performance production car, regardless of price.

As well as the one which could save your life.

NB. If you missed the 1st and 2nd Warning advertisements in this series, it could be in your best interests to contact Citroën. We will be pleased to send you a copy of these advertisements and also our CX brochure.



FUEL INJECTED CITROËN CX

Illustrated CX GTi, fuel injected with 5-speed box, £8203.81. (Sunroof optional extra.) Also available CX 2400 Pallas, fuel injected with C-Matic, £8227.48.
Prices include car tax, VAT and leather red seat belts, but exclude delivery charges, £31.95 (inc. VAT) and number plate. Prices correct at time of going to press. All Citroën Cars have a 12-month, unlimited mileage guarantee. Check Yellow Pages for nearest dealer and ask about our preferential finance scheme. Please enquire about our Personal Export, H.M. Forces and Diplomatic schemes. Citroën Cars Ltd, Mill Street, Slough SL2 5DE. Tel: Slough 23808.

LOMBARD

Why Callaghan must stay

BY MALCOLM RUTHERFORD

IT IS DIFFICULT not to feel sorry for Mr. James Callaghan, the leader of the Labour Party. Two years ago he was widely regarded as a successful Prime Minister — certainly much better than his predecessors had suggested and considerably better than his predecessor, Harold Wilson. The economy had been brought back from the brink, the government machine worked reasonably well and the fortunes of the party had revived. There were even prospects of winning the general election.

Dried up

How different it is today! Hardly a week goes by without headlines appearing about the Labour leader being rebuffed by the National Executive or the left wing. Mr. Callaghan cannot even go to China which he will do next month, without somebody raising questions about whether the Labour Party should pay or, even more astutely, whether such a trip will be regarded as an affront to the Soviet Union.

Mr. Callaghan is 68. The next general election is unlikely to take place before 1984. Not even memories of Konrad Adenauer or General de Gaulle, nor current reflections on Ronald Reagan, who could be President of the United States in his seventies, do much to encourage the thought that the present leader of the Labour Party could be seeking to return to Downing Street in four years' time.

And yet an odd thing has happened. When he was Prime Minister, Mr. Callaghan used to put it around from time to time that he would be quite happy to retire to his farm if the party did not like what he was doing. Those stories have dried up. Nowadays when the Labour leader makes a major appearance — for example, on television — the question he asks himself is simply this: could anyone else in the party have done it better? The answer is Mr. Denis Healey perhaps, but as for the others, Mr. Peter Shore, Mr. Roy Hattersley, Mr. John Silkin, it is certainly not.

Mr. Callaghan is right. None of the rivals for the leadership have done anything much to en-

Marking time

Now, of course, all those arguments can be made in reverse. If Britain is still quarrelling with Europe over the budgetary contribution this time next year or the year after, that is pretty clear what Labour policy will be and no doubt it will command widespread support. But the point is that Labour needs to react to what is happening rather than reight the battles of the past. It cannot react yet because it does not know what is going to happen. We shall need to think about the Labour Party again in a year or two. Meanwhile, the best way of marking time is to keep Mr. Callaghan.


TV Radio

BBC 1

Indicates programme in black and white

6.40-7.55 am Open University (b/w only). 12.45 pm Midday News. 1.00 Pebble Mill at One. 1.45 Heads and Tails. 3.53 Regional News for England (except London). 3.55 Play School. 4.20 The Space Sentinels. 4.40 Wildtrack. 5.05 John Craven's Newsround. 5.10 Potter's Picture Palace. 5.40 Evening News.

F.T. CROSSWORD PUZZLE No. 4,251



6 Superior determination giving motorist extra speed (9)

7 Improbable one Pole to start (5)

8 Note that revolutionary tied (8)

9 Part of party given merited order (4)

10 Day clear material (7)

11 Victor raising game of other sportsmen (6)

12 Stay on pitch by railway (5)

13 Take evasive action you and I welcome (5)

14 Solution to Puzzle No. 4,250

15 Attendant worker takes to display (7)

16 Superior determination giving motorist extra speed (9)

17 Improbable one Pole to start (5)

18 Note that revolutionary tied (8)

19 Part of party given merited order (4)

20 Day clear material (7)

21 Victor raising game of other sportsmen (6)

22 Stay on pitch by railway (5)

23 Take evasive action you and I welcome (5)

24 Solution to Puzzle No. 4,250

25 Attendant worker takes to display (7)

26 Superior determination giving motorist extra speed (9)

27 Note that revolutionary tied (8)

28 Part of party given merited order (4)

29 Day clear material (7)

30 Superior determination giving motorist extra speed (9)

31 Note that revolutionary tied (8)

32 Part of party given merited order (4)

33 Day clear material (7)

34 Superior determination giving motorist extra speed (9)

35 Note that revolutionary tied (8)

36 Part of party given merited order (4)

37 Day clear material (7)

38 Superior determination giving motorist extra speed (9)

39 Note that revolutionary tied (8)

40 Part of party given merited order (4)

41 Day clear material (7)

42 Superior determination giving motorist extra speed (9)

43 Note that revolutionary tied (8)

44 Part of party given merited order (4)

45 Day clear material (7)

46 Superior determination giving motorist extra speed (9)

47 Note that revolutionary tied (8)

48 Part of party given merited order (4)

49 Day clear material (7)

50 Superior determination giving motorist extra speed (9)

51 Note that revolutionary tied (8)

52 Part of party given merited order (4)

53 Day clear material (7)

54 Superior determination giving motorist extra speed (9)

55 Note that revolutionary tied (8)

56 Part of party given merited order (4)

57 Day clear material (7)

58 Superior determination giving motorist extra speed (9)

59 Note that revolutionary tied (8)

60 Part of party given merited order (4)

61 Day clear material (7)

62 Superior determination giving motorist extra speed (9)

63 Note that revolutionary tied (8)

64 Part of party given merited order (4)

65 Day clear material (7)

66 Superior determination giving motorist extra speed (9)

67 Note that revolutionary tied (8)

68 Part of party given merited order (4)

69 Day clear material (7)

70 Superior determination giving motorist extra speed (9)

71 Note that revolutionary tied (8)

72 Part of party given merited order (4)

73 Day clear material (7)

74 Superior determination giving motorist extra speed (9)

75 Note that revolutionary tied (8)

76 Part of party given merited order (4)

77 Day clear material (7)

78 Superior determination giving motorist extra speed (9)

79 Note that revolutionary tied (8)

80 Part of party given merited order (4)

81 Day clear material (7)

82 Superior determination giving motorist extra speed (9)

83 Note that revolutionary tied (8)

84 Part of party given merited order (4)

85 Day clear material (7)

86 Superior determination giving motorist extra speed (9)

87 Note that revolutionary tied (8)

88 Part of party given merited order (4)

89 Day clear material (7)

90 Superior determination giving motorist extra speed (9)

91 Note that revolutionary tied (8)

92 Part of party given merited order (4)

93 Day clear material (7)

94 Superior determination giving motorist extra speed (9)

95 Note that revolutionary tied (8)

96 Part of party given merited order (4)

97 Day clear material (7)

98 Superior determination giving motorist extra speed (9)

99 Note that revolutionary tied (8)

100 Part of party given merited order (4)

101 Day clear material (7)

102 Superior determination giving motorist extra speed (9)

103 Note that revolutionary tied (8)

104 Part of party given merited order (4)

105 Day clear material (7)

106 Superior determination giving motorist extra speed (9)

107 Note that revolutionary tied (8)

108 Part of party given merited order (4)

109 Day clear material (7)

110 Superior determination giving motorist extra speed (9)

111 Note that revolutionary tied (8)

112 Part of party given merited order (4)

113 Day clear material (7)

114 Superior determination giving motorist extra speed (9)

115 Note that revolutionary tied (8)

116 Part of party given merited order (4)

117 Day clear material (7)

118 Superior determination giving motorist extra speed (9)

119 Note that revolutionary tied (8)

120 Part of party given merited order (4)

121 Day clear material (7)

122 Superior determination giving motorist extra speed (9)

123 Note that revolutionary tied (8)

124 Part of party given merited order (4)

125 Day clear material (7)

126 Superior determination giving motorist extra speed (9)

127 Note that revolutionary tied (8)

128 Part of party given merited order (4)

129 Day clear material (7)

130 Superior determination giving motorist extra speed (9)

131 Note that revolutionary tied (8)

132 Part of party given merited order (4)

133 Day clear material (7)

134 Superior determination giving motorist extra speed (9)

135 Note that revolutionary tied (8)

136 Part of party given merited order (4)

137 Day clear material (7)

138 Superior determination giving

Television

Drama—honest and half-baked

by CHRIS DUNKLEY

The fuss over *Antony Thomas' Death of a Princess* has been force fed so vigorously that, as with *Yesterday's Men* and *Days of Hope*, it has grown big enough to obscure the programme itself. Public discussion is concerned with newspaper rumours about Arab trade embargoes, sensational stories about diplomatic rows, fantasies about multimillion-pound bribes, and of course claims about outraged Saudi reactions.

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

FINANCIALTIMES

BRACKEN HOUSE, CANNON STREET, LONDON EC4P 4BY

Telex: 8884571, 883897

Telephone: 01-248 8600

Wednesday April 16 1980

Turning plans into reality

EXPECTATIONS ARE a vital factor in the success of any monetary policy against inflation. This is why the Chancellor decided to defy strong opposition from many of his official advisers and provided a "hostage to fortune" by publishing a medium term financial plan in last month's Budget.

However, as the details of the financial plan have been subjected to careful analysis, doubts about the Government's intentions have been replaced by scepticism about the possibility of reaching its goals by the route it has chosen. The projections of public spending, revenues and borrowing set out in the Treasury documents which appeared on Budget day provided no more than a sketchy, and in some ways, unconvincing, outline of the route to be followed. Monday's appearance by the Chancellor and his senior officials before the Commons Treasury Committee gave no evidence that the Government itself has a clearer map which shows exactly how it can reach its destination.

Projections

Doctrines about the financial strategy centre on the projections of public spending over the next four years. At the heart of the public spending plans is the prediction of an immense reduction in the financial requirements of the nationalised industries. The Treasury Committee spent much of its time on Monday trying to elicit a detailed explanation of the nationalised industries' newly-expected prosperity. The Government's answers were not entirely convincing.

The nationalised industries' net financial requirement of £2.3bn in 1979-80 is to be transformed into a net repayment of £400m (at 1979 prices) by 1983-84, leading to a net reduction of £2.7bn in public spending. This compares with a total reduction of £2.8bn in the public expenditure total and is thus absolutely crucial to the Government's spending plans. But the Chancellor was vague about how this remarkable financial turnaround would be achieved. He stated that about two-fifths of the improvement would come from the "elimination or reduction of losses" in coal, steel, shipbuilding and railways, and that about a quarter would result from the "elimination of underpricing" of electricity and gas, leaving 35 per cent to be raised from the other industries.

Unpalatable

Indeed the profits of BNOC could well make up for any shortfall in the other industries' performance. There is a curious analogy here with the broader impact of oil on the Government's finances. While the Government's estimates of public spending appear to have been over-optimistic, the forecasts of oil revenues are very cautious. Thus oil may well justify the Government's predictions about borrowing—the monetary growth, even if both the revenue and expenditure projections individually prove to be wide of the mark. Stressing the importance of oil to the financial strategy is clearly unpalatable politically. But the Chancellor will only succeed in encouraging the favourable expectations that he needs to make his policy work by bringing out clearly the realities behind his plans.

Supervising banks abroad

THE COMMUNIQUE from the central bank Governors on surveillance of the international banking market is most timely. Those who remember how the unaccustomed volatility and excitement of the foreign exchange markets led to the fall of Herstatt Bank and the near-collapse of the Franklin National Bank have been keeping their fingers crossed in recent weeks. Dollar bond prices have dropped dramatically before rebounding. The falls in the prices of silver and gold were almost as striking as the rises which preceded them. All in all there has been ample scope for adventurous banks to get themselves into real trouble.

In 1974, after the Herstatt affair had had its massive impact on the Euro-currency and foreign exchange markets, the central bankers broke new ground by suggesting (somewhat elliptically) that they would act as leaders of last resort to the euromarkets and that monitoring of the markets should be stepped up. Yesterday's communiqué is the central bankers' first fresh intimation on the matter of euro-market regulation since that time.

Control

This new communiqué follows a substantial amount of public and private discussion, so the message from the Governors is not as dramatic as is novel as the one in 1974. Nevertheless, it does tell us how Euro-market regulation is developing. The emphasis is very much on the prudential controls on keeping international banking safe, rather than on macro-economic controls aimed at curbing the growth of the international banking market to stop it undermining the monetary sovereignty of individual nations.

The most popular suggestion in the latter direction was for some form of global requirement which would help drive bank deposits back inside national frontiers. This suggestion has been on the back burner for some time; now, it would seem, the burner has been all but turned off. The communiqué does not even mention reserve requirements. The whole ques-

TO SAY that Sir William Barlow leaves the Post Office because of Government policy towards the nationalised industries in general and the Post Office in particular would be to go too far—but probably not much.

He was careful to say yesterday that he had good working relationships with civil servants and Ministers, and with Sir Keith Joseph, the Industry Secretary, in particular. Yet there remains the fact that he has been privately irked by tight financial limits imposed on the corporation by the present Government.

In particular, he believes that the telecommunications business should be given a looser cash rein, and he has been pressing hard to get an extra £150m pumped into telecommunications above the £1.5bn cash limit for this year.

Telecommunications, he has maintained, is in a period of strong growth, and on normal business criteria should be invested in strongly. It may be surmised that he has lost this battle, and that defeat has contributed to his decision not to stay on—as the Government wished him to do—as chairman of British Telecommunications when it is hived off from the rump of the Post Office later this year.

More generally, he is thought to have felt that the Government's attitude to the public sector has not created a helpful climate. Earlier this month, he succeeded Sir Francis Tombs, chairman of the Electricity Council, as chairman of the Nationalised Industries' Chairman Group; one of his major tasks, as he saw it, was to persuade the Government to relax cash limits and to take a more realistic view of their future prospects. It is likely that he felt that the target



Mr. Ron Dearing, the new deputy chairman and chairman-designate of Posts and Giro (left) and Sir William Barlow, chairman of the Post Office who has refused to be chairman of British Telecommunications. Who will now get the job?

gets contained in the public expenditure plans, of turning the state corporations round from a £2.3bn borrowing last year to making net repayments of £400m by 1983-84, were over-optimistic and would have to be modified.

All of these feelings, then, are likely to have confirmed his view that he was well advised to move back into the private sector while he still had at least a decade—he is now 55—on which to do major work.

What he has achieved in the two and a half years is which he has run the most publicly visible of the country's nationalised industries can be set out as follows:

First, he has fulfilled his pledge, made soon after his appointment, to push more power down the structure and to give his managers more of

their head. Though Sir William Ryland had set some of that process in train before his resignation, Barlow went further, stressing the need for openness and responsiveness at the lowest levels.

He has also kicked along the two major programmes in the telecommunications businesses—Prestel, the viewdata service, and the introduction of the System X all-electronic exchanges—and encouraged his managers to set Stakhanovite targets which have often been met. Prestel is a long way down the road to being a national system, and that only 18 months after the Prestel team was fully set up, System X was unveiled in Geneva last September, a year ahead of schedule, and the first exchange at Woodbridge, in Suffolk, in July.

In the postal business, he has seen two years of rising traffic and solid, on-target profits. National Girobank—which will form part of the slimmed down Post Office after the split—is

desperately urgent situation in which we as a union find ourselves."

Mr. Jackson had seen Post Office forecasts which show a downturn of 3.5 per cent in

considerably, the memories of last summer's troubles, which constrained the corporation to beg customers not to post letters are still vivid.

The rejection of a national productivity package by the Union of Post Office Workers last month was a bitter blow: Sir William quickly let it be known that postal management would bring in the necessary changes with or without union agreement. That may stave off industrial trouble for the future, but the chairman-designate of the Post Office, Mr. Ron Dearing, will have a close ally in the UPW, general secretary Mr. Tom Jackson—in securing the necessary changes.

The Government will certainly introduce plans to liberalise the market for subscribers' apparatus—Sir William was not over-concerned about that—but may also allow customers who lease lines from the Post Office to offer services on these lines to third parties, thus cutting deeply into Post Office revenue. Post Office opinion, including Sir William's, has been strongly against this, arguing that it would gravely harm

industrial relations generally in a delicate state. The postmen have yet to show how they will jump: the Post Office Engineers and Post Office Executives are reluctant to take part in wage restructuring, and no-one knows what will become of industrial democracy after the ending of the two-year experiment in January.

Yet Mr. Tony Carter, secretary-general of the Council of Post Office Unions and a veteran negotiator with the corporation paid a tribute last night to Sir William: "We had our disagreements with him, and they were sharp. But . . . he was dead straight." Secretary General of the Council of P.O. Unions.

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year, and is steadily becoming a major force in the banking world.

These are the satisfactions: as he said yesterday, there remain considerable problems for his successors.

The most obvious, in recent months, has been performance in the postal business. Though

deliveries have now improved

likely to have 1 million customers by early next year

FINANCIAL TIMES SURVEY

Wednesday April 16 1980

مکالمہ

Pharmaceutical Industry

This survey is published on the fiftieth anniversary of the Association of the British Pharmaceutical Industry. The world market, now worth £30.2bn a year, continues to expand and UK companies produce a big trade surplus.

Outlook far from bleak

By Sue Cameron

THE PHARMACEUTICALS industry—with estimated sales worldwide of \$85bn or £30.2bn last year—appears to be entering a new and in many ways more difficult phase of development.

It is having to face a dramatic growth in Government regulations on the research, development and marketing of its products. The start of an economic recession in the West is leading to cuts in public spending on health care, restrictions on pharmaceutical price rises in many countries and the increased use of generic drugs at the expense of the branded medicines that are the life blood of the research-based companies. Meanwhile the number of totally new drugs it is able to bring to the market each year is falling.

Yet new approaches to research are opening up the possibility of more fundamental and far-reaching discoveries being made than ever before—

albeit at a slower rate. New markets are also opening up for the major pharmaceutical companies and some of the better established ones are continuing to expand.

Prospects for the industry, as it becomes more mature, are therefore far from being totally bleak. And perhaps one of the reasons why it so often comes under attack is precisely because it is still highly successful.

Today, amid growing public suspicion about the safety of medicines, the biggest problem facing the industry is the increase in national regulations on drugs. It is estimated that the time required to test a new drug and obtain a marketing authorisation for it has doubled over the last 10 years, largely because of the extra regulations that now have to be met. The cost of bringing a new medicine to the market has also risen dramatically.

12-year average

The big pharmaceutical companies say they spend an average of £25m on a major product from the moment it is patented to the day it first goes on sale. The time needed to put it through various tests for toxicity and efficacy, through clinical trials—when it is tried on human patients—and through all the other regulatory hoops, add bureaucratic delays that are put in its path varies from 10 to 15 years but it can take longer. The average period is 12 years.

They are 12 years that eat into the effective patent life of a product. Drug patents in the UK and in most other European countries now run for 20 years.

But the need to take out a patent on a new drug at an early stage in its development means that medicines are only protected for an average of eight years after they first go on the market.

The net result is that the major companies are spending more on research and development while the period during which they can expect reasonably high returns on their investment is becoming shorter. There seems to be general agreement within the pharmaceutical industry that the longest and costliest regulatory delays on new drugs occur in the U.S. The trend in the U.S. is perhaps best summed up by Mr. Duco Akkerman, commercial director of the U.S.-based Dow group's pharmaceuticals division. In a paper given at an industry conference last year, he spoke of the "horror stories concerning the U.S. regulatory agencies."

He stated that the U.S. authorities usually have a reassuring answer for those who complain that the need to meet unnecessary regulations will make them uncompetitive. They are told not to worry because all their rivals will be made uncompetitive too.

Mr. Akkerman went on to criticise the pharmaceutical industry for its "lack of courage" in defending "its interests and its drug promotion practices."

He said drug producers had "simply been to passive in expressing our position to non-governmental bodies, to social bodies, to government bodies and, perhaps most important of all, to our customers."

In Europe, the needless

secrecy with which many of the big drug groups shroud their activities has certainly done nothing to brighten their image in the eyes of governments or the public.

The pharmaceutical companies stress that they are totally in favour of all moves that will substantially improve the safety standards of their medicines—a claim that is sometimes cynically dismissed on the grounds that this is exactly what anyone would expect them to say. But there is plenty of proof that the drug majors are hard hit by any suggestion—whether valid or not—that their products are dangerous or are in some way of a low quality.

Passed as safe

Debendorf, the U.S.-based Richardson-Merrell's prescription-only drug for the treatment of morning sickness during pregnancy, is a case in point. A lawsuit in the U.S. alleges that the medicine caused birth deformities led to sales of Debendorf falling to almost nothing in the UK. Yet most British doctors were presumably aware that the drug had been cleared by the UK Committee on the Safety of Medicines in 1978 and again last year. It was passed as safe by the committee for a third time at the end of last month.

What the pharmaceutical industry does say is that some of the increased tests and trials that are now required are unnecessary and do not lead to higher standards of safety.

The Japanese, for example, demand that almost all the work done on a new drug is repeated in Japan itself before a pro-

duct can go on sale there. Most pharmaceutical companies accept that this is reasonable as far as clinical trials are concerned because the Japanese sometimes react differently to European to a particular drug.

But the companies say there is nothing to be gained from repeating tests on mice in every country where they wish to market a new medicine.

Sometimes the industry is able to bypass regulations which it regards as unnecessarily tight. The UK is particularly stringent about the amount of data it requires before permission is given for clinical trials to go ahead, for example.

The result is that many companies with UK research operations simply carry out most of their clinical trials in other European countries.

The UK therefore achieves little by being stricter than virtually all Continental countries. But British policy may ultimately help to discourage further foreign investment in pharmaceutical research in the UK.

Although research spending is rising—partly because of the heavier regulatory burden—the number of totally new products coming on to the market each year is dropping. It is estimated that whereas there were some 90 new drugs launched on to the world market in 1960, the annual number today is under 50.

One reason for this is that the great days of the chemo-therapy discoveries are coming to an end.

Traditionally, chemical companies screened thousands of chemical compounds, hoping that perhaps one or two would prove to be useful medicines.

But experts in the industry now believe that most of the breakthroughs that can be achieved with this approach to research have already been made.

Today, many companies are concentrating on diseases, on biological mechanisms and on their own natural defences rather than on the screening of compounds. These new methods of tackling pharmaceutical research are not leading to the same spectacular number of discoveries that were a feature of the industry in the 1960s and the 1970s—almost year in and year out.

Successful

But they have led to the development of a number of highly successful drugs such as the beta blockers—used first in heart disease—and the H2 antagonists—used to treat stomach ulcers. Further discoveries in other fields, including immunology, are expected during the next few years as a result of this new approach to research.


Most of the world's great geographical drug markets are still expanding despite government attempts to curb spending on pharmaceuticals wherever possible because of the economic downturn. Over the last five years or so the world market for pharmaceuticals has risen from something in the region of \$40bn—£18.6bn—to about \$65bn—£31.2bn.

The year marks the 50th anniversary of the Association of the British Pharmaceutical Industry. Since it was founded, advances made by the drug industry as a whole have brought about a dramatic reduction in the number of victims claimed by certain diseases each year in the UK. In 1930, for example, 36,000 Britons died from tuberculosis, 3,497 from diphtheria and 28 from smallpox, although there were 11,593 cases of the latter.


In 1977, the latest year for which figures are available, only 900 people died from tuberculosis, none died from diphtheria and there were no cases of smallpox at all.

The two biggest killers in the West are still heart disease and cancer as they were in the 1930s, but the above figures can still be seen as a tribute to the pharmaceutical industry. Despite the problems that now face it, it continues to be a highly successful industry—both in terms of its financial performance and in terms of its contribution to advances in medical science.

We are proud to have received more Queen's Awards than any other enterprise



1979 For export achievement.



1979 For technological innovation.

A successful British pharmaceutical industry means healthier people throughout the world and a healthier balance of payments for Britain.

ICI Pharmaceuticals Division has a remarkable record of inventing and developing new drugs in such diverse areas as cardiovascular disease, breast cancer and antisepsis and making them available throughout the world. Last year we received a double Queen's Award (the Division's second double) bringing our total to eleven—more than any other enterprise in the UK.

The British pharmaceutical industry as a whole is highly successful. In 1979 it exported products worth £638 million,

making a substantial contribution to Britain's balance of payments and helping millions of people throughout the world live longer, healthier and happier lives.



Imperial Chemical Industries Limited
Pharmaceuticals Division
Alderley House, Alderley Park
Macclesfield, Cheshire



PHARMACEUTICALS II

Industry's flexible partnership with NHS

A FINE balance exists between the interests of the UK pharmaceutical industry and those of the National Health Service patient and taxpayer. The relationship is however also one of interdependence. The Health Service is still the industry's main customer accounting for about 35 per cent of total output mainly through the dispensing of prescriptions in chemist shops.

The NHS drugs bill has grown from £171m in 1970 to £592m in 1977 and will probably total about £593m in 1979/80. Nevertheless as a proportion of total NHS spending the drugs bill has continued to decline from around 3.2 per cent in 1970 to 7.1 per cent in 1976.

The bulk of the NHS drugs bill is accounted for by family practitioner service (FPS) spending—prescriptions written out by family doctors totalled £620m in 1978. In 1979/80 total FPS spending on drugs is expected to reach about £800m.

A further £128m, representing about 16 per cent of the total NHS drugs bill, will have been spent over the year by the health authorities on drugs supplied to hospitals. Spending on drugs by prescription, in the main through family doctors, is demand led and as such is not subject to Government cash limits.

Steady increase

The Royal Commission on the Health Service, which published its report in July, expressed "concern" over the size of the GP drugs bill. The commission noted that "total prescriptions dispensed and the average quantity of drugs prescribed have been rising steadily" and it suggested that there were some indications of "over-prescribing."

This charge has found support from some senior doctors concerned that 10 per cent of the drugs bill in England and Wales is spent on slimming pills, tranquillisers and cough medicines. However, the case has been strongly disputed by others within the health sector.

Other comments in the commission's report were equally controversial, including questions raised over the £71m that pharmaceutical companies spent on sales promotion in 1977—much of which is directed at family doctors.

The manufacturers, through the Association of British Pharmaceutical Industry (ABPI), argue that as a percentage of total sales to the

NHS the industry's promotional expenditure has remained constant and that most doctors appear to find promotion material and medical representations helpful.

Nevertheless the last Government attempted unilaterally to reduce drug promotion expenditure in two stages to 10 per cent of NHS sales in 1979. Other restrictions introduced recently cover the information contained in advertisements and the distribution of "approved fact sheets" to GPs when they are visited by medical representatives.

Successive attempts by Governments to limit the prescription drugs bill are, however, largely dependent on persuading patients not to ask for medicines they do not need and a mixture of information, exhortation and threats directed at doctors.

There is little to suggest these periodic pleas have had any real effect.

Although the expenditure by family practitioner services on drugs cannot be directly controlled, GPs' prescribing is monitored. In England and Wales if analysis shows a family doctor's prescribing habits to be markedly out of line with colleagues in his area, a regional medical officer from the Department of Health and Social Security may visit him to discuss his prescribing.

However, the process is laborious and often delayed. The Royal Commission found that in England only about 7 per cent of family doctors are visited in this way, although some 10 per cent prescribe at a cost of 25 per cent or more above the average per person for GPs in their area.

In theory the ultimate sanction against the doctor who "over-prescribes" is to stop part of his remuneration. In practice this rarely happens.

The Royal Commission discussed several other forms of control over GPs all of which are strongly opposed by the industry and the doctors. They include:

- Limited lists: Some countries including Denmark, Austria and New Zealand have drawn up lists of essential and effective drugs. Listed drugs are prescribed free or at low cost while patients pay the full cost of drugs not on the list. The commission said that despite the limited savings such a list might achieve—perhaps only £10m to £20m a year—lists should be introduced.

The ABPI in its response said such a system would harm individual patients, restrict innovation, damage drug exports by undermining the home market for non-listed drugs and would breach the basic principle that doctors should be free to prescribe what they consider best for their patients.

In addition the association said countries in Europe with limited lists spend considerably more on drugs than Britain.

● Generic prescribing: In 1977 about 85 per cent of the drugs prescribed by family doctors were prescribed by brand or proprietary name, although generic drug prescriptions tend to be cheaper. Despite the possibility that savings would be limited and chemists might have to be paid more, the Royal Commission said generic prescribing should be encouraged.

The ABPI however, pointed out that medicines with the same active ingredients do not necessarily have the same effects. Prescribing by brand supplies.

name, the association argued, would ensure consistency in treatment, and in addition it said savings might be less than 3 per cent—or less than 0.3 per cent of Health Service costs.

Because of the objections to both proposals it appears unlikely that either will be adopted—at least in the short term. There is, however, a series of developments in progress which could lead to greater control over health authority spending on drugs.

At present, individual health authorities are responsible for purchasing hospital drugs except for a small proportion—3 or 4 per cent—purchased centrally. These centrally purchased drugs—currently there are four on the list—are bought in centrally because at some stage it has been found necessary to secure and, if necessary, ration supplies to the individual health regions. Other than these special drugs the 14 regional health authorities are in effective competition for drug supplies.

The degree of central control over health authorities' drug hills is at present limited since the Department only sees that the final figure providing overall cash limits is adhered to.

However, there is a much greater degree of central "con-

trol" over the pharmaceutical manufacturers who supply the Health Service. This is achieved through the operation of the Pharmaceutical Price Regulation Scheme (PPRS), formerly the Voluntary Price Regulation Scheme. This is a system allowing departmental monitoring of the overall profits made by pharmaceutical manufacturers from supplying the NHS. The scheme, introduced in 1957 and subsequently revised and tightened on a number of occasions, provides the department with access to detailed annual financial information about suppliers which enables it to assess whether "reasonable" profits are being made. The profitability of drug companies became a controversial issue following a Monopolies Commission report on Hoffmann-La Roche and the subsequent settlement agreed in 1975 concerning the drugs Valium and Lithium.

The real strength of the present scheme stems from its flexibility. In an industry where research and development is

both costly and lengthy, the scheme allows these factors to be considered and weighed against apparent levels of profitability. The system therefore appears to have advantages over more rigid systems of price control operated elsewhere.

However, manufacturers claim that despite drug price increases, the combination of successively more stringent Government price controls and the existence of effective price competition has led to a fall in the profitability of the industry's sales to the NHS.

Thus the ABPI claims that between 1967 and 1976 return on capital fell from 27.2 per cent to 16.9 per cent and that, after tax, profit on NHS business amounts to only about 7 per cent of total sales to the health service at manufacturers' prices.

Two recent inter-related developments will probably strengthen scrutiny over the NHS drugs bill.

First, a report by the Supplies

Joint National Health Service and Departmental committee, will present a report in July on computerising information from prescription forms.

Second, a supplies council is being set up to look at whether the right price is being paid for all NHS supplies including drugs. Among its functions the council will have the task of advising both health authorities and the Secretary of State on purchasing policy and methods to improve the use of resources.

The setting up of the council could also lead to more central purchasing if this proves cost effective.

The Council is charged with carrying out its functions "in such ways as to encourage a strong and innovative UK health-care industry capable of satisfying the needs of the NHS and building up a successful export market". Within this general framework the partnership between the industry and the NHS should continue.

Paul Taylor

Concern over erosion of patent rights

THE DRUG industry is deeply concerned over what it sees as the steady erosion of the patent and trademark rights that protect its innovative products.

The attack of pharmaceutical patents and trademarks appears to be taking place on two fronts. On the one hand, some countries are changing their laws to weaken or effectively abolish patent protection. On the other, there is the more insidious growth in regulations governing the safety testing of new drugs—regulations which increase the time required to bring a drug to the market and so shorten its effective life.

The major pharmaceutical companies are not finding it easy to take action against this double-edged threat to their businesses. They maintain that patent protection is vital for them to continue to research and develop totally new medicines. They point out that they must secure reasonable returns—for a reasonable period of time—on any new drug to cover the

cost of developing it and to pay for innovative research that will lead to the discovery of other valuable pharmaceutical products.

● The reduction of patent lives.

But he only real sanction they have against government that decides to reduce patent protection is to withdraw from that national market altogether—a drastic step and one that could have adverse consequences for sales in future years. They can try to bring influence to bear on a particular country through international channels—but this can be ineffective, particularly in the case of developing nations that have no pharmaceutical industry of their own to safeguard.

One of the worst offenders is Yugoslavia. She has ruled that Yugoslav companies must own the trademark of any drugs they produce under licence from a foreign company. This law, combined with even more restrictive, nationalistic regulations on pharmaceutical technology, effectively forces West European and U.S. drug producers to hand over their expertise, lock stock and barrel—for little return—if they wish to operate in the Yugoslav market.

● The complete, legal withdrawal of patent protection for pharmaceuticals.

● Drug companies that own

licences as of right to all who apply for them—at low royalty rates.

● The reduction of patent lives.

Some Western countries including the UK—have strengthened patent protection for pharmaceutical products during the last few years. In Britain, drug patent terms were lengthened from 16 to 20 years in 1977; Italy, long a thorn in the side of producers of patent medicines, has now agreed to accept patents after years of cheerfully ignoring them; Japan and South Africa have both improved the protection given to patented drugs; and the European Patent Act, which is accepted by all members of the European Economic Community and by some other European countries, now confers 20-year patents for new chemical products instead of providing protection just for new chemical processes.

● Development stage

But despite these advances—from the point of view of the industry—patents still have to be registered early on in the research and development stage. The case against certain types of tests, or the frequency with which they have to be carried out, is often highly technical. The arguments certainly do not

have the same impact on the public as claims—however unfounded—that a certain preparation is dangerous. Witness the reaction over the past few months to charges that the U.S.-based Richardson-Merrell's Dehendorf encourages the birth of deformed babies, or that the Swiss-based Roche's Valium is addictive.

The drug companies are therefore going to have a hard time to persuade national regulatory authorities to reduce the number of tests required. Substantial increases in the number of civil servants employed by the regulatory authorities themselves would cut some of the delays but this is also going to be unpopular and public spending cuts.

Yet if increased regulations effectively shorten a drug's patent life—after it has been put on the market—there would seem to be a case for periodically reviewing the time limits placed on patent protection.

Sue Cameron

The next five years will see 3 original compounds from the Roussel U.K. research team


European partnership makes it possible

In the next five years, patients around the World will benefit from the introduction of 3 major new products researched and developed here in Britain by Roussel Laboratories Limited.

They are just part of the rich harvest of investments that the international Roussel Uclaf Group has made in British resource and expertise in recent years—investments which have led to the development of one of the UK's most advanced Research and Production units and which have created new job opportunities for over 500 British scientific, production and technical staff.

And Roussel Uclaf's commitment to the UK is yielding healthy dividends for British exports. Roussel Laboratories Limited now earns Britain nearly £13 million in export sales and the proportion of UK production allocated to overseas requirements is set for a further significant increase following the Parent Company's announcement that Britain is to be the major manufacturing and export base for another of the Group's important new products in 1980-1981.

Roussel Laboratories is part of the International Roussel Uclaf Group




Investment
In the past 10 years, the Roussel Uclaf Group has invested over £15 million in its UK subsidiary Roussel Laboratories Limited.

Research
Roussel's R&D unit at Swindon, Wiltshire, is part of Roussel Uclaf's international commitment to new product research.


Exports
Roussel Laboratories Limited has an annual turnover in excess of £40 million and exports to over 100 countries throughout the World.



Roussel Laboratories Limited
Roussel House, Wembley Park, Middlesex HA9 1NF.



ONE HUNDRED YEARS
WELCOME



1880 — 1980

In the service of
world health



The Wellcome Foundation Ltd
183 Euston Rd London NW1 2BP



THE QUEEN'S AWARD FOR
EXPORT ACHIEVEMENT 1979



Dr. Daniel Azarnoff, president, Searle Research and Development, who has authorised the £5m investment in a pilot plant for biotechnology at High Wycombe

The threshold of discovery

NEWS THAT an American multi-million-dollar company was planning to give £2.5bn in cancer research prompted The Lancet, in a leading article to caution that "few experts believe that another programme of empirical research would yield a cure-all 'wonder drug'."

The journal believes that the most cost-effective and quickest way of achieving dramatic results with the money would be to spend it investigating the geography of cancer and the striking variations in patterns of cancer world-wide. Given sufficiently large resources, it sees opportunities here that have never been available before: for example, in China, with a large and well-organised population, for the great majority of whom the environment is unlikely to change sharply in the next five or 10 years.

But Searle, together with other major drug companies, now has high hopes of a "second-generation" route to interferon, by way of genetic engineering—surgery in the laboratory upon the genetic material DNA to induce it to make the interferon molecule. Its British laboratories have published a significant step this year towards the use of this new technology, and its new pilot plant is being designed to accommodate the next stage of scaling up its laboratory work.

Wider uses

Another major area of development for naturally occurring agents is the fast-growing understanding of the opiate peptides—the various enkephalins and endorphins. They first drew attention because of their powerful analgesic action, which suggested an important role in controlling a patient's perception of pain, perhaps free from the side-effects of addiction. Now it is emerging that these agents may find much wider uses, not least in combating mental disorders. Several companies, among them Warner Lambert, Smith Kline and French, and Hoffmann-La Roche, are pursuing the possibility of using these powerful agents to restore the cognitive powers of a flagging brain, for example in the case of senile dementia.

These discoveries are indeed profound enough to lead medical scientists to believe that they may hold clues to several of the big disease problems still waiting for cures. Moreover, they are in areas where medical science in Britain has laid strong foundations for the efforts now being mounted by the pharmaceutical industry.

One such discovery is the interferons, powerful substances which the body produces as a defence against virus infection. When Isaacs and Lindenmann of the Medical Research Council's National Institute for Medical Research discovered interferons in 1957 they were recognised universally as having the possibility of combating virus infections as effectively as antibiotics attacked the big bacterial killers.

Moreover, interferons had the advantage over antibiotics of being substances the body already produces, if sometimes inadequately, unlike antibiotics which are foreign bodies and sometimes produce a strong reaction.

Discouraged

But so complex were the problems of isolating and purifying specific interferons for tests against specific diseases that most research teams became very discouraged.

Fundamental work continued on the role of these agents, however, and has shown that they help to regulate the body's natural defences against infections and cancers. Research in the laboratories of the Imperial Cancer Research Fund in London has shown that they slow down or "freeze" living cells as they proceed through their normal processes of replication. This must be an important clue to whatever prevents cells from running amok, as they do in cancer.

Quite recently, results of small clinical trials with pains-takingly purified traces of interferon have begun to show some encouraging results in cancer patients. Meanwhile, the drug industry's enthusiasm has been rekindled by the possibility of new techniques for making interferons instead of trying to separate them from donated blood.

One important new source is G. D. Searle, the U.S. pharmaceutical company, which announced plans last month to build a £5m biologicals pilot plant at High Wycombe to manufacture interferon by tissue culture. It is installing six 200-litre fermenters to provide what it claims will be the largest production capacity anywhere for interferon—3.6bn units of fibroblast interferon a month, made from connective tissue.

To put this figure into perspective, cancer patients are receiving 1m units per patient per month, for six to nine months. So this plant will cope with only a few hundred patients at a time.

David Fishlock

UK HOUSEHOLDS spent £320m last year on over-the-counter medicines which provide an important source of additional revenue for the pharmaceutical industry while easing the pressure on the National Health Service. Although prescription drugs provide the largest slice of income for the industry, in volume terms more medicines are bought over the counter than are prescribed by doctors.

Household medicines now represent about 10 per cent of the industry's total output. Most are branded products, all are purchased without prescriptions.

The expectation that the market for non-prescription medicines would vanish with the introduction of the NHS in 1948 has proved false. Although sales, profits and demand for these drugs has remained relatively static over recent years, a continued market for medicines bought by the public to treat minor ailments appears assured.

The importance of over-the-counter medicines and self-help has been reflected in a series of reports and statements. The Price Commission, in its report on the industry in 1978, concluded that "the NHS would be quite unable to deal with the extra demand that would be unleashed in the absence of medicines for sale over the counter."

The Royal Commission on the National Health Service in its report published last year said: "Intelligent self-medication and care can undoubtedly reduce demands on health services" and added that it is essential that society accepts the need for appropriate self-care.

The industry has stressfully shrugged off the image of the "proprietary" medicine as a second-rate product—although the trade association retains the name—the Proprietary Association of Great Britain.

In the wake of the changed status of the non-prescription medicine has come acceptance from politicians, health care planners and doctors.

Self-help

Thus Sir George Young, Health Minister, speaking last year at the association's 60th anniversary said: "The vast majority of over-the-counter medicines are made up of such things as temporary coughs, colds, indigestion and constipation which can be quite appropriately managed without consulting a doctor."

In fact the average member of the public consults his doctor less than four times a year and successive Health Secretaries have encouraged a greater reliance on self-help, including a visit to the chemist rather than the overworked doctor.

This endorsement of the use

of non-prescriptive medicines is in part a consequence of the pharmaceutical industry's own efforts. The industry has imposed its own measures of self-control and since 1968 all medicines, whether prescription or non-prescription, have been licensed. The advertising of products is also tightly controlled both by the industry's own pre-publication system of scrutiny and by the Government.

Against this background the industry has developed a wide range of products specifically aimed at the treatment of minor ailments. The Price Commission estimated that there are some 1,300 proprietary non-prescription medicines of which over 300 are advertised.

The four most important categories of over-the-counter medicines in terms of sales value are analgesics—pain killers like headache pills, cough and cold remedies, digestive and laxative preparations, vitamins and tonics. Together these household medicines account for about two-thirds of average household expenditure—less than 40p a week.

Although the list of active ingredients which may be used in these medicines is severely limited by the need for wide safety margins, manufacturers have been able to establish wide product differentials. The market for non-prescriptive medicines is complicated by the quality of the product since these drugs are medicines in

the same way as prescription products—and controlled by equally stringent regulations—but they are also consumer goods which must achieve retail distribution sales.

To ensure success in the market place, manufacturers see branding as vital. Without branding, they argue, the volume sales necessary to fund development and innovation could not be achieved. However, since the market for these medicines is more or less constant, competing brands can only increase market share at the expense of others.

The Price Commission, emphasising what was already known, that over-the-counter medicines have low price sensitivity, brand loyalty is high and customers are loathe to experiment. In addition, although overall household expenditure on non-prescription medicines increased by over 20 per cent last year, some medicines still represent less than 0.5 per cent of average household expenditure—less than 40p a week.

Even the largest sector of the market—analgesics—is worth less than £40m at shop prices and each sector of the market is highly fragmented. The top seven brands hold less than 60 per cent of the market with the remainder made up of 250 different brands. The Price Commission suggested that advertising in this sector can equal the direct costs of manufacture and

misleading and would push up prices.

The other function vital to the industry is continued innovation. In the absence of a cure for the common cold, research, estimated by the Price Commission to total about 4 per cent of sales revenue, is directed at releasing medicines to provide additional relief.

In the longer term, the industry is considering the potential for development of over-the-counter medicines containing drugs currently available only on prescription and the possibility of widening the scope of self-medication, for example by allowing the restricted sale of certain prescription medicines to patients with conditions diagnosed by a doctor as intractable and susceptible to occasional symptomatic treatment.

For the present however, pharmaceutical manufacturers are concerned with maintaining home and export sales, market share and profit margins in the non-prescriptive sector.

Manufacturers may hope for a slight dip in sales as a result of the Government's decision, announced in the Budget, to increase prescribing charges to £1 from December. However, previous prescription charges increases have resulted in only temporary sales gains. New winter's weather and the possibility of a flu epidemic are more important.

Paul Taylor



Making it better

The discovery of aspirin in 1899 is but one of many important 'firsts' in the field of medical research which have established Bayer among the world's leading pharmaceutical companies.

Other notable developments include analgesics and modern anaesthetics; world famous drugs for malaria, chagas disease, bilharzia, and tuberculosis; sulphonamides; new generations of penicillins; and major contributions in the fight against heart disease—the scourge of industrialised nations.

In many areas of health, Bayer products continue to bring relief and ease discomfort in many ways.

For dentistry, Bayer makes precision impression materials. In yet another area, its latest innovation, Baycast® is a lightweight cast material that can be used in most situations demanding a cast or splint.

Bayer's concern, dependability and imagination are helping to make life better, with no fewer than 6,000 products. With engineering plastics like Makrolon® crop protection and veterinary products, textile fibres such as Dralon® with Mafu® insecticides and the Delial® range of suntan cosmetics. It does so by calling on the skills and dedication of 170,000 employees throughout the

world and by spending over £200 million each year on research to find new ways of making the good, better. And the better, better still.

Bayer UK Limited,
Bayer House, Richmond,
Surrey TW9 1SJ

Bayer
Improving the quality of life

PHARMACEUTICALS VI

Training for profession's changing role

Advancing medical knowledge through major research programmes in cardiology, endocrinology, immunology, respiratory disorders, pain and psychotropics.



Progress through innovation

Sandoz Products Limited/Wander Pharmaceuticals
98 The Centre, Feltham, Middlesex TW13 4EP

AS STUDENTS, pharmacists become knowledgeable on the function of beta-blockers, the role of neuro-transmitters, and the importance of cell biochemistry and spend long hours on complex laboratory experiments investigating the interaction of drugs in animals.

But on graduation many face a different reality across the pharmacy counter for which their studies have left them ill prepared. What to recommend to cure a rash or a cough, how to cope with a customer who has swallowed the powder out of his capsules and brought the cases back for a refill, or a drug addict with an obviously forged prescription.

The contrast is just one example of a series of complex educational problems facing the

pharmaceutical profession. How can the demands of an ever-expanding scientific curriculum be combined with the teaching of the human skills needed to ensure patients do not misuse or abuse increasingly potent drugs?

And how can adequate continuing education be provided for an age when, according to some estimates, up to 90 per cent of knowledge in the medical sciences has been accumulated in the past ten years, and no one's qualifications will last anything like a working lifetime?

In particular, the problem is how to ensure that pharmacists are fully aware of new developments and specialisations when conventional lectures reach perhaps only 10 per cent of pharmacists.

"In Scotland we have already had a case of a man with four items on a prescription but only £1, asking which was the most important item to have. These are decisions which will be forced on pharmacists because there is no one else," Mr. James Bannerman, chairman of the Pharmaceutical Society's education committee and a past president of the society, commented.

The changing role of pharmacists has been particularly pronounced in the hospitals where new specialisations have emerged. Pharmacists have gradually been coming out from isolated basement pharmacies onto the wards as a full member of the health team. Sometimes their responsibility is to ensure that drugs are stored properly on the wards and that adequate supplies are available.

But increasingly, ward pharmacists are becoming involved in clinical judgments, assessing drug regimes most appropriate for a patient and trying to prevent dangerous interactions.

Drug information is another important new specialisation, usually organised at the hospital regional level and involving, like clinical pharmacy, the need for new patterns of education, much of it postgraduate. It was even revealed last month that regional pharmacy information officers are now co-operating to produce "independent assessments of new drugs" to allow comparisons with the claims of manufacturers.

Four years ago Dr. J. Swarbrick, then Dean of the School of Pharmacy at London University, finally gave up examining

pharmacists in 1970, has been

warned of an apparent failure "to give due emphasis in the curriculum to co-ordinating the physical, chemical and biological knowledge of drugs in such a way that the student had the confidence and ability to communicate and deal effectively with members of the public who came to him for advice and with physicians."

That particular school has done something about it. In a reorganised course a new third year pharmacy core includes lectures by doctors on selected diseases, their cause and alication and a new emphasis on drug information.

And from this autumn the school plans to introduce a new MSc course providing a scientific basis for the best selection and use of drugs, including clinical practice sessions at Northwick Park Hospital. Chemotherapy and drug metabolism will be taught by pharmacists while pathology and other therapies will be taught by medical staff from London hospitals.

Mr. Bannerman believes that the 17 British schools of pharmacy—ten in universities and seven in colleges of technology—are slowly moving towards a more patient-oriented and clinical approach while retaining the traditional core subjects of a pharmaceutical education, the chemistry of drugs, the pharmaceutical aspects of medicines and their action and use.

The Pharmaceutical Society,

which finally gave up examining

pharmacists in 1970, has been

anxious for some time to tighten up the requirement for the pre-registration year—the year all pharmacy graduates must serve under the supervision of a qualified pharmacist before being admitted as Members of the Pharmaceutical Society.

New regulations will come into

force in 1981 which will mean

stricter assessment of young

pharmacists. In the past, pro-

gress to MPS status has in-

progress been fairly automatic.

The society will maintain pre-

registration courses run by the

larger organisations such as

Boots and will be directly

responsible for students in

individual pharmacies.

Student will have to make

written submission and if

there is doubt about a student's

progress, the society will ask for

the pre-registration period to be

extended.

Attempts are also being made

to set up regional post-

graduate education committee

funded by health authorities,

but progress has been slow.

Perhaps the greatest potential

step forward in providing a

framework for postgraduate

work, continuing education and

for raising the status of phar-

macists and encouraging excel-

lence is the planned College of

Practitioners, due to be set up

next year.

Mr. Bannerman hopes it will

encourage the emergence of an

elite and that it will do for

pharmacists what he believes

the College of General Practi-

tions did for GPs. Entry

would be by examination or

unusually distinguished contribu-

tion to any aspect of phar-

macy.

One study, at Leicester Poly-

technic, suggested linking con-

tinuing education through

correspondence courses with

a College of Practice. The

Leicester group produced a trial

correspondence package, in-

cluding assessment on "the

respiratory tract, its structure

and function" and the response

from local pharmacists was

good.

But although co-operation be-

tween the health professions is

slowly increasing, a long term

plan put forward by Professor

A. M. Cook of the Welsh School

of Pharmacy six years ago for

a three year health science

course for medical, pharmacy

and dental students, followed by

further study for a professional

qualification still seems a long

way off.

The Pharmaceutical Society also approved last month the setting up of a research survey to pinpoint the future educational needs of its members. The performance of a sample of pharmacists with 20 or fewer years on the register will be assessed anonymously to see

the weaknesses lie.

The future educational needs of British pharmacists may yet be influenced by Britain's membership of the EEC. A draft directive has already been drawn up which would allow pharmacists of the EEC nations to practice throughout the Nine.

But the British undergraduate courses—three years in the universities or four at polytechnics—are shorter than in the rest of the EEC where five years is more normal. In Holland a pharmacy degree takes six years with the period of pre-

registration an integral part. But according to the Pharmaceutical Society, informal agreement has been reached that the second British "A" level year will count as the first year of a Continental university course.

This might clear the way for "harmonisation" and agreement within two or three years.

If the directive is accepted, British pharmacists hope that language and cultural barriers will be strong enough to save them from too much competition for jobs from countries such as France, which combines strict control of the number of pharmacists with over-production of pharmacy graduates.

Pharmaceutical education in Britain is clearly entering a period of rapid change. A report from the Royal College of Physicians of Edinburgh last year even advocated that the involvement of pharmacists, doctors and nurses in each other's undergraduate courses should be encouraged to allow the pharmacists' expertise in areas such as drug kinetics (the rate of movement through the body), the legal aspects of prescribing, and clinical trials to be more fully used by medical schools.

But although co-operation be-

tween the health professions is slowly increasing, a long term

plan put forward by Professor

A. M. Cook of the Welsh School

of Pharmacy six years ago for

a three year health science

course for medical, pharmacy

and dental students, followed by

further study for a professional

qualification still seems a long

way off.

Raymond Snoddy

"The health of nations is more important than the wealth of nations."

Will Durant
What is Civilization?


Sculpture
"The Great Doctor"
Wolfgang Reimann

Wyeth Laboratories shares this view, and has operated in support of national and world health for well over 100 years.

Wyeth Laboratories manufacture oral contraceptives, tranquillisers, hypnotics and a wide range of ethical pharmaceuticals together with the S-M-A range of baby foods.

Wyeth
Wyeth Laboratories
Huntercombe Lane South,
Taplow, Maidenhead, Berks.

TRAINING COURSE
for candidates intending to sit the
DIPLOMA IN
PHARMACEUTICAL MEDICINE
(Royal Colleges of Physicians UK)
The Pharmaceutical Medicine Liaison Committee (representing the ABPI, AMAPI and the University of Wales Institute of Science and Technology) invited pharmacists employed in the pharmaceutical industry who are interested in attending the above course to write for full details to:
Dr. D. K. Luscombe
Course Organiser for Pharmaceutical Medicine
Welsh School of Pharmacy, UWIST
Cathays Park, Cardiff CF1 3NU



...in sickness and in health...

Our business is concerned not only with making sick people well, but also with improving the quality of people's lives. Over the years we have achieved enormous success in both these fields. In fact, our extensive contribution to the major fields of medical research has made us one of the world's leading pharmaceutical houses.

But however illustrious our past may have been, the future looks even better. Indeed, as major projects have come to fruition, the new decade promises to be our most successful yet.

This year we are making an important new contribution to the treatment of rheumatism and arthritis. We have significant developments in the field of cancer treatment and new generation antibiotics are now in use.

In the longer term, as we continue to be involved in research programmes that touch the very frontiers of medical science, the prospects are even more exciting. The latest fruits of our endeavours for example can be seen in the research work on recombinant DNA, particularly in the production of human insulin, and in the development of very advanced fermentation techniques.


We believe it is work like ours that holds the promise of a better future for everyone.

لها من العمل

PHARMACEUTICALS VII

Ciba-Geigy

STAGES IN THE DISCOVERY AND DEVELOPMENT OF A TYPICAL DRUG



The high cost of marketing new products

IT TAKES as long nowadays to bring a new drug to the market as a new engineering system, five to 10 years, and costs between £1m and £2m to research, develop and prove a satisfactory new product. The risk of failure is high and much of the money may have been spent before flaws in the product are revealed.

There have been well-publicised cases where the flaws have been so obscure that they began to reveal themselves only when the manufacturer had invested in its production; and sometimes only when it was being used by very large numbers of people.

But the principal barrier to innovation in drugs is not the rapidly rising cost of research and development per se but public perception of risk. As one of the Welsh MPs, after six years as a rear health service medical student, following only for a moment or still seems a long

time ago, has instanced the outcry about possible hazards of vaccinating babies against whooping cough. Publicly given to babies who suffered fits after vaccination—and the evidence of a correlation, says Dr. Weatherall, "left much to be desired"—was enough to depress severely the numbers vaccinated in the late 70s. The incidence of whooping cough has risen alarmingly, and with it the death toll from the disease.

Immunisations

"Fear of the hazard of immunisation has generated illness and death from the natural disease on a scale far beyond what immunisation itself would cause," he wrote recently in the *Pharmaceutical Journal*.

The total recorded number of deaths in Britain in 1977 from toxic effects of drugs used therapeutically was 518. This figure gives no cause for complacency by the drug industry, and may anyway be an underestimate since other causes of death are likely to have been ascribed in some cases. But the figure should nevertheless be

compared with that of 34,000 who died the same year from lung cancer, when the carcinogenicity of tobacco smoke has been established beyond doubt since the early '60s.

Drugs that have surmounted the lengthy processes of safety evaluation demanded by government today cause iatrogenic disease—drug-induced afflictions—not because of the cupidity of the drug industry or of some slight idiosyncrasy of the sufferer. The idiosyncracy may, for example, be a cancer, where a particular type of cell in the body has run out of control. A drug powerful enough to arrest so specific a disease will inevitably hazard healthy living cells of the same and perhaps of a different kind.

But the idiosyncracy may also be a genetic inability to tolerate a particular chemical—one many people readily accept in the case of foods, for example. Or it may be an interaction with something else the person has eaten, or some other drug the patient is taking.

Idiosyncrasies of this kind can be so rare that they show up only when clinical trials have been extended to many

thousands of patients; in other words, once the drug is manufactured and available widely to doctors.

It took 40 years of painstaking statistical research to disclose the correlations between tobacco smoke and lung disease, even though once established the correlation was revealed to be very close, and the problem to be of epidemic proportions.

Warning signs

There is no doubt that a steady decline in the introduction of new drugs has followed the stricter requirements for safety testing following the thalidomide debacle of the early 60s. Thalidomide exposed a problem—teratogenicity—novel to toxicology. Where the drug industry was culpable was in failing to respond quickly to warning signs that something was amiss.

But Professor George Wibberley and Mr. Fred Steward of the pharmaceutical innovation group at Aston University point out that the decline in new products is not only because of tougher standards for "new

chemical entities" (NCE). The greatest decline for Britain has been in new products containing an active ingredient already available in some other product.

The Committee on Safety of Medicines has been deliberately discouraging the proliferation of products based on the same mechanism.

These researchers say that an NCE may be withdrawn from the market for other reasons than toxicity problems— inadequate efficacy or poor sales, for example. Their analysis of NCEs introduced in Britain between 1960-75 shows that since 1964, when the Daps Committee on the Safety of Drugs was set up, there has been a much lower rate of withdrawal.

Efficacy it seems, is no longer in question once products have been approved by the regulatory authority, which since 1968 has been the Committee on Safety of Medicines. The system has also greatly reduced, if not eliminated, the risk of a product performing poorly in sales.

Drugs available today are undoubtedly much safer than those of two decades ago. The

British Medical Journal recently described the concept of randomised, double-blind controlled trials of new drugs as one of Britain's most important contributions to medicine since the war.

But tighter controls are only part of the story. One of the most important factors is that the drug industry has a much better understanding of basic pharmacological mechanisms, for example of receptor mechanisms, leading to much more selective action upon the site of the disease, and fewer adverse reactions through interference with healthy processes in the body.

Another innovation has been much more selective drug delivery systems, able to deliver drugs at or close to the site of the problem. These systems are beginning to eliminate the grossly inefficient if time-honoured pill "three times a day before meals" whose efficacy is so often undermined by the complex chemistry of the alimentary system.

The drug industry now believes there is strong evidence that a limit is being approached—may even have

been reached—in the overall effectiveness of drug control mechanisms operating in such countries as Britain and the U.S. Tighter controls, it believes, could now have the result of diminishing benefits to patients, for example by depriving the sick of a new drug because of a remote risk or uncertainty about its behaviour.

Although many major targets of the drug innovators have been reached, notably among the infectious diseases, several major targets remain. They include most cancers, much heart disease, rheumatism and arthritis, multiple sclerosis, and several big problems endemic in the more impoverished countries, including malaria and leprosy.

Growing interest

There is growing interest in finding ways of accurately assessing the impact of drug control mechanisms to gauge how much good and how much—if any—harm they are doing at their current level of rigor. Three possible ways of making


this assessment have been suggested.

One would be to use scientific case studies, perhaps to investigate how a particular drug was treated by different national regulatory bodies, and correlate this with the impact on public health for each nation. It would require co-operation of both manufacturers and governments to be successful.

Another way would be to examine how the regulatory agency goes about its business; for example, which drugs it rejected or caused to be withdrawn from the market, and why, and what were the experiences of another country whose regulatory agency approved the product.

A third way would be to examine the market and how the availability or otherwise affects the patient and his progress. This study would probably be the most complex to organise, but its results could well prove the most convincing on whether we have reached a natural limit to the value of tighter controls on the toxicity of drugs.

David Fishlock



Research and innovation are our business

Better health is your dividend

Ciba-Geigy Pharmaceuticals

All the patient sees is the tablet—a few cubic millimetres of finished product. What he doesn't see is the concentrated effort—the thousands of hours spent in research, the skill of varied scientific disciplines, the experience of hospital doctors and general practitioners, and the able endeavours of qualified medical representatives, with the continual backing of the professional advisory services of an international organisation.

Ciba-Geigy Pharmaceuticals,
Horsham, West Sussex

CIBA-GEIGY

PHARMACEUTICALS VIII

"What on earth are Fisons doing in the field of medical research?"

Medical research, we suspect, isn't the first thing that springs to mind when our name is mentioned.

Unless, perhaps, you know anything about allergies and their treatment.

In fact, Fisons are (and have been for some years) in the forefront of research into the cellular basis of these widespread reactions.

As a consequence, they've produced a range of treatments which help prevent a lot of discomfort caused by allergies.

And help sufferers lead more normal, active lives.

Fisons Limited, Pharmaceutical Division, 12 Derby Road, Loughborough, Leicestershire LE11 0BB.

FISONS

Helping people lead normal, active lives.

Registered Trade Mark.

The strong emphasis on drug research is yielding a number of significant new developments. Here, and on the following two pages, SUE CAMERON looks at the progress of some of the leading pharmaceutical manufacturers.

Signs of success

BAYER

Pharmaceutical sales in 1979: £M3.4bn (£820m). Pharmaceutical sales as a proportion of total turnover: 30 per cent.

Pharmaceutical research spending: £35.8m (estimated). Main areas of pharmaceutical production and research: cardiovascular drugs; antibiotics; metabolic drugs; analgesics; painkillers; topical diseases; cancer. Main pharmaceutical products on the market: Adalat—a heart drug; Bayer—an antibiotic; Aspirin. Considered used to treat skin disorders.

THE GERMAN-BASED Bayer has just launched its antibiotic, Baypen, in the UK. The drug, which has been on the German market for 18 months, is a powerful, broad spectrum antibiotic and the group claims that it is particularly useful for the treatment of patients who have weak resistance or who are taking other medicines.

Bayer is planning to launch Baypen in other countries and it is working on a number of follow-up products—antibiotics that will have a slightly different range of applications. Yet, although this new drug shows signs of being highly successful, one of the biggest contributors to Bayer's profits is still Aspirin—discovered by the group in 1899.

Aspirin—a Bayer trade name in most countries although it is used as a generic term in some places, including the UK—is said by the group to be the most widely used drug in the world.

Bayer, like so many of its competitors, is concerned about some of the "ludicrous" regulatory obstacles that are put in the paths of those trying to bring a new medicine to the market place. It says it is conscious of the need for safety but deplores demands for totally risk-free drugs on the grounds that nothing can ever be 100 per cent safe.

The group says that the extra money and time needed to adhere to national regulations has forced it to narrow the range of its research and development operations. Money can only be spent once and it therefore has to concentrate on research projects which show promise at an early stage.

Bayer's range of pharmaceutical research areas is still wider than that of many other companies; if only because of the group's sheer size. And its pharmaceuticals business is accounting for a growing share of its total sales—in 1971 the division accounted for only some 11 per cent of world turnover as opposed to 20 per cent in 1973.

One reason for the growth of Bayer's pharmaceutical sales is its increased presence in the vital U.S. market. Six years ago it bought Cutler Laboratories and in 1978 it also purchased Miles Laboratories for \$250m. In 1978 sales at Cutler were \$256m while those from Miles were \$373m.

THE GERMAN-BASED Bayer has just launched its antibiotic, Baypen, in the UK. The drug, which has been on the German market for 18 months, is a powerful, broad spectrum antibiotic and the group claims that it is particularly useful for the treatment of patients who have weak resistance or who are taking other medicines.

Bayer, like so many of its competitors, is concerned about some of the "ludicrous" regulatory obstacles that are put in the paths of those trying to bring a new medicine to the market place. It says it is conscious of the need for safety but deplores demands for totally risk-free drugs on the grounds that nothing can ever be 100 per cent safe.

The group says that the extra

money and time needed to adhere to national regulations has forced it to narrow the range of its research and development operations. Money can only be spent once and it therefore has to concentrate on research projects which show promise at an early stage.

Bayer's range of pharmaceutical research areas is still wider than that of many other companies; if only because of the group's sheer size. And its pharmaceuticals business is accounting for a growing share of its total sales—in 1971 the division accounted for only some 11 per cent of world turnover as opposed to 20 per cent in 1973.

One reason for the growth of Bayer's pharmaceutical sales is its increased presence in the vital U.S. market. Six years ago it bought Cutler Laboratories and in 1978 it also purchased Miles Laboratories for \$250m. In 1978 sales at Cutler were \$256m while those from Miles were \$373m.

Confident of future

BECHAM

Pharmaceutical sales for the year ending in March, 1979: £324.6m.

Pharmaceutical sales as a proportion of total group turnover: 33.1 per cent. Total research spending for the year, including pharmaceuticals research: £31.3m.

Estimated spending on pharmaceuticals research alone: £26m.

Major pharmaceutical research and production areas: antibiotics; allergy vaccines; drugs for gastro-intestinal disorders; cardiovascular drugs; vitamins available without prescription.

Major products on the market: Amoxil, Pyopen, Ticar, and Penhritin—antibiotics; Pollinax—used against hay fever; Maxilon—for treating gastro-intestinal disorders.

UK-BASED Beecham claims that the effects of unlicensed competition on its best-selling Amoxil—amoxycillin—sales in the U.S. have been "exaggerated." The claim is accepted in many quarters of the pharmaceutical industry but the group clearly has been affected—especially as unlicensed competition was accompanied by

interesting new products and some likely-looking drugs in its laboratories.

It claims that Ticar, another of its antibiotics, is making an important contribution to its profits in the U.S. and is actually more important in America than the troubled Amoxil. Earlier this year Ticar was launched in Japan, where the market for it could well prove to be even bigger than that in the U.S.

Beecham is also "very close" to launching Augmentin, an oral antibiotic which the company says is effective against a broader range of bacteria than any comparable drug now on the market.

The group is doing research on a number of anti-viral and anti-inflammatory products and says it has one of the latter undergoing clinical trials at present. The drug, which will be used to treat such illnesses as rheumatoid arthritis if the trials prove successful, is said to be "very promising."

Beecham is looking for expansion primarily in its overseas markets because, as it puts it, "we have such a large market share in the U.K. now."

During the past year Beecham, like other UK-based drug groups, has also been hit by the strength of sterling and by the turmoil that followed the revolution in Iran. Iran has always been an important export market for British drugs.

Yet the group is confident about its long-term prospects and even in the shorter term, Beecham is launching some

UK-BASED Beecham claims that the effects of unlicensed competition on its best-selling Amoxil—amoxycillin—sales in the U.S. have been "exaggerated." The claim is accepted in many quarters of the pharmaceutical industry but the group clearly has been affected—especially as unlicensed competition was accompanied by

interesting new products and some likely-looking drugs in its laboratories.

It claims that Ticar, another of its antibiotics, is making an important contribution to its profits in the U.S. and is actually more important in America than the troubled Amoxil. Earlier this year Ticar was launched in Japan, where the market for it could well prove to be even bigger than that in the U.S.

Beecham is also "very close" to launching Augmentin, an oral antibiotic which the company says is effective against a broader range of bacteria than any comparable drug now on the market.

The group is doing research on a number of anti-viral and anti-inflammatory products and says it has one of the latter undergoing clinical trials at present. The drug, which will be used to treat such illnesses as rheumatoid arthritis if the trials prove successful, is said to be "very promising."

Beecham is looking for expansion primarily in its overseas markets because, as it puts it, "we have such a large market share in the U.K. now."

During the past year Beecham, like other UK-based drug groups, has also been hit by the strength of sterling and by the turmoil that followed the revolution in Iran. Iran has always been an important export market for British drugs.

Yet the group is confident about its long-term prospects and even in the shorter term, Beecham is launching some

UK-BASED Beecham claims that the effects of unlicensed competition on its best-selling Amoxil—amoxycillin—sales in the U.S. have been "exaggerated." The claim is accepted in many quarters of the pharmaceutical industry but the group clearly has been affected—especially as unlicensed competition was accompanied by

interesting new products and some likely-looking drugs in its laboratories.

It claims that Ticar, another of its antibiotics, is making an important contribution to its profits in the U.S. and is actually more important in America than the troubled Amoxil. Earlier this year Ticar was launched in Japan, where the market for it could well prove to be even bigger than that in the U.S.

Beecham is also "very close" to launching Augmentin, an oral antibiotic which the company says is effective against a broader range of bacteria than any comparable drug now on the market.

The group is doing research on a number of anti-viral and anti-inflammatory products and says it has one of the latter undergoing clinical trials at present. The drug, which will be used to treat such illnesses as rheumatoid arthritis if the trials prove successful, is said to be "very promising."

Beecham is looking for expansion primarily in its overseas markets because, as it puts it, "we have such a large market share in the U.K. now."

During the past year Beecham, like other UK-based drug groups, has also been hit by the strength of sterling and by the turmoil that followed the revolution in Iran. Iran has always been an important export market for British drugs.

Yet the group is confident about its long-term prospects and even in the shorter term, Beecham is launching some

UK-BASED Beecham claims that the effects of unlicensed competition on its best-selling Amoxil—amoxycillin—sales in the U.S. have been "exaggerated." The claim is accepted in many quarters of the pharmaceutical industry but the group clearly has been affected—especially as unlicensed competition was accompanied by

interesting new products and some likely-looking drugs in its laboratories.

It claims that Ticar, another of its antibiotics, is making an important contribution to its profits in the U.S. and is actually more important in America than the troubled Amoxil. Earlier this year Ticar was launched in Japan, where the market for it could well prove to be even bigger than that in the U.S.

Beecham is also "very close" to launching Augmentin, an oral antibiotic which the company says is effective against a broader range of bacteria than any comparable drug now on the market.

The group is doing research on a number of anti-viral and anti-inflammatory products and says it has one of the latter undergoing clinical trials at present. The drug, which will be used to treat such illnesses as rheumatoid arthritis if the trials prove successful, is said to be "very promising."

Beecham is looking for expansion primarily in its overseas markets because, as it puts it, "we have such a large market share in the U.K. now."

During the past year Beecham, like other UK-based drug groups, has also been hit by the strength of sterling and by the turmoil that followed the revolution in Iran. Iran has always been an important export market for British drugs.

Yet the group is confident about its long-term prospects and even in the shorter term, Beecham is launching some

UK-BASED Beecham claims that the effects of unlicensed competition on its best-selling Amoxil—amoxycillin—sales in the U.S. have been "exaggerated." The claim is accepted in many quarters of the pharmaceutical industry but the group clearly has been affected—especially as unlicensed competition was accompanied by

interesting new products and some likely-looking drugs in its laboratories.

It claims that Ticar, another of its antibiotics, is making an important contribution to its profits in the U.S. and is actually more important in America than the troubled Amoxil. Earlier this year Ticar was launched in Japan, where the market for it could well prove to be even bigger than that in the U.S.

Beecham is also "very close" to launching Augmentin, an oral antibiotic which the company says is effective against a broader range of bacteria than any comparable drug now on the market.

The group is doing research on a number of anti-viral and anti-inflammatory products and says it has one of the latter undergoing clinical trials at present. The drug, which will be used to treat such illnesses as rheumatoid arthritis if the trials prove successful, is said to be "very promising."

Beecham is looking for expansion primarily in its overseas markets because, as it puts it, "we have such a large market share in the U.K. now."

During the past year Beecham, like other UK-based drug groups, has also been hit by the strength of sterling and by the turmoil that followed the revolution in Iran. Iran has always been an important export market for British drugs.

Yet the group is confident about its long-term prospects and even in the shorter term, Beecham is launching some

UK-BASED Beecham claims that the effects of unlicensed competition on its best-selling Amoxil—amoxycillin—sales in the U.S. have been "exaggerated." The claim is accepted in many quarters of the pharmaceutical industry but the group clearly has been affected—especially as unlicensed competition was accompanied by

interesting new products and some likely-looking drugs in its laboratories.

It claims that Ticar, another of its antibiotics, is making an important contribution to its profits in the U.S. and is actually more important in America than the troubled Amoxil. Earlier this year Ticar was launched in Japan, where the market for it could well prove to be even bigger than that in the U.S.

Beecham is also "very close" to launching Augmentin, an oral antibiotic which the company says is effective against a broader range of bacteria than any comparable drug now on the market.

The group is doing research on a number of anti-viral and anti-inflammatory products and says it has one of the latter undergoing clinical trials at present. The drug, which will be used to treat such illnesses as rheumatoid arthritis if the trials prove successful, is said to be "very promising."

Beecham is looking for expansion primarily in its overseas markets because, as it puts it, "we have such a large market share in the U.K. now."

During the past year Beecham, like other UK-based drug groups, has also been hit by the strength of sterling and by the turmoil that followed the revolution in Iran. Iran has always been an important export market for British drugs.

Yet the group is confident about its long-term prospects and even in the shorter term, Beecham is launching some

UK-BASED Beecham claims that the effects of unlicensed competition on its best-selling Amoxil—amoxycillin—sales in the U.S. have been "exaggerated." The claim is accepted in many quarters of the pharmaceutical industry but the group clearly has been affected—especially as unlicensed competition was accompanied by

interesting new products and some likely-looking drugs in its laboratories.

It claims that Ticar, another of its antibiotics, is making an important contribution to its profits in the U.S. and is actually more important in America than the troubled Amoxil. Earlier this year Ticar was launched in Japan, where the market for it could well prove to be even bigger than that in the U.S.

Beecham is also "very close" to launching Augmentin, an oral antibiotic which the company says is effective against a broader range of bacteria than any comparable drug now on the market.

The group is doing research on a number of anti-viral and anti-inflammatory products and says it has one of the latter undergoing clinical trials at present. The drug, which will be used to treat such illnesses as rheumatoid arthritis if the trials prove successful, is said to be "very promising."

Beecham is looking for expansion primarily in its overseas markets because, as it puts it, "we have such a large market share in the U.K. now."

During the past year Beecham, like other UK-based drug groups, has also been hit by the strength of sterling and by the turmoil that followed the revolution in Iran. Iran has always been an important export market for British drugs.

Yet the group is confident about its long-term prospects and even in the shorter term, Beecham is launching some

UK-BASED Beecham claims that the effects of unlicensed competition on its best-selling Amoxil—amoxycillin—sales in the U.S. have been "exaggerated." The claim is accepted in many quarters of the pharmaceutical industry but the group clearly has been affected—especially as unlicensed competition was accompanied by

interesting new products and some likely-looking drugs in its laboratories.

It claims that Ticar, another of its antibiotics, is making an important contribution to its profits in the U.S. and is actually more important in America than the troubled Amoxil. Earlier this year Ticar was launched in Japan, where the market for it could well prove to be even bigger than that in the U.S.

Beecham is also "very close" to launching Augmentin, an oral antibiotic which the company says is effective against a broader range of bacteria than any comparable drug now on the market.

The group is doing research on a number of anti-viral and anti-inflammatory products and says it has one of the latter undergoing clinical trials at present. The drug, which will be used to treat such illnesses as rheumatoid arthritis if the trials prove successful, is said to be "very promising."

Beecham is looking for expansion primarily in its overseas markets because, as it puts it, "we have such a large market share in the U.K. now."

During the past year Beecham, like other UK-based drug groups, has also been hit by the strength of sterling and by the turmoil that followed the revolution in Iran. Iran has always been an important export market for British drugs.

Yet the group is confident about its long-term prospects and even in the shorter term, Beecham is launching some

UK-BASED Beecham claims that the effects of unlicensed competition on its best-selling Amoxil—amoxycillin—sales in the U.S. have been "exaggerated." The claim is accepted in many quarters of the pharmaceutical industry but the group clearly has been affected—especially as unlicensed competition was accompanied by

interesting new products and some likely-looking drugs in its laboratories.

It claims that Ticar, another of its antibiotics, is making an important contribution to its profits in the U.S. and is actually more important in America than the troubled Amoxil. Earlier this year Ticar was launched in Japan, where the market for it could well prove to be even bigger than that in the U.S.

</div

Major market U.S.

Drugs business forges ahead

HOECHST

Pharmaceutical sales in 1978: DM4,282m. (£1,019m).

Pharmaceutical sales as a proportion of total group turnover: 17.7 per cent.

Pharmaceutical research spending in 1978: DM440m. (£104.7m).

Main pharmaceutical products and production areas: diuretics; drugs for the treatment of diabetes; antibiotics; drugs for the treatment of circulation disorders; psychotropics—anti-depressants; tranquilisers; heart drugs; vaccines.

Main pharmaceutical products on the market: Basic—a diuretic; Dacell and Esglucan—both for the treatment of diabetes; Frisium—a tranquilliser; Merital—an anti-depressant; Reverin—an antibiotic; Quinte-Virelon—a vaccine; Sargentin—a heart drug.

THE GERMAN-BASED Hoechst is the biggest pharmaceutical company in the world—and it is expecting its drugs business to grow more quickly than many

of its other chemical operations over the next few years.

The group's research is directed to diseases and to the study of substances that occur naturally in the body rather than to the more traditional chemotherapies. It believes this is the approach which all large, sophisticated pharmaceutical groups will have to take—sooner or later—leaving the screening of chemical compounds to some of their smaller competitors.

The group has discovered a way of synthesising insulin—although this achievement has not yet led to a new product on the market.

Hoechst is looking for growth from some of its psycho-active drugs, such as Frisium. This is a tranquilliser which works without slowing down or otherwise impairing a patient's movements—which means people can take it and still safely drive or undertake other mechanical tasks.

Germany is still Hoechst's most important pharmaceutical market, accounting for some 35 per cent of the group's sales.

But the drugs giant says the U.S. and Japan—particularly the latter—are expected to provide an increasing contribution to its business.

The Japanese pharmaceutical market is smaller than that of the U.S., but Hoechst says it has already passed America in terms of both sales and profits for the group. Hoechst points out that Japan is a newer drugs market than that of the U.S. and there is therefore more growth to be had there. On the other hand the sheer size of the U.S. market "will tell."

South America is also expected to provide a larger market for Hoechst pharmaceuticals as its medical services and its distribution systems grow and improve—although this will only happen in the longer term. Western Europe continues to be an important outlet for the group's drugs although Hoechst complains of "excessive Government controls" in Spain and Italy.

The group says the general increase in national regulations

on drugs and their development is already hampering innovative pharmaceutical research. At one time around 50 per cent of Hoechst's research work on drugs was devoted to totally new products and the rest to non-innovative improvements and refinements on existing pharmaceuticals. Today only 25 per cent of the research effort is put into new

It stresses that this is not because of any change in its own policy—it has been forced to spend less on break-through medicines because of the extra time and cost required to bring a drug to the marketplace.

Hoechst adds that it is in an excellent position to withstand the increasing regulatory burden the industry has to bear because of its size. But it warns that present trends on patient lives, safety-testing and the data required by national authorities will lead to less competition in pharmaceuticals and could well "crucify" some of the smaller drug companies.

Group to broaden range

HOFFMAN-LA ROCHE

Pharmaceutical sales in 1978: Sfr 2,325m. (£581m).

Pharmaceutical sales as a proportion of total turnover: 48 per cent.

Pharmaceutical research spending: Sfr 636m. (£159m).

Main areas of pharmaceutical production and research: drugs for use on the central nervous system, including tranquillisers and sleeping pills; cardiovascular drugs; drugs for the treatment of rheumatism and inflammatory diseases; drugs for against tropical diseases.

Major products on the market: Valium and Librium—both tranquilisers; Mogadon and Rohypnol—both sleeping pills; Etrinac—an anti-infective agent; Rodanil—used against Chagas' disease, a South American form of sleeping sickness; Focalin—used to prevent any weakening of the bone structure in patients who have undergone radiotherapy.

Major pharmaceutical products on the market: Keyflex and Distacol—both ... antibiotics; Penicillin V-K—also an antibiotic; Oncoril—used for the treatment of cancer; Distalgesic—a pain killer; Furoprorin and Distamine—both anti-nauseant drugs.

A LARGE slice of the U.S. pharmaceutical research budget is currently being devoted to broadening the group's range of medicines—a range in which antibiotics have featured heavily in the past.

The company is concentrating on disease mechanisms and molecular biology rather than the traditional screening of chemicals. It is now looking at recombinant DNA technology, better known as genetic engineering, with a view to developing human insulin initially—Lilly was one of the first producers of commercial insulin and still holds a substantial share of the U.S. market for insulin.

The group is also looking at cardiovascular disease, virus infections and mental diseases. It is understood to have a number of new drugs in the research pipeline—mainly in its better established therapeutic areas.

One reason why Lilly is spending substantial sums on its research is that it believes pharmaceutical groups which fail to keep abreast of the leaders in developing new products could find themselves out of the race.

As well as placing greater emphasis on its research, Lilly is also trying to increase its share of overseas markets. The UK is Lilly's second largest area of operations outside the U.S. At present some 55 per cent of the group's UK output is exported—mainly to the Middle East and to other European countries.

The company's research spending in 1979: \$1.653m. (£477m).

Pharmaceutical sales as a proportion of total group turnover: 69.5 per cent.

Pharmaceutical research spending in 1979: \$185m (£57.4m).

Main pharmaceutical research and production areas: heart drugs; anti-arthritic drugs; anti-depressions; treatment of Parkinson's disease; vaccines.

Major products on the market: Indocin and Clinoril—both used against arthritis; Aldomet and Moduretic—used to treat the high blood pressure that often leads to heart disease; Meformin—a broad spectrum antibiotic; Tryptizol—an anti-depressant; Timoptic—used to treat glaucoma.

THE U.S.-BASED MERCK, better known in the UK under the name of its subsidiary, Merck Sharp and Dohme, is increasing its research spending by 21 per cent this year to \$227m. The move reflects the breadth of the group's pharmaceutical operations and its determination to establish itself as the "pre-eminent drugmaker, worldwide, in the 1980s."

The group now has a peculiarly strong record on innova-

Important pharmaceuticals market. The group says it is not frantically searching for a purchase in the U.S. but it would certainly be interested if a suitable buy presented itself.

Roche is already in a strong position in the U.S. It is believed that the Americans probably accounted for between 40 per cent and 50 per cent of its pharmaceutical sales worldwide in 1978, the latest year for which figures are available. But its good performance in the U.S. has been largely based on sales of its tranquilisers, Librium and Valium—in all likelihood the two drugs that are best known to the general public.

Yet growth in the sales of both tranquilisers—particularly Valium which is coming to the end of its patent life in many countries—is now starting to slacken in the U.S. and in other parts of the world. Roche is therefore keen to widen its U.S. product range. It believes its prospects there are good but admits that they depend on the group's ability to introduce new

drugs on to the American market.

Roche is also looking for increased sales of its pharmaceutical products in Western Europe and in Japan, where it has a research centre at Kamakura.

The company's research is centred at Basle in Switzerland, at Nutley, New Jersey, in the U.S. and at Welwyn Garden City. It also funds basic research with all findings being published in immunology and molecular biology at Basle and at Nutley. Its research approach is geared to studying natural organisms and the body's natural defences. But it admits that it has little in the way of new products in its laboratories at present.

It expects its mainstays over the next few years to be its benzodiazepines, such as Valium and Librium. It proudly points to Valium as one of the world's great drug success stories, adding that the product can be used in the treatment of epilepsies—it has muscle relaxant properties—as well as those suffering from stress and anxiety.

SWISS-BASED ROCHE

is keeping an eye open for a possible acquisition in the U.S., its most

new proprietary medicines when it was first launched in the U.S. in 1978. This year the group is planning to introduce at least four new drugs to the American market, including Moduretic, one of Merck's fastest-growing products outside the U.S.

Five products are due to be launched outside the U.S. this year and Merck claims to have a series of strong possibilities in the pipeline.

A vaccine against serum hepatitis is undergoing clinical trials in the U.S. and Merck says the development of a vaccine for infectious hepatitis is now feasible. The group is also preparing to launch a new product for the treatment of dry-eye syndrome.

Just over half of Merck's total sales are outside the U.S. but the group says its share of the total pharmaceuticals market is "still relatively small, in many significant therapeutic and geographic areas." It is thought to have about 5 per cent of the U.S. market and less than 1 per cent of some of the other major drug markets outside America. It reckons that opportunities for growth are "very great," particularly in Japan, Australia, New Zealand and Brazil.

Hoping to double market share

beta blockers are starting to grow rapidly in the U.S., the largest single pharmaceutical market in the world.

But ICI believes it may have some more acres up its sleeve as far as new drugs are concerned.

Within Europe, ICI feels there is still plenty of room for increasing sales, particularly sales of beta blockers.

In Northern Europe—the UK, Sweden, Holland—beta blockers account for up to 45 per cent of the market for drugs for high blood pressure and heart problems.

But further south there is a strong preference for older products, such as peripheral vaso dilators.

ICI is therefore engaged on convincing the Italian and German medical professors of the scientific rationale for using more beta blockers.

ICI's biggest problems on the pharmaceutical front are the increasing regulatory delays involved in bringing a new drug to the market, and the present strength of sterling. More than 70 per cent of the group's sales are overseas and in 1979 its trading profit on pharmaceuticals dropped from £68m to £66m even though sales rose by £24m. The reason was mainly the strong pound.

ICI has a major shareholding in a joint venture set up with the Japanese-based Sumitomo group in 1973. There is evidence that Western countries are

co-operated with Japanese concerns in the pharmaceutical field stand a far better chance of being able to take advantage of market opportunities there than those that go in "cold."

Within Europe, ICI feels there is still plenty of room for

increasing sales, particularly sales of beta blockers.

In Northern Europe—the UK, Sweden, Holland—beta blockers account for up to 45 per cent of the market for drugs for high blood pressure and heart problems.

But further south there is a strong preference for older products, such as peripheral vaso dilators.

ICI is therefore engaged on convincing the Italian and German medical professors of the scientific rationale for using more beta blockers.

ICI's biggest problems on the pharmaceutical front are the increasing regulatory delays involved in bringing a new drug to the market, and the present strength of sterling. More than 70 per cent of the group's sales are overseas and in 1979 its trading profit on pharmaceuticals dropped from £68m to £66m even though sales rose by £24m. The reason was mainly the strong pound.

ICI has a major shareholding in a joint venture set up with the Japanese-based Sumitomo group in 1973. There is evidence that Western countries are

Pfizer's commitment to people

For nearly five years a member of the ABP, is continuing to invest in research and development, in the work of people engaged in human and animal health, in the pharmaceuticals market, in the success of other worthwhile human activities, and in the future of other worthwhile human activities.

During the next 50 years, Pfizer intends by continued commitment to research and progressive commercial practices, to achieve success in all its product areas for the benefit of those whom the company in the modern pharmaceutical industry are in business to directly or indirectly.

AGRICULTURAL

Our Agricultural Division supplies a wide range of products to the major sectors of the agricultural industry—cereals, oilseeds, animal health, animal feed, and pharmaceuticals. The Agricultural Division also offers an extensive range of services to veterinarians, farmers and millers.

CHEMICALS

Our Chemicals Division serves the pharmaceutical and chemical industries with a wide range of both pharmaceuticals and chemicals mainly based on fermentation technology. A major product is citric acid, widely used in dairy, jams and pharmaceuticals. Other important products include the performance-reducing insecticides.

PHARMACEUTICAL

The Pharmaceutical Division supplies and markets its products based on pharmaceuticals, animal health, and pharmaceuticals with active technical ingredients. Research is conducted in a number of areas, including the development of the tropical disease schistosomiasis, the antibiotic Research Division, and the Research Division based in the U.S. The Queen's Award for Technological Achievement to Central Research Division of Pfizer Limited

Strong U.S. links

RESEARCH

With laboratories at Sandwich in Kent and in France, Japan, and the U.S.A., the Pfizer research and development effort will this year cost worldwide in excess of £26,000,000. At Sandwich, 470 scientists are engaged in research to discover and develop new forms of pharmaceuticals for health, agriculture and animal health, and to produce and market pharmaceuticals and other products. The success of our research depends on our ability to work closely with our customers and suppliers to provide quality products to its customers and their patients.

Pfizer plays a major role in the community. It has helped support charities and other organisations, and actively involved in education and local enterprises.

PEOPLE

Our people are the cornerstone of our success. We are committed to providing a stimulating environment for our employees, and to developing their skills and potential.

FINANCIAL

Pfizer has the largest European pharmaceuticals sales in the world. Pharmaceuticals are expected to grow in the world as associated companies and others to multinationals. In 1979 a total of 70% of the pharmaceuticals and chemical production was accounted for by the U.S. and Canada, the major suppliers to overseas customers. We are continuing our expansion to meet the growing needs of the pharmaceuticals market.



The Queen's Award for Technological Achievement to Central Research Division of Pfizer Limited

ame
lets
S.
uticals
ES LIMITED
England 1979
REQUIRED
parts analysing and
dical equipment and
ionally known for
Street, EC4A
S.A.
nd)
3227 FARM
no
TIRHEUMATICS
TAMINS

PHARMACEUTICALS X

WE ARE THERE
IN FIVE
CONTINENTS!

Hungary's contribution to the world's pharmaceutical industry is significant: Hungary provides 2% of total world production ranking seventh-eighth in the export league.

Beside pharmaceutical fine chemicals, intermediates, pharmaceutical specialties, know-how and licences are also included on the export list of Medimpex, the exclusive organisation for the foreign trade of Hungarian pharmaceutical products.

Representative in the U.K.
The Champion/Exp. and Imp. Ltd
Golden House,
29 Great Pulteney Street,
London W.1.

medimpex-hungary

A lot
of healthy
competition
A little
healthy
criticism

They're good for everybody's health

Within the pharmaceutical industry it surprises no one that sources of good can be both commercial and competitive... and vulnerable to criticism. For that is the way it is in our business.

In the last half-century, especially, our industry has contributed notably to dramatic clinical progress, saving or salvaging millions of lives. Yet in a nation that even today derides 'trade' there is still perhaps some vague thought that it is indecent for profit to be allied to health. But without some spur, micro-chip technology does not transform our way of life, diseases do not disappear. And without profit what industry could support the 9,999 individual struggles for discovery that fail for every one that wins through?

It must have been some bluff Yorkshireman who said, 'A man who never made a mistake never made anything'. Be sure the pharmaceutical industry, which makes so much all people need, has made its mistakes, despite the fact that every new drug today runs a gauntlet of scrutiny and review that is ever more critical.

Perhaps the critics—even those few whose motives are sometimes as suspect as their assertions—are right to demand the perfection no one would ask of any other scientific or commercial organism. Everybody knows that sometimes cars crash,

electricity electrocutes and that surgery, too, has its risks, but few accept that a medicine blessed by millions may adversely affect a few.

Of course most people neither hear the thanks nor see the gratitude of the millions. Doctors may. Pharmacists may. Nurses may. For it is in their hands that medicines are safely placed, safely prescribed, safely administered. That is why the body of good opinion about the medical profession is, quite properly, greater than the industry's.

The energy and innovative capacity of the industry has many brakes. New medicines performe slowly, some say too slowly, to the sick. Ill-informed comment hurts those decent thousands whose work in pharmaceuticals brings them more rewards than money.

In its success, the industry aids the Government and the people, and asks in return neither subsidy nor crutch. It exports without exhortation. Its plants and laboratories strive with little strife.

That symbol? It is the Ankh, which for 5,000 years has stood for enduring life. When first it appeared on an ancient Egyptian wall, a man might hope that life would endure for 27 years.

Today in our Western world and beyond it, three score years and ten are a reality, not a dream. In that achievement the pharmaceutical industry has had its part.


The Ankh was adopted 25 years ago as the symbol of

 **Sterling-Winthrop**

Proud to be a member of the British Pharmaceutical Industry

Sterling-Winthrop Group Limited includes:

Winthrop Laboratories • Sterling Research Laboratories • Winthrop Pharmaceuticals • Sterling Health • Sterling Organics • Sterling Industrial • Sterling Roncraft • Tyneside Printers • Isal • Sterling-Winthrop Ireland
Sterling-Winthrop House, Surbiton-upon-Thames, Surrey KT6 4PH.



UK expansion likely

SANDOZ

Pharmaceutical sales in 1979:
SicFr 2.133bn (£52.3m).

Pharmaceutical sales as a proportion of total turnover: 45 per cent.

Pharmaceutical research spending: estimated at £81m.

Major areas of pharmaceutical production and research: cardiovascular drugs; psychotropics; painkillers; endocrinology; drugs for the treatment of asthma.

Major products on the market: Visken and Viskoldix—both cardio-vascular drugs; Parlodel—for fertility problems; Sandoz-migran—for treating migraine; Zadiven—for asthma.

The Swiss-based Sandoz estimates it now costs more than £22m and 1,500 man-years to bring a new drug on to the market. It says the growth of

"well-intended regulations" on the testing and registration of drugs is effectively putting up barriers against the development and marketing of new medicines.

Sandoz states that regulatory hurdles are worst in the U.S. but even in the UK it takes one to two years to have a new drug registered. Like other companies in the pharmaceutical industry, it believes that the biggest problem is understaffing in drug-regulating bodies such as the UK's Committee on the Safety of Medicines.

The U.S. is the Sandoz group's largest market and is estimated to be nearly three times greater than the group's other major markets—West Germany, France, Japan and Switzerland. The UK is still a comparatively small market for Sandoz pharmaceuticals but the group says it is now "giving more

attention to Britain than

It is looking "favourably" on the UK in terms of investment—despite Britain's economic problems. But it says that Government efforts to restrict and reduce spending on the marketing of new drugs "squeezes middle-sized companies like ourselves."

The group's research, which is concentrated in the U.S., Switzerland and Austria with a fairly high proportion of clinical trials being carried out in the UK, is oriented to various disease areas rather than to the traditional screening of chemical compounds.

At present Sandoz is looking into the whole field of immunology in addition to its other well-established research field. Its cyclosporin A, which is designed to overcome rejection problems after transplant operations, is currently undergoing clinical trials in the UK and in a number of other countries.

THE UK-BASED Wellcome Foundation spends an extremely high proportion of its income on research and development—partly because of its unusual, if not unique, tradition as a major pharmaceutical company.

Basically, the group operates much like any other but, under the will of Sir Henry Wellcome, all its shares are owned by the Wellcome Trust which puts all the money it receives from the Foundation into the support of medical research around the world.

The research activities of the Trust and the Foundation are a registered charity—there are run on completely different lines and are quite independent of each other. But the historical link between them perhaps explains the breadth of the Wellcome Foundation's pharmaceutical research and the emphasis it places on Third World markets.

It collaborates with the World Health Organisation on research and at present it is looking at two new vaccines against tropical diseases—one

of them for use against malaria. It also has a promising anti-viral drug undergoing clinical trials and if all goes well it will be marketed under the name Zovirax. It is hoped that Zovirax will prove to be not only highly effective but also particularly safe because, as Wellcome puts it, "it causes the virus to commit suicide without destroying the cell."

The company is looking at a new immunosuppressant for cancer patients who subsequently develop one of the Herpes diseases, such as cold sores or shingles. In addition it is looking at a new generation prostacyclin, the prostaglandin which prevents the formation of blood clots in the arteries and which is used in the treatment of cardiovascular diseases. The Wellcome Foundation, whose research is geared to both traditional chemo-therapy and the synthesising of the body's natural defences, is also working on interferon.

The company is particularly strong in Australia, although it has subsidiaries and offices in over 50 countries. It believes that as Third World countries develop their medical and pharmaceutical services, it will be in a particularly good position to open up the new and larger markets they will provide for its drugs.

The Wellcome Foundation's history and tradition may cause it to take "a more altruistic view" of Third World diseases than some of its more conventional competitors in the pharmaceutical industry, but if it suffers from the same problems as they do, its chief complaint is the growth of regulations on safety testing throughout the world.

Some companies refuse to break down their figures for pharmaceutical and veterinary products. Roche pharmaceutical figures do not include its substantial vitamins business.

Discount price war claims casualties

The pharmaceutical distribution chain looks set for a period of rationalisation. With the number of High Street chemists continuing to fall and casualties expected shortly among the wholesalers as a result of a fierce discount price war.

Although the net reduction in the number of small chemist shops appears to have peaked in 1975 and despite the fact that chemists appear to be the only beneficiaries of the current wholesale price war, the longer-term fortunes of the retailers appear to be bound up with those of the wholesalers.

The root cause of the current turmoil within the wholesaling sector is the breakdown of the retail price maintenance system over the past two years, and the emergence of a cut-throat price discounting war. The resale price maintenance system (RPM)—which legally at least is still operating—banned pharmaceutical wholesalers and retailers from selling medicines at lower prices than those laid down by the manufacturers.

RPM was abolished for nearly all goods in 1974 but its continued use for drugs was upheld—at the request of the manufacturers—by the Restrictive Practices Court in 1970. The main argument put before the court was that RPM ensured a better service. Fears expressed at the time that its abolition might lead to a price war between wholesalers, who would then reduce the number of deliveries to chemists and stop stocking some slower moving pharmaceuticals, thus reducing patient service, could now become a reality.

These arguments are still supported by the major drug companies like Smith Kline, Swiss based Hoffmann La Roche, Glaxo and Beecham. Some companies also argue that the system is in the interests of retail chemists particularly in the field of across-the-counter or non-prescriptive drugs.

With the blessing of successive governments these drugs now represent a £320m a year market in the UK and, it is claimed, play a major role in easing the burden on the already overstretched resources

of the National Health Service and the general practitioner in particular.

The danger now seen by some is that the breakdown of retail price maintenance could lead to undercutting by the big supermarkets and multiples, further eroding the competitive position of the High Street chemist shop.

A survey published in February showed that although the rate of decline in the number of small chemist shops has slowed from a peak in 1975 when there was a net reduction of 238, the net reduction last year was still about 100.

The multiples' higher volume of trade enables them to offer lower prices as well as improving their ability to secure bulk-buy discounts. The major problem of RPM either direct from the manufacturer or through the wholesaler has always been that of policing the system. Few wholesalers have openly broken the system, but in increasing numbers they have managed to find loopholes in it. Some offer longer credit periods or extra goods while others have offered discount periods or extra goods while others have offered discount non-RPM goods as part of an overall package.

Not new

Wholesalers' discounts are, however not new. Some "cowboy" operators have been around in the past few years that major wholesalers such as Vestric, Barclay, Sangers and Macartney have joined in. Uni-chem, a chemists' co-operative, has run a type of discount scheme—based on redistributing profits to members as a dividend—for some time. Nevertheless several factors have now brought the issue to a head. Not least of these was the publication last November of a report on the payment of retail chemists for the Department of Health.

The report, prepared by the Independent Profit Assessment Panel as part of an evaluation of how much chemists should be paid for dispensing NHS prescriptions, effectively declared that retail price maintenance was dead.

The report recognised that, despite continued resistance from the manufacturers, RPM had finally gone by the board. The panel estimated that wholesale discounts on medicines may already be worth about £26m to retail chemists in England and Wales.

Once allowances have been made for small "piral" chemists without the turnover to justify big discounts, the panel concluded that an average sized independent chemist should be able to obtain an average rate of discount of about 5 per cent. It was on this basis that the £26m figure was calculated.

The importance of the figure to the Department was that the size of discounts had not been reflected in payments to chemists for prescriptions. Chemists remained the main beneficiaries of the discount system.

The main recommendation of the panel was that chemists should be allowed a 27 per cent return on capital employed instead of 16 per cent. This would be worth about £16m a year to retail chemists but if they have been "overpaid" by £26m a year because of discounts the recommendations would leave them worse off.

Although the figures contained in the report are the subject of much disagreement between chemists, wholesalers and the Government, the report did provide the first real insight into the changed relationship within the industry.

Since then the Government has accepted the panel's recommendation that an inquiry into wholesaling discounts ought to be set up.

In addition, drug manufacturers have stepped up their pressure on wholesalers in an attempt to enforce the apparently doomed RPM system.

Most observers feel however that such moves are unlikely to succeed and that, although most wholesalers would like some form of rationalised discount system, the pressure on smaller wholesalers' profit margins—where volume sales cannot be increased—is more likely to lead to some going to the wall.

P.T.

Stiefel Laboratories (UK) Ltd. extends good wishes to the ABPI on the occasion of its 50th anniversary

STIEFEL
Research in Dermatology

Drug research is cost effective

A REPORT last year from the Office of Health Economics (OHE), "think tank" of the Association of the British Pharmaceutical Industry, argued that incentives to innovate in drug development would be a more effective way of attacking the spiraling costs of health care than any attempt to ration the technological resources of the National Health Service. Rationing of resources would stifle innovation in the more advanced areas of medical innovation in Britain. Rationing would also increase the bureaucracy, it said.

The OHE report followed hard upon a report from the Advisory Council on Applied Research and Development (ACARD), the Government's scientific advisers, urging it to heed more closely the way its main overseas trading rivals are encouraging their industries to innovate.²⁰ A recurring theme in several ACARD reports in recent months is that in the technologically advanced industries Britain tends to think much too narrowly of its domestic needs and constraints—to the detriment of its export opportunities.

A choice

The OHE, since its creation in 1962, has conducted many dispassionate investigations of highly emotional aspects of health care. In its study of health care resources it finds that the Government has a choice between having the latest technologies available unevenly throughout the National Health Service, owing to their novelty as well as their cost, or of risking that Britain will fall behind in the development of medical technology. "Rationing works only when there are fair shareings in the elderly."

Wellcome Foundation and tradition may be a more alluring Third World does competition in its more competitive in the pharmaceutical industry, from the same products. Its chief competitive strength—through

courage and new drug innovation, as a most cost-effective way of treating illness than surgery and related techniques. They cite the new drugs for treating TB and other infectious diseases in the early days of the health service brought enormously cost-effective treatments to health care. They claim evidence that these successes are being repeated today, in the treatment of diseases which previously need complicated surgery, such as gallstones, brain abscess and stomach ulcers.

The introduction of cimetidine as a treatment of peptic ulcers in 1976 may prove to be the most rewarding all British drug invention. The discovery was made by Professor James Black, Dr. W. A. Duncan and their group at Smith Kline and French Research Institute in Britain. Previously, treatment had depended upon alterations in diet, rest and palliative drugs such as antacids and absorbents. When this failed, it usually meant surgery and, often, serious after-effects.

From a search of about 700 compounds, Black, Duncan and Co. and two agents which block acid secretion in the stomach, Cimetidine, the one they chose, was the first histamine H₂-antagonist to be marketed. It is reported that the drug, marketed as Tagamet, sold £150m to Smith Kline's home in 1978, virtually doubling the group's pharmaceutical sales. It has also produced a new term in U.S. financial circles—"tagamania," naming the search for the drug company with the next big innovation. (This could well be a drug that helps to restore the powers of memory and reasoning in the elderly.)

The cephalosporins today have annual sales worldwide exceeding \$800m. They are non-toxic drugs, resembling the penicillins in some—but not all—of their properties. They can be used safely for most patients who react adversely to penicillins. Glaxo in Britain, Eli Lilly in the U.S. and Fujisawa in Japan are the main companies behind their development. Britain, through the National Research Development Corporation, has earned over £70m in royalties from the development of compounds and processes based upon this discovery.

Similarly, the researchers find much of the controversy over drug prices in the past two decades "misguided" because it has focused not attempts to restrict the profits of the multinational companies which are innovating in this field. They believe, as may be beneficial approach, in controlling health care resources and to encourage health care workers to be more

Professor Black was closely associated with a major British discovery for the treatment of angina pectoris, the severe chest pain consequent upon a narrowing of the main arteries of the heart and other irregularities of this organ. This was ICI's discovery of the beta-adrenoceptor blocking agents or "beta-blockers," which reduce the heart rate and increase the amount of exercise a patient can take without suffering pain.

The first, propanolol, also turned out to be a useful drug for treating high blood pressure, and, still more significantly, one which helped medical science to explain the function of noradrenaline, the natural heart stimulant whose action it blocks.

ICI's elevation to the ranks of the big four British-owned pharmaceutical groups followed its discovery of halothane, one of the biggest advances ever made in anaesthesia.

For Beecham, the breakthrough commercially was its work on the semi-synthetic penicillins. These followed the work Sir Ernst Chain and H. W. Florey began at Oxford University just before World War II, which led to publication of the first experiments on the isolation and development of penicillin in 1940.

First cousins

Britain failed to capitalise upon this development, but learned from its mistake when a fresh opportunity arose after the war, with the discovery in the same laboratory at Oxford of a family of beta-lactam antibiotics called the cephalosporins. They turned out to be "first cousins" to the penicillins.

The cephalosporins today have annual sales worldwide exceeding \$800m. They are non-toxic drugs, resembling the penicillins in some—but not all—of their properties. They can be used safely for most patients who react adversely to penicillins. Glaxo in Britain, Eli Lilly in the U.S. and Fujisawa in Japan are the main companies behind their development. Britain, through the National Research Development Corporation, has earned over £70m in royalties from the development of compounds and processes based upon this discovery.

One further area of British innovation is noteworthy for the success it has achieved in competition with the privately-owned pharmaceutical groups. This is the Radiochemical

Centre, wholly State-owned by the UK Atomic Energy Authority, but competing worldwide. More than 80 per cent of sales of radio-active substances will exceed £40m this year are earned outside the UK. More than four-fifths of its earnings are from radio-pharmaceuticals and kits used in diagnosing disease, or from radiochemicals mainly used for research in the life sciences. In each case its chief competition comes from the drug companies.

The Radiochemical Centre is

a research-based company reinvesting a proportion of turnover typical of the pharmaceutical industry in research and development. It has established itself as market leader with its diagnostic kits for radio-immunoassay in obstetrics and gynaecology.

Source: Resources in health care, OHE publication No. 64, 35p. Industrial innovation, HMSO, £1.

David Fishlock



Most pharmaceutical companies now spend between 8 and 14 per cent of their turnover on research and development

Biotechnology: a new British industry

A REPORT from the Government's scientific advisers earlier this month, urging support at a crucial stage in the development of what they perceive as a major new industry for Britain summarises concisely its prospects for new drugs. Through biotechnology, the fruits of research in "genetic engineering"—in which the genetic material (DNA) of micro-organisms is modified—will be harvested as new medical products.

"An immediate and valuable prospect for recombinant DNA research is the production of new, cheap, safe vaccines for viral diseases of man and animals including some, such as hepatitis, not yet challenged effectively. Even when a vaccine is already in production, the existing methods of antigen preparation will be much simpler and cheaper and the products will be purer and less hazardous."

The scientific advisers, led by Dr. Alfred Spinks, a pharmacologist and former research director of ICI, point to progress in Britain towards a vaccine for hepatitis B; to prospects for microbial enzymes in treating chronic or physiological disorders, and inborn errors of metabolism; to cultivation of antibody immunoglobulins as precise and sensitive analytical tools for diagnosing diseases; and to the manufacture of new synthetic drugs of a complexity beyond reach of conventional chemistry.

In some of these areas, notably that of antibody immunoglobulins, British research is right at the forefront of medical science and ripe for further development.

In January, the Luxembourg-based research company Biogen,

engaged in vigorous development of their own research and development capability," said Dr. Hubbard.

A recent survey of research and development by the three main German chemical groups in Chemical and Engineering News suggests a high level of interest in the new technology in all three companies. Dr. Klaus Weissermeier, research director of Hoechst, is quoted as saying: "It will take time, of course. But this is normal when you begin in any new field. Our hope is that some of our future synthetic workers will be 'bacteria'."

If the experiments of Biogen's backers and of several of the established drug companies are successful, pure man-made interferon cultivated from genetically modified organisms could be one of the first products of recombinant DNA research to reach the market.

But hard on its heels is a vaccine against influenza. Late last year, Searle Research Laboratories in High Wycombe reported success in transplanting a key viral gene into bacteria, as a major step towards a genetically engineered organism to breed the drug. From Edinburgh University at the same time came news of success in transplanting the genes from the hepatitis B virus into bacteria.

Vigorous

Dr. William Hubbard, president of Upjohn, speaking in London recently, summarised the current industrial interest in genetic engineering, a pattern which he found "reminiscent of the development of electronically based entrepreneurial research corporations" in the '50s. Among companies with a strong pharmaceutical interest he cited Genentech, near San Francisco, which in collaboration with Eli Lilly has announced success with a way of making human insulin.

Hoffmann-La Roche, Merck Sharp and Dohme, ICI, Searle, Eli Lilly and Upjohn were "all

potential organisms or on the products of genetic manipulation."

Potential products from the application of genetic manipulation to biotechnology range widely throughout the fields of therapy, prophylaxis and diagnosis. Interferon—a substance with which among British companies, Burroughs Wellcome alone has persevered since its discovery in 1957—is one of the most exciting prospective products of the new technology.

The Department of Biochemistry at Imperial College in London has just disclosed plans to set up a pilot plant to make interferon by genetic engineering.

Nor, in the view of Sir William Henderson, chairman of the Genetic Manipulation Advisory Group (GMAG), the Government's watchdog on hazards from the new technology—makes it plain that the fears raised initially by research workers in the field have proved largely unfounded, as the researchers gained a better understanding of the mechanisms they were modifying.

The report urges GMAG and the Health and Safety Executive to "continue as rapidly as possible to reduce constraints upon genetic manipulation experiments while maintaining an adequate degree of safety." It applauds the special attention GMAG is giving to procedures designed to encourage industrial application; and also the continuing study by GMAG of biological containment, aimed at reducing the requirements for physical containment of the new processes.

But it warns of its worries with the draft EEC Directive on genetic manipulation which, if agreed in its present form, would create, on the basis of premises now known to be mistaken, a slow and inflexible system of controls both for experiments and the use of modified organisms. This is analogous to the situation already commonplace in the chemical industry, where improvements in process are rarely patented.

Regulation of experiments in genetic engineering, on the grounds that such experiments could yield pathogenic organisms against which man (or other living things) has no natural defence, is another worry of the drug industry at the moment. The report on biotechnology from the British Government's scientific advisers who include Sir William Henderson, chairman of the Genetic Manipulation Advisory Group (GMAG), the Government's watchdog on hazards from the new technology—makes it plain that the fears raised initially by research workers in the field have proved largely unfounded, as the researchers gained a better understanding of the mechanisms they were modifying.

The report urges GMAG and the Health and Safety Executive to "continue as rapidly as possible to reduce constraints upon genetic manipulation experiments while maintaining an adequate degree of safety."

Stanford University, which developed the transplant technology used to slice up and recombine the genetic material, is trying to patent the restriction enzymes used to slice and sew up DNA. If Stanford is successful, all drug companies may have to pay a royalty to the U.S. university.

Dr. Hubbard ventured the view that it would be "a very long time" before the patent questions were resolved.

Meanwhile the industry is proceeding in a "state of the art" frame of reference—not seeking patents on donor or

host cells, a slow and inflexible system of controls both for experiments and the use of modified organisms.

But it warns of its worries with the draft EEC Directive on genetic manipulation which, if agreed in its present form, would create, on the basis of premises now known to be mistaken, a slow and inflexible system of controls both for experiments and the use of modified organisms.


A plan to create a company based on this world-famous team of "genetic engineers" is expected to be put before the directors of the National Enterprise Board within a few weeks. The plan, which has been taking shape for nearly a year, involves the Laboratory of Molecular Biology, funded by The Medical Research Council. It envisages a research-based company structured to offer large manufacturing companies such as pharmaceutical firms an export service in the new technology of genetic engineering.

D.F.

We're researching now for the next 50 years.

MSD have been in this country for 52 years. We have played a large part in developing medicines that are now part of the everyday vocabulary, like cortisone, penicillin, streptomycin. And we have created effective treatments for the control of high blood pressure, arthritis, mental illness and pain.

Future research (with a worldwide R and D expenditure this year of more than £100m) will revolve more closely around biological research and the rational analysis of just how the body functions at a molecular



level. Then, when that is understood, we can devise specific substances to modify body mechanisms.

One principle of MSD research philosophy remains the same—collaboration with scientists outside the industry in universities and institutes throughout the world, not only in chemistry and pharmacology but in the key areas of cell biology, virology and immunology.

It is going to be an exciting 50 years.

MSD MERCK SHARP DOHME

Merck Sharp & Dohme Limited, Hoddesdon, Hertfordshire, EN11 9BU

PHARMACEUTICALS XII

Liaison between doctor and chemist grows stronger

THE PHARMACIST sees himself as the natural partner of the doctor in monitoring the high-technology products of the pharmaceutical industry. A small proportion of registered pharmacists in Britain, about 5 per cent, work for the drug industry. The great majority, 62 per cent, are in general practice in retail pharmacies, dispensing the drugs that doctors prescribe.

According to the Pharmaceutical Society, some 6m people use these chemists shops every day, seeking medicines, dietary aids, birth control technology, surgical dressings and appliances, and healthcare products.

But about 10 per cent of the customers are also seeking medical advice. Mr. Sharpe believes the pharmacist is well qualified to act as a "filter" between public and doctor, both on the grounds of his understanding of disease and the trust invested by the public.

In this role he can normally be expected to differentiate between the pain of, say, indigestion and an ailing heart, or to prescribe for such afflictions as dandruff or head lice. For the patient it often means the reassurances he is seeking, no matter whether the advice is that the trouble will quickly pass or that he will not be wasting his doctor's time by consulting him.

"Over-the-counter" advice of this kind is given free. But increasingly, with the encouragement of the National Health Service for an expanding role for the pharmacist in health care, pharmacies are setting aside a place for more private consultations, whether for pregnancy tests or for fittings for aids such as surgical stockings.

At the same time the pharmacist is advising the doctor on the performance and "cost-effectiveness" of new drugs. At the moment this feedback from pharmacist to doctor is most evident in hospital pharmacies, where about 12 per cent of British pharmacists are employed. Here the doctor is well accustomed to consulting his colleagues from the dispensary, says Mr. Sharpe. The practice is beginning to spread to health centres—both the area health authority centres and private arrangements in which a group of doctors set up their own dispensary.

The society is anxious to see this close rapport between the two professions spreading more widely, seeing it as an additional safeguard for the patient against unforeseen flaws in increasingly complex products, and as a way of safeguarding the NHS against overpricing by the drug manufacturers.

For this reason pharmacists believe that the drug industry

should make the information it pours into doctors' surgeries just as freely available to them. They often interpret the technicalities for the patients. They are often the first to spot signs of an adverse reaction to a new drug.

Still more important, they are in an excellent position to compare the performance of different drugs—perhaps widely different in price—prescribed for the same condition.

But the immense diversity of health care products available from the modern pharmacy brings the profession into conflict at some points both with doctors and with the drug industry.

An example of a service pharmacists believe they are well qualified to undertake is blood pressure testing. They view with alarm the appearance of America's coin-in-slot tests in department stores and supermarkets, which provide a figure unsupported by any advice on its meaning, much less any follow-up questions to establish how representative it might be.

Definition

For Mr. Sharpe, a medicine is any preparation with an active therapeutic ingredient.

This is a definition which excludes the dietary aids urged by advertising upon the indisposed. But it certainly includes pain-killers and cough mixtures.

The pharmaceutical Society's policy is that medicines should not be available from self-service stores, for two basic reasons. One is that this form of marketing deliberately encourages children to pick out items for purchase. The other is that it believes the pharmacist has a duty to intervene with advice on medical products, for example to be sure to see the customer proposing to buy more than one preparation containing the same active ingredient.

In this way he may be able to prevent "double dosing" with a drug such as aspirin—the cause of most cases of poisoning in Britain—simply because the customer was unaware of the contents of his purchases.

Recent limits on the number of aspirin in tablets in packs sold by supermarkets represent an "uneasy compromise" between the pharmacist's professional concern and supermarket interests, Mr. Sharpe believes.

The retail trade argues, of course, that it can provide

over-the-counter medicines in many places lacking a pharmacy. Although Britain averages one pharmacy to every 5,000 people, the distribution is somewhat uneven, with large rural areas of Kent, Sussex, Yorkshire, etc. bereft of pharmacists.

This worrying situation for the pharmacists has led to some fierce battles with the Department of Health over the last decade.

Mr. Sharpe is also chairman of the Pharmaceutical Services Negotiating Committee—the first president of the society to hold this office simultaneously.

In this role, quite separate from the society, he is negotiating on behalf of the full spectrum of pharmacy interests—from those of the Boots chain to those of the owner-manager—for a satisfactory remuneration for dispensing health care.

"There's no question that we have public sympathy, but you can't bank public sympathy," he

says.

Battle is joined at the moment not only over the issue of what the pharmacist should earn in his basic role as dispenser of NHS prescriptions, but what he should receive for shouldering an increasing advisory role in the nation's health care.

So far the NHS has shown little willingness to provide cash to help keep the pharmacist afloat of a fast-advancing technology. Neither has it been willing to subsidise pharmacies in rural areas where, in present terms, it is proving uneconomic to keep them open.

D.F.

NHS REMUNERATION OF PHARMACY CONTRACTORS

	1975	1980	% Increase
Retail Prices Index (1974=100)	119.8	243.3	105
Net ingredient cost	20.95	22.30	14.2
Fee + on cost (gross profit)	20.34	20.59	7.5
Value of prescription	£1.29	£2.89	124
Gross profit %	26.4%	20.4%	
GP £ for an average contractor	£11,580	£20,000	73.5
24,000 prescriptions per annum			
Discount recovered from wholesalers	1.9p	14p	
Adjusted GP £	£12,206	£24,820	103

Source: Pharmaceutical Journal

Industry sensitive over pricing policy

THE PRICING of drugs—whether they are drugs that save lives or drugs that merely stop a splitting headache—is a sensitive issue and it is therefore not surprising that the pharmaceutical industry is sometimes accused of overcharging for its products.

The industry may do much to help the sick, but it also makes its living from them. Some of its detractors—spurred on by a moral indignation that few other manufacturing industries can arouse—claim that it actually exploits those who are ill.

Critics point to the hefty profits made by most major pharmaceutical groups, to the parallel importing of drugs, to the sums spent on researching and manufacturing me-too products and to the widely ranging prices that are sometimes charged for the same medicine by the same company in different European countries.

These arguments for suggesting that the drug companies set their prices at as high a level as a given market will bear all contain a certain amount of truth. Yet the industry strongly denies that the prices of its drugs are unreasonably high and much—though not all—of the evidence appears to be in its favour.

No-one denies that drug prices vary considerably even

in the nine countries of the EEC—let alone outside it—and this fact has been used as

the basis of attacks on the industry by such bodies as the

Bureau European des Unions de Consommateurs. The bureau brought out a report last year which showed that the retail price of a basket of selected drugs—cardio-vascular drugs, antibiotics and psycho-tropics—which includes tranquillisers—was substantially higher in Holland, West Germany and Denmark than in Belgium, the UK, France or Italy.

The report pointed out that Holland, West Germany and Denmark have no government controls on the price of drugs. It concluded that the lack of State regulation often enabled the "drug oligopolies" to use "their exceptional powers" to set prices at the highest possible levels in certain markets.

The pharmaceutical companies say that direct comparisons of drug prices in different European Community countries mean little because they take no account of exchange rates, varying rates of inflation and differing purchasing powers. If the prices of the consumer unions' basket of drugs is adjusted for national purchasing powers, for example, the differential between Holland—the most expensive country—and Italy—the cheapest one—narrows considerably.

The industry also says that in countries where there is rigid price control, it is failing to make an adequate return on its investment. It is particularly critical of countries like France, where prices are controlled on an individual product basis, and it claims that ultimately poor profitability will force companies to cut their research spending. This will lead to fewer new medicine being discovered, developed and marketed.

The need for high profits that

will enable companies to invest adequately in further research is one of the most powerful arguments in the industry's armoury. The number of completely new drugs coming on to the market each year is now substantially lower than it was two decades ago.

Questionable

But it is questionable how far government controls on pharmaceutical prices are to blame for this state of affairs. The growth of regulations on safety testing, which has led to a heavy increase in the time and money required to put a drug on the market, is also partly responsible. And some drug companies admit that from a purely scientific point of view, all the "obvious" pharmaceutical breakthroughs may have already been made. From now on it is going to be far harder to find new drugs—no matter how much is spent on research.

The big drug companies can, in theory, exercise various sanctions against countries whose pricing regulations they dislike.

Ultimately, a drug company could even withdraw from a

particular geographic market and the industry sometimes gives vague warnings at this might happen. But the threat is an empty one, certainly as far as the EEC countries are concerned. The picking may be poorer than wished for but they are still too good to be abandoned.

The fact remains that prices in countries where there is government regulation are still lower than in those where there is virtually none. This has led to what is known as parallel importing, which means that entrepreneurs buy drugs in a cheap, government-regulated country—such as the UK—and sell them profitably in an expensive State such as West Germany.

But the point about parallel imports is that they are estimated to account for only some 2 per cent to 3 per cent of the total European drug market. The figure suggests that the "real" difference between drug prices in various European countries—taking into account all the relevant factors—is negligible. If it were as great as has sometimes been claimed, then market forces would ensure that parallel importing were carried out on a far greater scale.

One other factor that is often overlooked by those who attack the pricing policies of the major drug companies is the competition offered by the so-called me-too drugs. These

S.C.



A world leader

The Glaxo Group of Companies, Clarges House, 6-12 Clarges Street, London W1Y 8DH.

هذا من العمل

A bonanza down under

BY RICHARD LAMBERT, FINANCIAL EDITOR

TEN YEARS after the Poseidon bubble, foreign investors are moving back to Australia in a big way. Stockbrokers in London and New York are dusting down their old address books while international bankers are relearning the exchange control rules. The reason is that a long-awaited investment boom is now under way in Australia's resource-based industries.

Financing the projects which have already been agreed will require the support of very substantial volumes of foreign capital. The inflows are likely to be on such a scale as to have a lasting impact on Australia's financial system, and on the shape of the economy as a whole.

Estimates of how much money could be involved seem to increase almost monthly. A year ago, a survey of major mining and manufacturing projects undertaken by the Department of Trade and Commerce recorded that investment proposals amounting to A\$12.4bn (£6.2bn) had either been firmly committed or were at an advanced stage of planning.

A similar study in October took the figure up to around A\$16bn. More recently, officials in the Reserve Bank have been talking of figures in the region of A\$15bn to A\$20bn—without taking anything into account for the Rundle oil shale prospect. Bringing that into production could ultimately cost A\$10bn or more.

For comparison, capital spending by the mining industry between 1967 and 1977 amounted to some \$9bn.

In addition, major investments will have to be made in public utilities and infrastructure to back up resource developments on this scale. For instance, current plans call for an increase in electricity generating capacity from 22,000 megawatts to 41,000 megawatts by 1990. The likely cost is put

at roughly A\$10bn in 1980

prices.

There is, of course, scope for debate about these estimates. But there is no room for argument about the momentum which is already apparent in certain sectors of the economy. To take one example, the country's sole steel producer—BHP—is heading for record output this year and is having to rein in exports to meet home demand. In marked contrast to its worldwide competitors, it is currently running just about at capacity.

This upsurge in activity has also brought a surge in oil exploration activity—and some success. Five years ago it was estimated that Australia would be producing around 35 per cent of its own oil requirements in the mid-1980s, down from the present figure of 65 per cent.

Estimates of how much money could be involved seem to increase almost monthly. 9

of black coal, of which 8m tonnes was steaming coal for power generation. Government officials now say that on a conservative estimate coal exports could quadruple by the year 2000. The International Energy Agency has come out with a much higher figure: it says that demand for Australia's coal exports will then be around 195m tonnes, of which 110m will be for steaming coal.

Until recently there was no prospect of mines being developed at anything like the rate needed to make such a figure feasible. Prices have been poor, and the coal producers are still coming out with very depressed profit figures. But whereas export prices for steaming coal were around A\$22.24 a tonne 12 months ago, contracts are now being fixed in the mid-A\$30s, and a new sense of optimism has developed in

Since then, the estimate has risen to about 60 per cent.

All this adds up to a transformation in the country's energy balances. In 1977 Australia was a net exporter of energy to the tune of 22m tonnes of oil equivalent. It expects an eightfold increase in this figure by 1986, and has projected a figure of 290m tonnes by 1991. At that stage, it would be one of only three net energy exporters in the Organisation for Economic Co-operation and Development.

Australia's processing industries have also been given a great boost by its plentiful supply of relatively cheap and secure energy. International comparisons are notoriously vague, but as a guide Government officials indicate that the incremental cost of base load electricity to heavy industry in Australia runs to roughly

1.5 cents per kilowatt hour. This, they say, is about half the U.S. figure, and less than a quarter of the cost in Japan.


This helps to explain the rush to build aluminium smelters in Australia. At the last official count, production of aluminium—"congealed electricity"—was expected to rise from 270,000 tonnes in 1979 to over 1m tonnes by 1985 with the great bulk of the increase scheduled to be sold overseas.

The Government is anxious to encourage other processing industries based on domestic raw materials, and further down the line there is the possibility of uranium enrichment and coal liquefaction. "Quite plainly," says Mr. Malcolm Fraser, the Prime Minister, "We don't want to be just a 'hole in the ground'."

Projects on this scale represent an enormous challenge to a country with just 14m people. As an indication, it has been estimated that in terms of gross national product the North West Shelf project is over 100 times larger for Australia than the Alaskan pipeline was for the U.S.

According to a recent analysis by Mr. Alister Matlland, chief economist of the ANZ Banking Group, an average of A\$3.2m in 1980 prices would be required annually for mining and petroleum projects in the 1980s. A further A\$400m a year will also be needed for mining and oil exploration during the decade. The study suggests that only around A\$1bn a year could come from domestic sources, leaving about A\$2.6bn to be raised overseas.

This assumption is based on the physical limitations of the capital market—until this year, no company had raised more than A\$100m through a rights issue—and of the banking system. Combining all the major trading banks together would not produce a banking giant by international standards, and the risks of being



more exposed on term loans to the current climate.

So there seems bound to be a major effect on the Australian economy. It is estimated that between 70 and 85 per cent of budgeted expenditures on projects will be spent on Australian-produced materials, goods and services. The impact on the balance of payments will be reinforced as the years go by and resource exports start to build up.

Then in the current climate

and cheapening imports would readjust the current account back towards deficit. Another would be accelerating money supply and rising rates of inflation.

A third would be an attempt to choke off the domestic money supply consequences by various measures like high interest rates and a credit squeeze, and a fourth would be controls on inward capital movements.

Any of these four possibilities coming individually or more probably in combination, would

industry in the form of tariffs, import quotas or subsidies come to 26 per cent in 1977-78 and the figure was much higher than that in some of the more import-prone sectors.

Mr. Stone suggested that such protection was out of place at a time when Australia badly needed to employ scarce capital resources more frugally. But the logic runs slap into a major political problem. Unemployment is running at over 6 per cent—and manufacturing industry is a far greater employer of labour than the resources sector.

A third of the private sector workforce is engaged in manufacturing, and a wholesale attack on tariff barriers could have painful consequences in the short term. By contrast, the mining sector accounted for under 2 per cent of total employment last year—although it provided nearly two-fifths of Australia's exports in 1978-79.

There is an obvious parallel here with the UK, and the way that exploitation of the North Sea has squeezed manufacturers in the implications of these trends. He argued that Australia was likely to remain a net importer of capital throughout the 1980s, which meant that the balance of payments on current account would need to remain in deficit.

In that event, he said, increased exports of goods and services would need broadly to be matched by increased imports if a number of other alternatives were to be avoided. One would be an appreciating exchange rate, which by reducing exports

Today's Events

Affairs, Subject: Effects of Soviet expansion for British foreign policy. Witnesses: Mr. Kaser, Mrs. V. Yorke and Mr. L. Turner. Orders for Britain and Northern Ireland.

House of Lords: Debate on Opposition motion on Government domestic policies. Trees (Replanting and Replacement) Bill, second reading.

Mrs. Margaret Thatcher presents British Press Awards, Savoy Hotel, London.

Mr. Albert Booth and Mr. John Prescott, Opposition spokesmen on transport, address constituency Labour Party meeting, Community Centre, Dover.

Royal Yachting Association annual meeting, Savoy Hotel, London, 4 pm.

Overseas: Second day of talks

in Washington between Mr. Menachem Begin, Prime Minister of Israel, and President Carter on Palestinian autonomy.

North Atlantic Treaty Organisation 1980 Economic Colloquium opens, Brussels (until April 18).

European Parliament in session.

PARLIAMENTARY BUSINESS House of Commons: Timetable motion, Housing Bill, Port of London (Financial Assistance) Bill, second reading. Motions on the Shipbuilding (Redundancy Payments Scheme) (Amendment) Bill, second reading.

Select Committees: Public Accounts, Subject: Equity sharing schemes and national loan fund of wages (March). Index of industrial production for Wales (fourth quarter).

COMPANY MEETINGS A.C. Cars, 41, High Street, Thames Ditton, Surrey, 4. British Wit, Midway Hotel, Castleford, Runcorn, 12.

This new Prime System has been designed to improve the productivity of managers, secretaries, clerical and technical staff of large commercial and industrial organisations. It has already revolutionised procedures in national and international businesses.

Prime's Office Automation System will run on any Prime 50 series computer. It combines the features of word processing, comprehensive electronic mail, document management, administrative support, and text management with the routine data processing of an advanced business.

Management Communications and Support: Electronic mail with capabilities to annotate, send, receive, acknowledge, forward, or redirect. Document management including filing, retrieval and archiving. Executive management planning and scheduling functions including diaries, message logging and reminders.

Word Processing: Ability to create, store, and retrieve a document; update, modify, and delete that document. Standard letter libraries for batch correspondence.

Text Management: Extensive dictionary with initial 60,000 word vocabulary, automatic proofreading, spelling check, hyphenation, multi-lingual translation.

PRIME

OFFICE AUTOMATION SYSTEM



PRIME

Computer

The Hounslow Centre, Lempstone Road, Hounslow, Middlesex, TW3 1JB. Telephone: 01-572 7400.

Read the Prime Facts! on this new system. Phone Michael Grant on 01-572 7400 for the brochures—or clip the coupon.

Name: _____
Company: _____
Position: _____
Tel: _____
(Please clip coupon to your card/letterheading and mail today)

Russian oil

From Mr. J. Walbott-Wilson

Sir.—Further to your recent article on the probable decline in Soviet oil production I would like to make some further comments. It is interesting to consider Russia's medium term supply of oil—and coal—in relation to the world wide availability of these commodities.

It may not be generally realised that the United States depends on natural gas for 30 per cent of its energy requirements and in order to fulfil this demand the U.S. gas industry produces 45 per cent of the total annual production of natural gas.

Recent deep exploration below 25,000 ft in the U.S. has proved some significant additional reserves of natural gas which is essential for both energy requirements and feedstock for the petro-chemical industry in that country. The Soviet Union has over five times the proved gas reserves of the U.S. in fact about 40 per cent of the total world reserves yet produces 26 per cent of the world total annual production.

The Soviet oil industry currently produces approximately 12m barrels per day and it is expected that this figure will start to decline in 1981 at a fairly considerable rate, perhaps 10 per cent per year. Current Soviet exports to the West amount to 1.3m barrels per day and are contracted solely to earn desperately needed foreign currency to pay for the imports of food and Western technology. The Soviet ability to find and develop their very considerable potential for additional oil and gas production is so weak that it will be impossible for them to meet their future requirements.

The point is that they have the oil and gas and more coal than any other nation in the world.

It is not difficult to understand the Russian interest in the Middle East and the possible appealing tragedy to mankind should they make a false move simply due to the poor performance of a nationalised Soviet industry.

John H. Walbott-Wilson, 1, Egerton Gardens, SW3.

Ownership by workers

From the Secretary Cooperative Productive Federation

Sir.—Mr. Robert Oakeshott is working in industry of the productive resources with which they work. It would clearly help to improve industrial relations, to increase incentives and productivity and at the same time make possible the development of an incomes policy that could be accepted as fair by trade unions since restraint on their part in wage claims would no longer tend to lead automatically to gains by other sections of the community.

Mr. Oakeshott should, however, surely draw a clear distinction between workers' co-operatives and various forms of employee shareholding. In a co-operative productive society the return paid on share capital is limited and any surplus ear-

An advertising monograph

From the Head of Economics and Research, Advertising Association

Sir.—In reviewing (April 10) the latest Advertising Association's monograph "Advertising as a barrier to market entry," Winstan Fletcher made some rather sweeping statements

that has never been clearly explained. But the "Barris to entry" arguments never go away in academic or political circles—irrespective of what party is in power—and secondly, because a considerable number of academics have actually requested copies of the original presentation—presumably because of its rather original nature!

M. J. Waterson.

The Advertising Association, Abjord House, 15, Wilton Road, SW1.

Restrictions in loan agreements

From Mr. G. Selbie

Sir.—In the piece entitled "Hidden menace" (April 5), Lex rightly makes the case for greater disclosure of restrictions in loan agreements. But Lex's implication of sinister motives on the part of banks ("An unseen enemy could be striking a blow to the economy by incorporating restrictions in loan agreements that are shrouded in banking secrecy") is going to far and suggests a search for the financial equivalent of "red under the bed." It ignores the fact that this discrimination against co-operatives will be removed before the 1980 Finance Bill reaches the statute book. The discrimination against co-operative productive societies in this matter tends to result in their ploughing back a lower proportion of earnings than the companies with which they compete. The experience of the Mondragon co-operatives aug-

ments that industrial co-operatives can be very successful when worker members assets when earnings are ploughed back.

Paul Derrick.

Co-Operative Productive Federation.

30, Wandsworth Bridge Road, SW6

restrictions, rather than being shrouded in secrecy, are well known with minimum net assets, debt equity ratio and interest cover ratio being amongst the most common.

In the case of a company requiring to borrow from a number of banks, the danger of entering into a variety of possibly conflicting restrictions with individual banks can be overcome by raising funds on a syndicated basis using a recognised lead bank. Such an exercise often turns out to be a useful discipline for all parties in working out a minimum number of simple, standard restrictions which can be readily incorporated in a company's identifiable long before any actual breach, hence giving time for corrective action. In the event of a subsequent re-negotiations of the terms of the loan, the commitment of banks to the syndicate prevents individual banks from stepping planning procedures. Any possible breach should then be out of line to the detriment of all.

It is worth adding that a syndicated loan enables the company to satisfy its existing banking relationships without taking up the company's own management time involved in negotiating separate loan agreements while giving the finance director or treasurer the opportunity to take the advice of an experienced lead bank in tailoring the restrictions.

This does not invalidate the tenor of your leading article but it does put the matter rather better in perspective and clearly indicates that we are not talking about a declining industry, but one in renaissance.

G. H. Hafer.
Barclays Merchant Bank,
49 Church Street,
Old Laleworth,
Middlesbrough.

Rowntree 10% lower but increases payment

HIGHLIGHTS

REFLECTING reduced margins brought about by a more difficult trading environment and the competitive structure of world confectionery markets, pre-tax profits of Rowntree Mackintosh fell some 10 per cent to £40.43m in 1979 compared with £45.07m in 1978.

At mid-year, the surplus had slipped more than £2m to £9.31m, and the directors said at that time that full-year profits were unlikely to reach 1978's record level.

The results were particularly affected by the high sterling exchange rate, the transport strike, high interest rates coupled with larger borrowings and the increase in VAT.

The directors note that a 2.7 per cent reduction in the UK confectionery industry's volume market place following the rise in VAT rate. Nevertheless, the group's UK confectionery division achieved higher turnover and volume, increasing its market share.

1979 1978
Turnover £000 £000
Operating profit 601,321 562,705
Net profit 11,000 9,100
Net assets 40,432 45,070

Associates 2,415 8,525
Profit before tax 40,432 45,070
Tax 8,525 8,118
Net profit 31,707 35,952
Minority 1,717 1,704
Attributable 31,192 35,248
Extraord. debits 5,988 999
Dividends 7,832 7,020
To reserves 10,222 27,223
Total £3.5m adjustment in translation of overseas net assets and £1.5m rationalisation costs in Australia.

Group turnover improved from £562.7m to £601.32m, although sales volume remained virtually static.

Trading profits fell from £51.73m to £46.57m after sales and profits.

The overseas division, comprising Australia, Canada, Eire and South Africa, achieved higher

depreciation of £11m (£9.1m) and interest charges increased from £6.66m to £8.55m. The pre-tax surplus includes £2.42m this year, arising mainly from the group's 20 per cent share of the Associated Biscuit Manufacturers.

The dividend is stepped up from 6.5p to 7.25p net with a final of 4.75p and absorbs £7.8m (£7.02m).

Export sales rose slightly from £61.3m to £63.4m, although the directors say that some sacrifice of profit margins was necessary to achieve these results.

The European division also increased its market share, again at the expense of immediate profits, and was adversely affected by the strength of the pound since a proportion of its supplies are manufactured in the UK.

They add that the level of interest rates will be an important factor in profitability and indications are that the present high rates will continue for longer than has previously been forecast.

See Lex

ALTHOUGH the year's trading was affected by industrial disruption, Senior Engineering Group ended 1979 with pre-tax profits little changed at £5.07m, against a restated £5.09m, on turnover up from £54.52m to £60.91m.

The results reflect a pick up in profitability in the second six months after a first-half fall from £2.73m to £2.42m. Activity levels recovered well by the end of 1979 and the group has made a good start to the current year.

However, the effect of the national steel strike began to cause problems by the end of March and the directors say it is probable that the cumulative effect will be felt in a reduction

in demand from customers in the coming weeks.

But with the group's factories well equipped to continue the improvement in productivity and despite the difficult economic conditions, the directors have planned for considerably improved results this year.

Earnings per 10p share are shown as 6.82p (6.44p) before tax and as 4.93p (3.47p) after. The dividend total is improved from 1.3032p to 1.5p net, with a final of 0.75p.

Interest charges rose from £47,000 to £104,000, but with SSAP 15 adopted, tax was lower at £1.4m (£2.51m). After minorities and dividends, retained surplus emerged at

£2.55m, compared with £1.6m.

comment

Senior Engineering scrambled back from the ravages of the haulage and engineering strikes to end 1978 with pre-tax profits about even with 1978 levels. The shares put on 21p yesterday to 22p following publication of the results.

The company is now worried about the residual effects of the steel strike but after checking its order book is calling for considerably improved results this year. The acquisition of Boiler Tube Company of America last November pushed interest costs up last year but it could make a significant contribution to 1980 results. The yield of 10 and P/E of 6.5 provide good support.

WITH second half pre-tax profits improving from £3.22m to £3.99m, Bowthorpe Holdings reports a 17 per cent advance from £8.52m to £7.62m for 1979. Sales rose from £43.99m to a record £49.85m, of which exports amounted to £7.6m, against £6.91m.

After tax up to £3.67m (£2.74m) and an extraordinary credit of £1.36m (£nil), profit attributable is £5.11m (£3.53m). Stated earnings per 10p share are up from 8.8p to 9.4p, and the final dividend is raised from 9.95p to 1.443p, making the total 2.7p against 1.995p.

The extraordinary item resulted from the surplus on the sale of the company's Crawley site. Share of profit of associates amounted to £96,000 against £75,000.

The company designs, manufactures and sells accessories and components for use mainly in electronic, telecommunications, aero-space and electric supply industries.

comment

More than half Bowthorpe's sales are made outside the UK but the strength of sterling at

the end of last year has knocked little of the shine of the company's results. Profits before tax are 17 per cent better (24 per cent up in the second half), gross margins have edged further ahead, and as foreseen at the interim stage, shareholders get a healthy dividend increase.

Bowthorpe is basically a low technology group with an increasing emphasis on the more sophisticated end of the market—changes at the top last year were designed with this development in mind.

Besides continuing difficulties at Bowthorpe EMP and Power Progress last year's progress was fairly widespread with exceptional performances from the admittedly small operations in France and South Africa.

Bowthorpe is fortunate to have both a solid range of low price products and the considerable potential of interests tied to the exciting markets of defence, electronics and telecommunications.

Even in the current unexciting stock market firmament, it does not quite deserve a glamour rating—a point

reflected in the p/e of 11.5 and yield of 3.5 per cent at 10p.

Home Charm advances to record £2.8m

AS ANTICIPATED at the interim stage, when profits had advanced from £0.88m to £1.16m, record 1979 results are reported by Home Charm, the home improvement and DIY concern. Including this time £189,654 on the sale of properties and quoted investments, pre-tax surplus for the year climbed from £2.1m to £2.78m, on sales, excluding VAT, of £11.15m against £9.16m.

Three new stores have been opened this year, adding 88,000 sq ft, and plans to open seven more stores totalling 164,000 sq ft before the end of 1980 are well advanced.

comment

Home Charm's pre-tax growth slowed from 41 per cent at the interim stage to 32 per cent at year-end, but the company still seems to be making the most of the interest in DIY. Much of the group's earnings progress stemmed from its new openings. In 1979 there were five new stores at a cost of around £350,000; this increased total selling base by 20 per cent and was written off above the line. The value of group sales rose by 41 per cent in 1979, but actual volume growth was about half of this figure. This year Home Charm plans to open 10 new stores, all of them 25,000 sq ft (or larger) "superstores". By the end of 1980 this will mean a third of the group's 98 stores will be of this type, widely believed to be the main growth area in the UK home improvement market. The company is also continuing to expand its own brand name products; in 1979 these represented 30 per cent of group turnover, up from 17 per cent the year before. The board has put the total net dividend up by 60 per cent, yielding 2.4 per cent at 13.69. Calculated on a full tax charge, the p/e is not small at 14. With more and more consumers (like Comet and W. H. Smith) going for a piece of the DIY pie, the real question for Home Charm may now be just how long it expects to be able to carry on its impressive and hectic rate of growth.

Ready Mixed Concrete Limited

PRELIMINARY ANNOUNCEMENT

RESULTS FOR THE YEAR ENDED 31 DECEMBER 1979

Second half improvement brings 29% profit rise for year

	1979 £000	1978 £000
Turnover	749,577	632,190
Operating profit:		
United Kingdom	26,549	20,700
West Germany	14,353	10,897
Other countries	9,364	6,446
	50,266	38,043
Profit on disposals of properties	561	662
Associated companies	690	518
Interest	(4,237)	(2,672)
Profit before taxation	47,280	36,551
Taxation	(15,561)	(11,511)
Outside shareholders' interests	(6,104)	(4,388)
Earnings before extraordinary items	25,615	20,652
Basic earnings per share	33.0p	28.0p

In the early part of the year, severe weather conditions affected the Group's operations but there was a strong recovery with the return of more normal weather.

The Directors are to recommend a final dividend of 4.9p per share which together with the interim of 3.35p makes a total of 8.25p per share for the year (1978 6.7p).

The 1979 Report and Accounts will be posted to shareholders on 7th May 1980.

Ready Mixed Concrete Limited, RMC House, High Street, Feltham, Middlesex TW13 4HA.

THE RMC GROUP
Ready Mixed Concrete Limited, RMC House, High Street, Feltham, Middlesex TW13 4HA
RMC Holdings Limited, 100 Newgate Street, London EC1A 7AA
RMC International, 100 Newgate Street, London EC1A 7AA
RMC Australia, 100 Newgate Street, London EC1A 7AA
RMC Canada, 100 Newgate Street, London EC1A 7AA
RMC France, 100 Newgate Street, London EC1A 7AA
RMC Germany, 100 Newgate Street, London EC1A 7AA
RMC Italy, 100 Newgate Street, London EC1A 7AA
RMC Spain, 100 Newgate Street, London EC1A 7AA
RMC Switzerland, 100 Newgate Street, London EC1A 7AA
RMC United States, 100 Newgate Street, London EC1A 7AA

Bowthorpe ahead to over £7.7m

Smiths Inds. down £1.72m midway after poor start

AGAINST CONTINUING low demand from the motor vehicle and marine industries, Smiths Industries picked up from a poor start to the current year, although pre-tax profits for the first six months to February 2, 1980 were down at £9.26m, compared with £10.95m. Sales increased from £10.95m to £14.95m.

During the first quarter, profits of the group's UK activities were reduced by about £3m as a result of the engineering strike, which was followed by related disputes in parts of the company's UK aerospace businesses.

The directors say results of recent months have shown an improvement on last year and in the absence of major disruption it is expected that this will continue.

High interest rates and acquisition for cash in the latter part of 1978-79 were the main reasons for an increase in interest charges from £1.6m to £1.72m for the full year.

The tax for the period took £2.08m (£3.84m). The net interim dividend is up slightly at 3.7p (3.6135p) per 50p share—last year's total was 9.75p on record profits of £25.14m.

An analysis of sales and trading profits down from £12.14m to £10.98m shows (in 1980): UK: Supplied to industries—aerospace £21,900 (£20,500) and £10,000 (£2,047), marine £6,300 (£7,350) and £1.94 loss (£79 profit), vehicle manufacturer £19,950 (£19,400) and £32 (£518), other industries £28,450 (£24,250) and £3,628 (£3,411). Supplied through distribution trades—£40,000 (£38,100) and £3,590 (£4,021). Overseas subsidiaries £35,850 (£32,250) and £2,773 (£2,065). Less internal sales £2,850 (same).

Activities under the other industries category more than recovered the ground lost in the first quarter and showed an improvement on the previous year; the main contributor being the medical, tubing, specialist connector and time control businesses.

Results of the distribution businesses held up well in the second quarter despite static demand in increasing competitive markets.

Overseas subsidiaries generally had a satisfactory half-year, particularly in North America where good results were sup-

DIVIDENDS ANNOUNCED

	Date	Corre- tional payment	spend- ing	Total div. for last year
Aberthaw and Bristol	5.51	July 3	4.75	8.44
Bank of Scotland	7.75	June 2	6.02	12.25
Bowthorpe	1.44	July 1	0.95	2.39
Dares Estates	0.68	May 10	0.5	1.13
Doratz	3.37	May 28	2.92	5.47
Forward Technology	2.3	May 30	2	4.37
Home Charm	1.6	May 30	0.99	2.3
Horace Cory	0.7	May 30	0.38	1.3
Lamont Holdings	1	July 1	0.3	0.3
London Pavilion	12.5	June 13	12.6	12.5
Photos (London)	3	June 23	2.74	6
Photax (London)	2	May 23	1.83	3.5
Ready Mixed Concrete	4.9	—	3.25	6.7
Rowntree Mackintosh	4.75	July 9	4.25	7.25
Rugby Portland Cement	2.5	July 7	2.09	3.98
Senley Engineering	0.75	June 2	0.65	1.3
Smiths Inds. Int'l.	3.7	June 11	3.61	9.75
Standard Chartered	16	June 6	7.71	26

Dividends shown pence per share net except where otherwise stated.

* Equivalent after allowing for scrip issue. † On capital increased by rights and/or acquisition issues. ‡ For 9 months.

Second half boost for Photax

Photax (London)

THE \$2.3BN TEXAS PACIFIC DEAL

Guessing game on how Seagram will spend its new funds

BY IAN HARGREAVES IN NEW YORK

LAST FRIDAY, three hours after the deadline imposed by the bidder, Seagram of Canada, answered one of two main questions arising from the Sun Company's \$2.3bn bid for its U.S. oil and gas interests.

Seagram said it wanted to sell, and that the buyer would almost certainly be Sun, although the letter of intent signed by both sides does give Seagram the freedom to consider rival offers made before April 25.

It was a difficult decision. Energy is Seagram's only significant non-liquor activity, contributing 7 per cent of its sales and 23 per cent of operating income in 1979.

Sun made the decision easier by making a generous, some say too generous, offer carefully structured to assure Seagram's natural fears that, like others before, it might be selling its oil too cheaply. The offer values the proven oil reserves of

rate of return, Seagram will take up a 49 per cent stake in Texas Pacific's unexplored oil and gas territory and 25 per cent in its production activities.

So, Seagram is a willing seller. But that leads to the second question: what does Seagram want with all that cash?

No one knows the answer. In the frustration caused by this ignorance, Wall Street analysts who follow Seagram have been reduced to weaving more spectacles around the mere size of the numbers involved. The deal, says one, will more than double Seagram's book value.

If the cash were not sufficiently alluring—and Sun has offered a mixture of straight cash and floating rate notes—Sun has also held out to Seagram the prospect of maintaining a stake in Texas Pacific.

The deal says that once Sun has recouped its \$2.3bn plus \$400m capital spending and a suitable

(part of its \$496m long-term debt) but that hardly counts as more than a speck in the context of a bid. As for drinks activities, they are doing very nicely indeed without the need for grand developments. Sales in the drinks business have in-

creased by 24 per cent in the last four years, operating profits by 45 per cent. And even a grand development like the take-over last year of the Sandeman port and sherry company late last year cost only \$37m.

There is no suggestion that Seagram needs the money for its drinks business. The company does have a \$55m debenture issue to finance this year increased by 24 per cent in the last four years, operating profits by 45 per cent. And even a grand development like the take-over last year of the Sandeman port and sherry company late last year cost only \$37m.

The immediate answer to the question of Seagram's plans for its new funds, everyone is certain, is acquisitions outside the

drinks industry. Acquisition of what? Everyone is guessing again.

The most obvious purchase for a cash-rich Canadian company would be in natural resources, particularly energy, and indeed Seagram is reported

for some years at Colgate-Palmolive has brought that company's name into contention. Certainly there could be significant in the fact that of the up and coming executives Seagram chose to profile in its 1979 annual report, eight had significant experience with other companies, several of them in cosmetics and toiletries. Another name which entered the list of speculation this week is the Liggett Group, currently trying to resist a takeover from Grand Metropolitan of Britain and rumoured to be looking for a white knight.

Another thought is in packaging or bottling, where Seagram is heavily dependent upon outside suppliers. A further possibility is that Seagram will go for something in the consumer sector.

Beyond that, outsiders are guessing on slim evidence. The fact that Mr Philip Beckman, the company's president, worked

for some years at Colgate-Palmolive has brought that company's name into contention. Certainly there could be significant in the fact that of the up and coming executives Seagram chose to profile in its 1979 annual report, eight had significant experience with other companies, several of them in cosmetics and toiletries. Another name which entered the list of speculation this week is the Liggett Group, currently trying to resist a takeover from Grand

Metropolitan of Britain and rumoured to be looking for a white knight.

Whatever the choice it is evident that Seagram, under no pressure other than its own, will pressure to make a good business decision, has chosen to sell and to set Texas Pacific's locked-in resources to work in some other field, just as last year, under no pressure whatsoever, Seagram decided to sell its famous Park Lane headquarters building for \$663m in a lease-back transaction.

The family of Mr. Edgar Bronfman, Seagram's chairman, which last year accounted for 32 per cent of the company's liquor sales, is not to be confused with the other wing of the Bronfman

family which owns big stakes in Edger Equities and Branson bidders last year for Woolworth, has a reputation for canny decisions.

There are many who remain to be convinced that the decision to sell the high yielding potential of Texas Pacific is canny, but Seagram seems to have concluded that with its slightly declining oil and gas output and need for heavy capital spending to release the potential of its 3m acre undeveloped fields, that a highly active management is capable of netting even larger returns elsewhere.

With the company's return on equity running at 9.3 per cent (its highest point since 1974) and return on sales (10.9 per cent) and return on average total assets (11.7 per cent) both at ten year peaks, the company will have to do very well to do better than it has done so far.

Strong gains at Saudi International Bank

BY DUNCAN CAMPBELL-SMITH

SAUDI INTERNATIONAL Bank, the London-based consortium bank half-owned by the Saudi Arabian Monetary Agency (SAMIA), yesterday reported net profits up 66 per cent to £2.4m (\$3.3m) for the year ended December 31, 1979, against £1.4m for 1978. Total consolidated assets also jumped 61 per cent to £785.2m. The growth was supported by additional equity capital of £13m from the existing shareholders, which helped lift total capital and reserves to £41.6m. Losses, after provisions for

possible losses, grew by 47 per cent to £20m. Commenting upon the proportion of total assets represented by this figure, Mr. Edgar S. Felton, chief executive officer of the bank, emphasised the importance of a rapid growth in deposit business as the basis of future client relationships with the bank in Saudi Arabia.

At the same time, loan volume has grown less quickly than anticipated. Narrow margins on eurodollar syndicated business have not encouraged an aggressive stance in that

market. Within Saudi Arabia, the bank has been constrained by a high cost of rival funds, relative to the low costs enjoyed by domestic Saudi banks.

Saudi International is 45 per cent owned by Western banks

— notably Morgan Guaranty Trust Company, which has 20 per cent — and this precludes it under SAMIA rules from opening a branch within the Kingdom.

In other respects, though, the bank's singular ownership structure has clearly stood it in good

stead. Aside from interest income on its increased capital, fee earnings in Saudi Arabia made a main contribution to 1979 profits. Contingent liabilities on guarantees and confirmed letters of credit grew during the year from £37.5m to £66.4m.

On this basis, said Mr. Felton, and "a special expertise within Saudi Arabia," SIB looks forward to strong growth which will involve none of the embarrassment to its shareholders experienced by some other consortium banks.

Record rise at Bankers Trust

By Our Financial Staff

RECORD EARNINGS of \$37.7m for the first quarter of the year are announced by Bankers Trust New York Corporation. The net total shows a gain of \$10.8m on the comparable period, while share earnings have risen from \$2.20 to \$3.15. The figures are struck before securities transactions and exclude a \$6.5m gain on the sale of 16 branches in metropolitan New York.

Mr. Alfred Brittan the chairman said that the earnings improvement resulted from strong securities trading and foreign exchange results, and increased commission and other income, partially offset by higher operating expenses.

However, he warned that results for the first quarter should not be taken as indicative of the full year, pointing to economic uncertainties.

Foreign exchange income totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

Decline at KAISER resources

BY JOHN MAKINSON

KAISER RESOURCES, the Vancouver-based natural resources company, has reported a sharp fall in first quarter earnings from C\$12.5m to C\$48.000 (\$US.8464,406).

The figures exclude discontinued operations on which Kaiser has shown an exceptional gain of C\$232.4m. This results primarily from the sale of Candian oil and gas interests to Dome Petroleum.

If discontinued operations are included, net operating income shows a fall from SC14.1m to C\$3m. Sales for the period

dropped from C\$96.3m to C\$60.6m.

The company said that the lower earnings were mainly the result of a two-month strike by mine workers at Sparwood, British Columbia. Metallurgical coal shipments for the period totalled only 840,000 long tons, almost half the 1.5m tons shipped in the first quarter of 1979.

Kaiser recently purchased 9m of its own shares at C44 per share. Almost half of the total was acquired from Kaiser Steel, the California integrated steel

maker, which has announced its intention of selling its entire holding in the resources company.

Kaiser still owns around 4.5m shares, representing 25 per cent of Kaiser's remaining share capital. The British Columbia Resources Investment Corporation has an option to buy these shares, which would provide the steel company with a much-needed cash injection of \$200m.

The option was originally due to expire on April 15 this year, but has since been extended to April 30.

Decline at Northwest Industries

CHICAGO—The successful run of 36 successive quarterly earnings gains by Northwest Industries has been brought to an end by a downturn in the first quarter of this year.

Chiefly responsible for ending the nine-year-long upturn in the March quarter were substantial increases in interest costs

and the general malaise that has prevailed in the replacement battery industry for the past nine months, said Mr. Ben W. Heineman, president of the diversified industrial group.

These two influences were major factors behind a reduction in earnings for the three months ended March 31 to about 97 cents a share from \$34.1m, AP-DJ

U.S. QUARTERLIES

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN QUARTERLY reported a record \$1.2m for the first quarter, up by \$0.3m.

ALLIS-CHALMERS reported a record \$1.2m for the first quarter, up by \$0.3m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m from last year. Securities trading profits amounted to \$12.4m for the quarter, an increase of \$8.7m.

AMERICAN HOSPITAL SUPPLY totalled a record \$13.4m for the first quarter, up by \$9.6m

Financial Times 1980
Companies and Markets
Inds
which owns his
Equities and has
last year for his
decisions
are many who
have been
convinced that the
high price
of Texas
but Seagram
concluded that
and need for
spending in
order fields. This is
management
even larger
the company's
running at its
highest point
return on sales
sets 11.7 per cent
year peaks, to do very
than it has
er.

Dutch insurance group tops earnings forecast

By OUR FINANCIAL STAFF

PROFITS ahead of forecast are reported by Dutch insurance group Amer which has emerged from 1979 with a 20 per cent gain in net profits at F1 115.1m (£36.6m).

Half-way through last year net profits were running some 15 per cent ahead and, at the time, Amer suggested that, for 1978 as a whole, a gain of at least 15 per cent would be achieved.

At the per share level Amer has finished the year with F1 16.12 compared to F1 14.49m. Total dividend is going up from F1 6 to F1 6.6 a share, plus an unchanged F1 0.50 in share.

Life sums assured rose to F1 37.5bn from F1 46.6bn with trading profits from this quarter improving to F1 98.8m from F1 74.5m. Indemnity insurance opportunities in the Netherlands and the rest of Europe are more restricted because of the monopoly position of state run Post Offices and nudated

provided F1 15.9m, against F1 20.1m.

Last month Amer, which is the second largest insurance group in Holland after Nationale Nederland, announced a \$1.34m takeover bid for International of Atlanta of the U.S. life insurance, consumer credit and property group.

The proposed deal, a relatively large one for Amer, follows recent acquisitions in the UK and Australia.

Elsevier-NDU, the recently merged Dutch publishing group sees good prospects for the development of electronic information systems in the U.S. and Japan, writes Charles Batchelor from Amsterdam.

Opportunities in the Netherlands and the rest of Europe are more restricted because of

legal controls, the Board said

The company expects a further rise of its turnover in the U.S. this year, from F1 47m in 1979 following two recent acquisitions.

Elsevier-NDU spent F1 10m last year on acquisitions, including congressional information services (CIS) and Education and Economic Systems (EES).

Elsevier-NDU now plans to

consolidate its position and no

more major acquisitions are

expected, it said. It hopes to

achieve at least an unchanged

profit this year on 10 per cent

higher turnover.

The integration of Elsevier and NDU went ahead as planned last year. Profits came under pressure from the development costs of a new encyclopaedia and the costs of disposing of a magazine publishing subsidiary.

The talks between Sig.

Carlo de Benedetti, Olivetti's

managing director, and M.

Roger Farous, chairman of

Saint-Gobain, are understood

to have taken place in the

framework of the EEC's recent initiative aimed at

strengthening the data-processing sector in the community.

An eventual agreement

between the two companies

also represent a further

significant step in Olivetti's

broad strategy to strengthen

its electronics sector. The

Italian company recently

entered in a joint venture

with Memorex, the U.S. com-

puter group, in which the

Italian company will control

a 60 per cent stake.

Other recent international

agreements between Olivetti

and other major electronics

concerns include a distribution

deal with Hitachi of

Japan and the U.S. I.P.L. com-

pany in the medium and large

computer market, and a

manufacturing deal in the

telecommunications sector with

the French Matra group.

The Italian company also

confirmed yesterday that it

will report an operating

profit for 1979 and will return

a dividend for the first time

since 1974.

Apart from Ugine Actier,

the other large specialised

company which could be affected

by a reorganisation is Creuzot,

Loire. Creuzot has also lost

money in its special steel division

in recent years, but has

gradually been correcting these

problems. It has been widely

suggested that Creuzot's

activities could be linked with

Usinor's.

Sacilor is known to have been

talking recently to Pechiney

Ugine Kuhlmann, the

aluminium and chemicals

company, which was saddled

with heavy debts at the time.

Since then, Sacilor has made no

secret of its ambition to expand

even further in this sector, on

the grounds that many of the

problems have been muffled over.

Sacilor is second largest steel

company, took over Acieries d'Ugine

Kuhlmann, the

aluminium and chemicals

company, which was saddled

with heavy debts at the time.

Since then, Sacilor has made no

secret of its ambition to expand

even further in this sector, on

the grounds that many of the

problems have been muffled over.

Sacilor is second largest steel

company, took over Acieries d'Ugine

Kuhlmann, the

aluminium and chemicals

company, which was saddled

with heavy debts at the time.

Since then, Sacilor has made no

secret of its ambition to expand

even further in this sector, on

the grounds that many of the

problems have been muffled over.

Sacilor is second largest steel

company, took over Acieries d'Ugine

Kuhlmann, the

aluminium and chemicals

company, which was saddled

with heavy debts at the time.

Since then, Sacilor has made no

secret of its ambition to expand

even further in this sector, on

the grounds that many of the

problems have been muffled over.

Sacilor is second largest steel

company, took over Acieries d'Ugine

Kuhlmann, the

aluminium and chemicals

company, which was saddled

with heavy debts at the time.

Since then, Sacilor has made no

secret of its ambition to expand

even further in this sector, on

the grounds that many of the

problems have been muffled over.

Sacilor is second largest steel

company, took over Acieries d'Ugine

Kuhlmann, the

aluminium and chemicals

company, which was saddled

with heavy debts at the time.

Since then, Sacilor has made no

secret of its ambition to expand

even further in this sector, on

the grounds that many of the

problems have been muffled over.

Sacilor is second largest steel

company, took over Acieries d'Ugine

Kuhlmann, the

aluminium and chemicals

company, which was saddled

with heavy debts at the time.

Since then, Sacilor has made no

secret of its ambition to expand

even further in this sector, on

the grounds that many of the

problems have been muffled over.

Sacilor is second largest steel

company, took over Acieries d'Ugine

Kuhlmann, the

aluminium and chemicals

company, which was saddled

with heavy debts at the time.

Since then, Sacilor has made no

secret of its ambition to expand

even further in this sector, on

the grounds that many of the

problems have been muffled over.

Sacilor is second largest steel

company, took over Acieries d'Ugine

Kuhlmann, the

aluminium and chemicals

company, which was saddled

with heavy debts at the time.

Since then, Sacilor has made no

secret of its ambition to expand

even further in this sector, on

the grounds that many of the

problems have been muffled over.

Sacilor is second largest steel

company, took over Acieries d'Ugine

Kuhlmann, the

aluminium and chemicals

company, which was saddled

with heavy debts at the time.

Since then, Sacilor has made no

Dollar improves

The dollar improved in late trading in the foreign exchange market yesterday, rising to DM 1.3060 from DM 1.3172 against the D-mark, and to Swiss Fr. 1.7850 from Fr. 1.7925 in terms of the Swiss franc. It also rose to Yen 232.80 from Yen 231.30 against the Japanese yen, and finished around the highest level of the day against major currencies in general. Trading was nervous, influenced by commercial considerations, rather than any new factors. On Bank of England figures, the dollar/trade-weighted index rose to 89.9 from 89.2.

Sterling's index, as calculated by the Bank of England, was unchanged at 72.7, after rising to 72.8 at noon from 72.7 in the morning. The pound opened at \$1.340-2.1920, and touched a peak of \$2.2010-2.2020, before easing to around \$2.1975 at lunch and \$2.1950 by mid-afternoon. In late trading, sterling fell to \$2.1840-2.1850 as the dollar gained ground, and closed at \$2.1830-2.1860, a fall of 1.75 cents on the day. The pound rose to DM 4.1650 from DM 4.1275 against the D-mark, and to Swiss Fr. 3.9025 from Fr. 3.8240 in terms of the Swiss franc.

D-MARK—Weaker within the European Monetary System and against the dollar, following expectations of a continuing increase of payments deficit in Germany, and effects of anti-inflation measures and higher interest rates in the U.S.—The D-mark inclined against most of its EMS partners, and the dollar, at the Frankfurt fixing. The Bundesbank did not intervene. The dollar rose to DM 1.3910 from DM 1.3700, and sterling to DM 4.1590 from \$1.3400. Within the EMS the Irish punt improved to DM 3.7580 from DM 3.7300, the French franc to DM 43.26 per 100 francs from DM 43.16, the Dutch guilder to DM 91.36 per 100 guilders from DM 91.23, and the Belgian franc

to DM 6.2220 per 100 francs from DM 6.2400. On the other hand the Danish krone fell slightly to DM 32.16, per 100 kroner from DM 32.18, and the Italian lira to DM 2.1440 per 1,000 lire from DM 2.1480.

ITALIAN LIRA—Rather erratic within EMS, and falling around the highest level of the day against major currencies in general. Trading was nervous, influenced by commercial considerations, rather than any new factors. On Bank of England figures, the dollar/trade-weighted index rose to 89.9 from 89.2.

Sterling's index, as calculated by the Bank of England, was unchanged at 72.7, after rising to 72.8 at noon from 72.7 in the morning. The pound opened at \$1.340-2.1920, and touched a peak of \$2.2010-2.2020, before easing to around \$2.1975 at lunch and \$2.1950 by mid-afternoon. In late trading, sterling fell to \$2.1840-2.1850 as the dollar gained ground, and closed at \$2.1830-2.1860, a fall of 1.75 cents on the day. The pound rose to DM 4.1650 from DM 4.1275 against the D-mark, and to Swiss Fr. 3.9025 from Fr. 3.8240 in terms of the Swiss franc.

D-MARK—Weaker within the European Monetary System and against the dollar, following expectations of a continuing increase of payments deficit in Germany, and effects of anti-inflation measures and higher interest rates in the U.S.—The D-mark inclined against most of its EMS partners, and the dollar, at the Frankfurt fixing. The Bundesbank did not intervene. The dollar rose to DM 1.3910 from DM 1.3700, and sterling to DM 4.1590 from \$1.3400. Within the EMS the Irish punt improved to DM 3.7580 from DM 3.7300, the French franc to DM 43.26 per 100 francs from DM 43.16, the Dutch guilder to DM 91.36 per 100 guilders from DM 91.23, and the Belgian franc

EMS EUROPEAN CURRENCY UNIT RATES

	ECU	Currency amounts	% changes	from	% changes	adjusted for	Divergence	Overpayment limit %
	central rates	against ECU	April 15	central rates	rate	divergence		
Belgian Franc	39.7687	40.5403	+1.89	+1.00	+1.53	+1.53		
Danish Krone	7.72238	7.84020	+1.52	+0.63	+1.63	+1.52		
German D-Mark	2.88208	2.92191	+0.89	+0.71	+1.15	+1.15		
French Franc	1.04100	1.05200	+0.92	+0.92	+1.15	+1.15		
French Guilder	2.74382	2.78582	+0.68	+0.68	+0.82	+0.82		
Irish Punt	0.686201	0.672249	+0.51	+0.51	+0.58	+0.58		
Italian Lira	115.79	117.747	+1.70	+1.22	+1.22	+1.22		

Changes are for ECU; therefore positive change denotes a weak currency. Adjustment calculated by Financial Times.

EXCHANGE CROSS RATES

April 15	Pound	Sterling	U.S. Dollar	Dauhsham's	Japan's	Yen	French Franc	Swiss Franc	Dutch Guilder	Italian Lira	Canada Dollar	Belgian Franc
Pound Sterling	1	2.186	1.906	552.6	8.605	1,903	4,540	1,233	2,692	66.70	50.62	
U.S. Dollar	0.488	1	2.528	4,504	1,726	2,077	1,233	864.5	1,186	50.62	50.62	
Belgian Franc	7.72238	7.84020	+1.52	+0.63	+1.63	+1.52						
Danish Krone	2.88208	2.92191	+0.89	+0.71	+1.15	+1.15						
French Franc	1.04100	1.05200	+0.92	+0.92	+1.15	+1.15						
French Guilder	2.74382	2.78582	+0.68	+0.68	+0.82	+0.82						
Irish Punt	0.686201	0.672249	+0.51	+0.51	+0.58	+0.58						
Italian Lira	115.79	117.747	+1.70	+1.22	+1.22	+1.22						

THE DOLLAR SPOT AND FORWARD

April 15	Day's Spread	Class	One month	% Three	%
			months	months	months
UK	2.1840-2.2020	2.1850-2.1860	0.20-0.30c dis	-1.37	-0.55-0.65dis
Ireland	1.9725-1.9820	1.9725-1.9755	0.10c pm-dis	0.30	-0.25-0.15pm
Netherlands	2.0570-2.0770	2.0760-2.0790	0.05c pm-dis	0.40	-0.25-0.15pm
Belgium	20.38-20.53	21.61-20.53	5c-4c pm	1.87	-1.9-2.0pm
Denmark	5.8770-5.8835	5.8860-5.8835	0.50-1.00c dis	-1.53	-2.25-2.75dis
W. Ger.	1.8860-1.9000	1.9045-1.9055	1.63-1.53p dis	9.95	-2.43-2.13
Portugal	50.30-50.80	50.60-50.80	2pm-13pm	-1.30	-4pm-41dis
Spain	1.30-1.35	1.30-1.35	10-25c pm	-2.98	-6.75-7.5pm
Italy	680.30-683.75	683.00-683.75	30c pm	-1.37	-1.37-1.37pm
Norway	6.0840-6.1020	6.0870-6.1000	2.20-2.1070pm	4.59	5.70-5.20pm
France	4.3590-4.3825	4.3800-4.3825	2.32-2.22pm	2.21	5.70-5.70pm
Sweden	12.90-12.95	12.95-12.95	1.30-1.20pm	-0.50	-0.50pm
Japan	250.75-252.90	252.75-252.85	1.30-1.15pm	5.05	6.65-5.35pm
Austria	13.48-13.54	13.52-13.54	10.40-9.80pm	2.82	2.50-2.50pm
Switzerland	1.7820-1.7855	1.7845-1.7855	1.95-1.77pm	12.17	4.35-4.27pm

1 UK and Ireland are quoted in U.S. currency. Forward premiums and discounts apply to the U.S. dollar and not to the individual currency.

THE POUND SPOT AND FORWARD

April 15	Day's Spread	Class	One month	% Three	%
			months	months	months
U.S.	2.1840-2.2020	2.1850-2.1860	0.20-0.30c dis	-1.37	-0.55-0.65dis
Canada	2.0050-2.0105	2.0515-2.0525	0.53-0.43c pm	2.22	-0.63-1.05pm
Netherlands	4.53-4.57	4.53-4.54	3-2c pm	8.61	-7.61-8.61pm
Belgium	66.65-66.95	66.65-66.95	5c-5c pm	10.10	-10.10-10.10pm
Ireland	1.0200-1.1100	1.0105-1.1055	0.13-0.09c pm	8.28	-0.33-0.28pm
W. Ger.	1.42-1.47	1.42-1.47	31-2c pm	7.88	-8.88-8.88pm
Portugal	110.00-110.70	110.10-110.30	5-2c dis	-1.63	-2.20-10.10dis
Spain	107.70-108.00	108.10-108.10	7.41-4.1c pm	8.47	-8.47-8.47pm
Norway	11.14-11.22	11.15-11.19	3.32-2c pm	3.22	-3.22-9.81pm
France	9.57-9.62	9.58-9.60	4.34-3c pm	4.69	-10.49-9.49pm
Sweden	9.82-9.87	9.82-9.87	3.42-2c pm	3.88	-9.88-9.88pm
Japan	58.00-58.20	58.00-58.20	1.50-1.50pm	4.49	-4.49-4.49pm
Austria	52.39-52.75	52.50-52.90	2.15-1.50pm	7.30	-5.30-4.30pm
Switzerland	2.83-2.91	2.85-2.91	1.20-1.15pm	12.17	4.35-4.27pm

Belgian Franc is not convertible francs. Financials: Iran 68.75-68.80. Six-month forward dollar 1.02-1.12c dis. 12-month 1.04-0.50c dis.

Based on trade weighted changes from Washington agreement December, 1971 (Bank of England Index=100).

CURRENCY RATES

CURRENCY MOVEMENTS

April 14	Bank	Special Drawing Rights	European Currency Unit	April 15	Bank of England	Morgan Guaranty Changes %
April 14	Bank	Special Drawing Rights	European Currency Unit	April 15		

Lull in recent demand for Gilts attracts profit-taking

Equities open easier but rally to close little changed

Account Dealing Dates
Options
First Declara. Last Account
Dealing Dates Dealings Day
Mar. 24 Apr. 10 Apr. 21
Apr. 24 Apr. 24 Apr. 25 May 6
Apr. 28 May 8 May 19
Now times dealings may take place from 9 am two business days earlier.

A lull in the recent strong support of Government stocks signalled a slightly easier tendency at yesterday's opening and the downturn gathered momentum as short-term operators took some of the profits gained over the previous few days. Loose stock from bidders less certain of a big response to tomorrow's £100m issue of long tap stock Treasury 12½ per cent 2004-08, also hastened the decline at 9 am, when indigestion was being experienced following heavy purchases of Gilts.

Other factors generating caution among prospective buyers included publicity given to the high level of wage settlements since the summer, increased labour friction at BL and continuing international tension over Afghanistan and Iran. The slightly softer tone in sterling yesterday and a return to tight conditions in money markets may also have inhibited demand.

The progressive fall resulted in the longs losing more than a half of Monday's gains ranging to 11½ and the shorts surrendering nearly all of that day's improvements. However, a continuing demand for the special low-coupon tap, Exchequer 3 per cent 1984, enabled the authorities to float stock at 70½ and then withdraw; the stock, which had remained dormant for some considerable time, was reactivated on Monday at 70.

Standard fall

Leading equities began easier with the accent firmly on Glaxo following the group's late announcement on Monday of poor interim profits; although overall interest was small yesterday, Glaxo slipped 3 for a two-day fall of 22 to 218½. Elsewhere, most good-quality stocks tended to rally from cheaper early levels and the FT 30-share index, after registering a loss of 2.5 at 10.00 am, picked up to close a mere 0.4 off at 437.8. Only the Oil sector commanded any real business, and here several secondary issues attracted a relatively brisk trade which faded towards the close.

Demand for traded options fell away and only 358 contracts were completed against the previous day's 973.

FT-ACTUARIES SHARE INDICES

These Indices are the joint compilation of the Financial Times, the Institute of Actuaries and the Faculty of Actuaries

EQUITY GROUPS & SUB-SECTIONS

Figures in parentheses show number of stocks per section

Tues., April 15, 1980									
	Mon., April 14	Fri., April 11	Thurs., April 10	Wed., April 9	Year ago (approx.)				
1 CAPITAL GOODS (173)	236.35	+0.2	18.82	6.75	6.68	236.94	234.22	228.52	231.22
2 Building Materials (28)	231.25	-0.1	17.50	6.81	7.20	231.04	228.08	227.31	224.26
3 Contracting, Construction (28)	349.19	-	27.54	7.05	4.41	349.30	346.20	346.45	348.28
4 Electricals (16)	623.36	-	13.34	4.05	9.77	623.24	613.75	609.84	602.70
5 Engineering Contractors (11)	288.66	+1.6	26.84	9.12	4.76	288.66	272.72	273.05	263.64
6 Mechanical Engineering (74)	158.52	+0.2	21.70	8.36	5.82	158.17	157.24	156.12	160.71
7 Metals and Metal Forming (16)	160.71	+0.4	21.91	10.13	5.47	160.95	162.73	161.64	160.77
8 CONSUMER GOODS (DURABLE) (49)	215.44	+0.4	15.66	5.91	7.87	214.49	211.61	211.04	212.55
9 Lt. Electronics, Radio, TV (14)	310.31	+0.7	11.78	4.26	10.85	308.01	298.99	291.79	304.70
10 Household Goods (4)	107.46	-0.4	27.75	10.26	4.29	107.98	107.64	107.99	107.08
11 Motors and Distributors (21)	102.89	-0.2	24.13	9.68	4.92	103.13	103.14	102.12	103.22
12 CONSUMER GOODS (NON-DURABLE) (73)	215.06	+0.3	18.91	7.21	6.50	214.49	212.24	212.09	215.75
13 Breweries (14)	265.37	+0.5	16.66	6.62	7.05	265.19	258.62	259.22	251.74
14 Wines and Spirits (5)	297.05	+0.4	18.34	6.29	6.72	295.87	293.20	292.02	291.38
15 Entertainment, Catering (17)	288.86	-2.1	19.62	5.51	6.34	289.51	286.51	292.58	288.35
16 Food Manufacturers (21)	187.47	+0.4	20.88	7.82	5.87	186.81	185.68	184.73	184.00
17 Food Retailing (13)	295.41	-0.1	13.35	4.77	9.01	295.41	291.74	290.46	290.36
18 Newspapers, Publishing (13)	414.13	+0.4	24.52	7.27	5.56	412.24	412.63	405.52	405.67
19 Packaging and Paper (15)	129.66	-	24.55	9.01	5.02	128.70	126.75	126.75	129.38
20 Stores (3)	217.45	+0.9	14.05	5.38	9.26	215.55	211.64	210.71	212.07
21 Textiles (24)	121.80	+0.7	29.62	12.65	4.21	121.06	119.32	118.87	118.58
22 Tobacco (3)	201.61	-	22.88	11.48	3.93	201.20	201.58	201.58	201.88
23 Toys and Games (5)	32.66	+1.4	46.04	15.53	2.67	32.31	32.51	31.80	36.83
24 OTHER GROUPS (97)	198.25	-	17.75	7.38	6.74	198.35	197.42	196.56	202.36
25 Chemicals (16)	255.43	-0.7	20.97	8.13	5.46	257.52	254.97	254.99	251.25
26 Pharmaceutical Products (7)	190.18	-0.8	13.52	6.88	8.97	191.74	190.30	190.22	216.16
27 Office Equipment (6)	109.22	-	19.42	7.46	5.97	109.01	108.52	108.46	108.18
28 Shipping (11)	246.32	-0.2	17.24	6.62	10.27	247.40	242.36	241.50	242.27
29 Miscellaneous (57)	258.29	+1.0	17.22	7.04	7.24	258.41	252.71	252.30	256.35
30 INDUSTRIAL GROUP (492)	223.22	+0.2	18.77	7.04	6.67	222.02	220.54	220.23	220.45
31 Oils (8)	718.60	-0.2	31.00	7.10	3.45	718.39	710.85	728.84	719.67
32 500 SHARE INDEX	262.48	+0.1	28.97	7.05	5.60	262.48	260.87	259.80	261.97
33 FINANCIAL GROUP (118)	195.70	+0.1	—	6.23	—	195.42	195.25	195.83	196.67
34 Banks (6)	212.08	-	45.86	7.22	2.66	212.04	206.42	204.78	204.98
35 Discount Houses (10)	222.44	-1.0	—	8.97	—	221.24	215.33	214.99	217.09
36 Huf. Purchase (5)	203.71	-1.8	16.12	4.87	8.05	206.05	199.68	199.10	192.25
37 Insurance (10)	176.73	-1.0	—	7.17	—	174.36	176.08	176.39	172.58
38 Insurance Composite (9)	125.50	-0.5	—	8.33	—	124.72	122.71	121.51	129.94
39 Insurance Brokers (10)	304.16	+0.9	16.21	6.73	8.69	301.59	298.87	298.87	325.26
40 Merchant Banks (14)	278.00	-0.3	14.45	6.15	4.25	278.00	276.74	276.55	280.55
41 Miscellaneous (57)	124.86	-2.9	16.70	7.93	5.24	124.63	122.59	122.59	121.28
42 Investment Trusts (109)	210.28	+0.8	—	6.22	—	208.00	205.83	205.83	210.80
43 Mining Finance (4)	197.71	-1.9	12.61	4.84	9.62	198.38	195.74	195.51	191.48
44 Overseas Traders (19)	387.84	-2.7	13.08	6.94	9.36	394.52	395.68	393.99	368.33
45 All-SHAKE INDEX (50)	246.47	-	—	6.78	—	246.30	242.36	242.85	243.54

FIXED INTEREST PRICE INDICES

Tues., April 15									
	Mon., April 14	Fri., April 11	Thurs., April 10	Wed., April 9	Tues., April 8	Thurs., April 3	Wed., April 2	Year ago (approx.)	
1 British Government	101.89	-0.24	0.44	2.99	—	1 Low	5 years	5.08	
2	106.54	-0.78	0.33	3.31	—	2 Coupons	15 years	12.02	
3	109.86	-0.79	0.29	4.51	—	3 Medium	5 years	14.86	
4	122.00	-0.37	—	1.78	—	5 Coupons	15 years	11.80	
5	105.76	-0.59	0.35	3.70	—	10 Irredeemable	15 years	11.85	
6	49.32	14.27	49.68	49.49	49.41	100p F.P.	49.26	49.26	50.85
7	47.65	14.12	47.69	47.06	46.88	100p F.P.	46.88	46.88	46.88
8	61.45	14.68	61.68	61.01	61.01	100p F.P.	61.08	61.08	61.08

Recession signalled as U.S. output falls again

By Jurek Martin in Washington

INDUSTRIAL PRODUCTION in the U.S. declined by 0.8 per cent last month, providing further evidence that the economy is slipping into recession. This is the second consecutive monthly fall.

The Federal Reserve Board, which issues the data, revised its estimate of the February performance and now calculates that industrial output dropped in the month by 0.2 per cent, although it previously expected a small advance.

Although, like most other economic indicators, the March output index was clearly influenced by the slump in the car industry, it also revealed a fairly broad decline in economic activity.

The production of consumer durables was down 1.4 per cent in March. Home goods, including electrical appliances and furniture, were down by 1.7 per cent, the second consecutive fall of this magnitude, while car output fell to

Thousands more join BL Cars pay revolt

BY ARTHUR SMITH, MIDLANDS CORRESPONDENT

MORE THAN 22,000 BL Cars workers were on strike or laid off last night, as thousands more employees joined the pay revolt.

Sir Michael Edwards, the BL chairman, pulled back from any important initiative to break opposition to his decision to impose unilaterally 5 per cent pay offer linked to fundamental changes in working practices.

He arrived in London yesterday, from a visit to South Africa. Meanwhile, strikes disrupted production of the most profitable models — Land-Rover, Range Rover, Rover Saloons, Jaguar, TR7, dropheads, the Sherpa van and the Mini.

The decision of Mr. Moes Evans, general secretary of the Transport and General Workers Union, to give official support to workers who resisted the pay

package continued to prompt walkouts yesterday. About 9,700 strikers made the Swindon bidy plant the twelfth to join the dispute.

The company has agreed to a request from Mr. Evans for a meeting tomorrow. National leaders of the other 10 unions representing the 86,000 manual workers within the cars division are expected to attend, but not Sir Michael.

BL has insisted that it will make no concessions on pay or working practices. The company may prefer to allow the public clash between two big unions to spread confusion among strikers.

While the TGWU has given full support to members who resist the package, the Amalgamated Union of Engineering

Workers is urging workers to cross picket lines and accept it.

Senior BL executives have made clear that they are not prepared to accept the present situation. Sir Michael is expected to take a tough initiative in the hope of stemming mounting industrial unrest.

At Longbridge, Birmingham, where workers have rejected the strike call, production of the Mini was halted yesterday because of strikes by components suppliers.

The shut-down and lay-off of about 2,500 workers came as BL was unveiling to the Press the new facility for production of the Mini Metro — scheduled for launch in the autumn and the key to the company's viability.

The new metro. Page 6.

Bazooka raid on ministry by French terrorists

BY DAVID WHITE IN PARIS

FRENCH terrorists reach a new pitch of audacity yesterday when what seemed to be a Soviet-made bazooka was used in a series of dawn attacks on government buildings in Paris.

Callers to a news agency and a radio station claimed responsibility on behalf of the Direct Action group. Nobody was hurt in the attacks, which damaged three buildings attached to the Ministry of Transport.

They were made in open defiance of the French police, who thought they had broken up the group at the end of last month. Fifteen people allegedly connected with Direct Action were charged after a round-up made in co-ordination with one by the Italian police.

A caller to the Agence France-Presse news agency yesterday demanded their release, and said the attacks would continue until they were freed.

Direct Action is believed to have links with the Italian Red Brigades, four alleged members of which were caught in the South of France in last month's sweep.

Yesterday's raids, which occurred at about 6 a.m., began with an explosion which wrecked offices at a road traffic computer centre in southern Paris.

It was followed by rocket attacks on two buildings in the west of the capital. In the first, the bazooka was apparently aimed at ministry offices, but

hit premises used by a publishing company on the floor below. Police believe the attacks were carried out by the same group. Witnesses said the rockets were fired by three men in a car. Direct Action has used plastic explosives and automatic weapons but has never previously displayed weapons as sophisticated as a bazooka.

Since last month's arrests, responsibility has been claimed by the group for three incidents in Toulouse. These included spectacular attacks on two computer centres, Phillips Baker Systems and the local branch of the Franco-American company Cle Honeywell Bull, in which tapes and records were destroyed with apparently expert thoroughness.

Building society receipts 'only half level needed for mortgages'

BY MARTIN TAYLOR

BUILDING societies remain under intense pressure to meet mortgage demand. Net receipts of £200m last month were only still less than half the level societies say they need.

In the first three months of this year, societies have achieved net receipts of only £644m, compared with £777m at the same stage a year ago. House prices have risen by an average of 28 per cent in the 12 months till the end of March, according to the end of March, according to Nationwide Building Society.

This has placed an ever greater strain on building society funds.

However, societies have been able to sustain lending to some extent by utilising interest left in savers' accounts — £547m in the first quarter. Building

societies are still faced with considerable demand even though some managers have reported shorter mortgage queues, reflecting the lack of funds and the impact of record interest rates on repayments.

Last month £703m was lent to home buyers, compared with a monthly average of £740m in 1979 — although the number of loans made will have dropped by an even greater extent as a result of higher house prices.

Despite the pressure on funds, societies have so far ruled out any further increase in their rates. Instead, they have said rates are likely to reduce at a much slower pace when a general fall in interest rates occurs.

Interest on building society ordinary share accounts is 103 per cent — equivalent to 15 per cent gross for basic rate taxpayers. This compares with a three-month local authority loan rate of just over 17½ per cent.

Societies have faced further competition for funds over the last two months or so, from the 19th issue of National Savings Certificates.

One ray of hope for house buyers is that house prices have risen more slowly since last autumn. According to recent figures from Abbey National, the country's second largest building society — prices rose by only 2 per cent in the first quarter of this year, and actually fell in some areas.

NGA action closes Bristol newspaper

By Pauline Clark

THE EFFECTS of the national campaign of industrial action by print craftsmen increased yesterday as the Bristol United Press became the first major provincial newspaper owner to suspend publication.

Selective action by members of the National Graphical Association over an £80 minimum earnings claim has hit production of provincial newspapers all over the country for more than a fortnight. It has also disrupted the general print industry.

In most companies, mandatory chapel (union branch) meetings by NGA members and other forms of action have caused difficulties and delays in operations to employers who have stood firmly behind national advice not to give in to the union pressure for local settlements.

Mr. Jim Harrison, managing editor of Bristol United Press, said following the loss of 1m newspaper copies since March 27 and of £250,000 revenue, the group was suspending publication of the Western Daily Press, the Bristol Evening Post, and its weekly paper, the New Observer.

This follows a warning to NGA members last Friday that if they took any further industrial action they would be viewed as having dismissed themselves. The employers came to yesterday's decision after NGA members on the morning paper stopped work on Monday night. About 165 printers are affected.

Bristol United Press said resumption of publication would not take place until the national pay dispute was settled.

The Bristol group said yesterday it could no longer tolerate a situation in which it was repeatedly receiving complaints from readers, advertisers and newsmen.

Since industrial action started, national employers' representatives and the NGA have been in deadlock. Both sides have appeared to be more deeply entrenched in the last week.

The NGA has rejected the employers' offer of £75 a week minimum earnings and a 37½ hour week by 1981 in return for co-operation on working new technology.

THE LEX COLUMN

The short and long view at Rowntree

Index fell 0.4 to 437.8

the growth has required an increase in bad debt provision with a charge of £58m for the year.

The market initially saw Standard Chartered as seeing rather higher quality earnings, however, its yield is slightly lower than Bank of Scotland's at 8.2 per cent and its P/E ratio is around 3, against 11 more than 3.

Rugby, Portland

Rugby — Portland's heavy spending on new plant over the last two years of stagflation profits has brought a P/E ratio of 11, up from 8.5 in 1979.

Yesterday, for example, the Bank of Scotland reported a 19 per cent increase in annual pre-tax profits to £40.4m, and within that total the operating profits of the clearing bank were up by more like two-fifths, whereas the substantial investment credit and merchant banking interests suffered slight setbacks. The share price shed only 2p to 250p. On the other hand, the price of Standard Chartered Bank slipped 20p to 470p. Although the group's pre-tax profits improved by a sixth with the pro forma 1978 figure, the second six months produced slightly less than the first half despite the benefit of the £76m rights issue in May and the consolidation of Union Bank of California for the whole of the second half. At £169.8m, pre-tax profits are about £10m short of the market's hopes.

This is one reason why shareholders have no reason to be concerned about the 1979 performance. Another is that Rowntree's longer term strategy still looks sound. It claims to have increased its share of the UK market in the face of strong competition. Its sales on the Continent are now £145m — getting on for half the UK total — and although these are barely profitable, Rowntree is confident that it is building a business which will be as strong as its UK base. Profits will be under quite some pressure in the first half of the current year. But longer term prospects support the shares at 150p, where the yield of 7.1 per cent is covered three times by current cost earnings.

Two banks

The further away British banks are from the lush pastures of UK High Street retail banking, the less well are they doing. At one extreme the clearing banks are making the

Standard Chartered's overseas earnings in places like South Africa, Hong Kong and South East Asia appear to have been buoyant, but sterling deflated growth here by some 10 per cent. In the UK, high money rates have done no good at all to a group which is concentrated in wholesale banking and instalment credit. Including Union, there has been a big expansion of the balance sheet, with footings up from £9.4bn to probably around £13bn. But

last year pre-tax profits rose only 4 per cent to £15.1m, held back by the winter disruption and, had weather, "inadequate pricing and Rugby's inability to increase market share in the face of Blue Circle's push for volume in the UK. Now, though, cement prices have risen by 40 per cent between August and March, and the winter has been unusually mild. Combined with the low tax charge, economies from new, energy-efficient plant and interest savings from the rights issue, this should allow 1980 capital spending to be self-financed.

Certainly the group feels confident enough to promise that this year's dividend will be maintained, on the increased capital. The ex-rights P/E of 8.1 on fully-traded 1979 earnings should not rise as a result of the dilution, and the prospective yield is 10.6 per cent.

Weather

UK TODAY

TEMPERATURES above normal everywhere. Eastern areas dry with sunshines apart from coastal fog. Western areas cloudy with occasional rain.

All areas warm and dry, with maximum temperatures between 19C (66F) and 21C (70F), sunny or cloudy, with showers or rain later, except:

E. and N.E. England
Fog persisting in coastal areas, cold where fog persists.

Borders, Edinburgh, Dundee, Aberdeen
Fog on coasts.

Channel Isles, S.W. England, S. and N. Wales, Isle of Man
Max. temperatures 16C (61F), cloudy, bright intervals, occasional light rain.

S.W. Scotland, Glasgow, Argyl, N.W. Scotland, N. Ireland
Max. temperatures 14C (57F), cloudy, sunny intervals.

C. Highlands, Moray Firth, N.E. Scotland, Orkney, Shetland
Max. temperatures 12C (54F). Sunny intervals.

Outlook: Mainly dry with sunny intervals, temperatures near normal.

Forecast to mid-May: continuing mainly dry and warm, becoming unsettled later and cool particularly in the North.

WORLDWIDE

Y-day
midday
midday

°C °F °C °F °C °F

Aleppo C 15 59 Lisbon F 14 57

Algiers R 15 59 London C 4 57

Amman S 21 70 London F 20 68

Athens C 15 59 Luambala B 19 65

Sahrain C 30 86 Luar C 26 79

Barbados C 26 79 Manila C 11 52

Beruit S 14 57 Mairouz C 8 51

Bilbao R 10 50 Malaga S 15 51

Brigd. S 19 66 Malta F 16 61

Buenos Aires C 19 65 Mchez. F 17 63

Caracas C 26 79 Nairobi S 20 69

Carth. C 17 63 Nicosia F 13 55

Chicago S 4 33 Oslo S 12 54

Colombia C 20 68 Paris C 18 64

Conahan C 15 59 Perch C 12 54

Corfu F 18 64 Prague S 18 64

Cuba R 10 50 Raykjavik R 8 46

Dakar S 15 59 Rio de Janeiro C 18 64

Damascus C 26 79 Rio, F 17 61

Dublin C 16 63 Rome C 19 61

Dubrovnik C 20 68 Saarbr. R 24 78

Edinbgh. C 16 63 Stockholm C 18 64

Faro C 10 50 Tel Aviv F 17 57

Florance C 15 59 Tokyo C 2 48

Geneva C 20 68 Tunis C 14 53

Gibraltar S 15 59 Zurich C 18 64

Glasgow C 12 54 Tunis C 20 68

Grenada C 12 54 Tunis C 20 68

Helsinki R 10 50 Tel Aviv F 17 57

H. Kong S 21 70 Toronto C 4 38

Innsbruck S 18 64 Toronto C 4 38

Istanbul F 12 54 Valencia